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IL-1β is a pro-inflammatory cytokine critical for the protection against pathogens. 
The NLRP3 inflammasome mediates the maturation of IL-1β, however uncontrolled 
inflammasome activity contributes to the development of several diseases with 
strong impact on public health.   
The complement system is involved in the direct elimination of pathogens and in 
shaping adaptive immune responses. Particularly, paracrine and/or autocrine signals 
mediated by the complement fragments C3a and C3b regulate the induction and 
contraction of human Th1 responses.  
The function of C5a in T cells was still unexplored. Preliminary evidences supported 
a role for C5a in modulating the NLRP3 inflammasome. 
 
This thesis investigates the potential function of autocrine complement C5a-
mediated signals and the NLRP3 inflammasome within human CD4
+ 
T cells during 
Th1 effector responses.  
 
This work demonstrates that intracellular C5 activation (driven by T cell receptor 
and CD46 signaling) and C5aR1 engagement induce ROS production. These events 
lead to T cell intrinsic NLRP3 inflammasome activation and IL-1β secretion, which 
support IFN-γ production and Th1 induction in an autocrine fashion. Surface-
expressed C5aR2 negatively regulates this process. CD4
+
 T cells from patients with 
cryopyrin associated periodic syndrome (CAPS), which have mutated, 
constitutively-active, NLRP3 inflammasome, had overactive in vitro Th1 responses, 
normalised by NLRP3 inhibition. In collaboration with Dr. Erin West (NIH, MD, 
USA), in vivo significance of NLRP3 inflammasome activity within T cells was 
shown using models of viral infection, colitis and graft versus host disease (GvHD). 
Together, these data indicate the requirement for intrinsic NLRP3 activation for 
normal Th1 induction in mouse and human CD4
+
 T cells. This work resulted in the 
publication of a peer-reviewed original research article entitled “T helper 1 
immunity requires complement-driven, NLRP3 inflammasome activity in CD4
+
 T 







Finally, in the last thesis chapter, it has been investigated whether optimal production 
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1.1 The immune system 
 
1.1.1 The innate and adaptive immune system: introduction 
 
“An immune system of enormous complexity is present in all vertebrate animals... I 
find it astonishing that the immune system embodies a degree of complexity which 
suggests some more or less superficial though striking analogies with human 
language, and that this cognitive system has evolved and functions without 
assistance of the brain”. This quote by the immunologist Niels Kaj Jerne (The 
Generative Grammar of the Immune System, Nobel Lecture, 1984) reflects well the 
complexity and beauty of the mammalian immune system: an intricate network of 
plasma-soluble factors and different types of cells, which constantly orchestrates a 
wide range of effector mechanisms for the detection, prosecution, and elimination of 
exogenous viral, bacterial, or parasitic infections and self-dangerous entities (such as 
malignant cells) which threaten host viability.  
 
Traditionally, the immune system has been divided into two separate arms, the innate 
and the adaptive immunity. The former is mostly considered the ‘front-line’ of host 
defense, with immunological effectors providing immediate, robust and non-specific 
responses without the induction of immunological memory. The innate immune 
system is composed of soluble factors, including the complement system, and 
specialised cells mostly with phagocytic and secretory functions, such as 
macrophages, mast cells, dendritic cells (DCs), granulocytes (neutrophils, 
eosinophils, basophils) and natural killer (NK) cells (Medzhitov and Janeway, 2000; 
Geering et al., 2013).  
The “innate immune” recognition of microbial molecules, named pathogen-
associated molecular patterns (PAMPs) and noxious self-derived molecules (derived 
for example from infected, apoptotic or malignant cells), known as danger-associated 
molecular patterns (DAMPs), involves different pattern recognition receptors (PRRs) 
expressed by immune cells. Engagement of these receptors induces several 
protective effector functions specific for the cell which detects the incoming 







(TLRs), the Nod-like receptors (NLRs) and the retinoic acid inducible gene 1 (RIG-
I) like receptors (RLRs), and several proteins of the complement system (reviewed in 
Creagh and O’Neill, 2006). TLRs belong to a family of membrane-bound receptors 
which signal via the adaptor myeloid differentiation gene 88 (MyD88), the 
transcription factors nuclear factor B (NF-B) and interferon (IFN)-regulatory 
factors (IRFs), inducing the expression of pro-inflammatory cytokines such as the 
interleukins (IL)-6, IL-12, and tumor necrosis factor (TNF)-α (Takaoka et al., 2005). 
NLRs are cytoplasmic receptors of various microbial and non-microbial stimuli: 
while activated NOD1 and NOD2 trigger NF-B signaling and changes in gene 
expression, other members of this family trigger pro-inflammatory cytokine 
secretion as part of an inflammasome complex (Guo et al., 2015). RLRs are 
cytoplasmic sensors of RNAs, and their activation leads generally to the induction of 
type I IFN responses (Loo and Gale, 2011).  
 
The evolutionary younger adaptive immune system, on the other hand, provides 
selective responses to danger upon identification of specific molecules, known as 
antigens, by two classes of cell types, B and T lymphocytes. These cells possess an 
extremely diversified repertoire of antigen-specific recognition receptors which 
enables the specific detection and clearance of pathogens/danger and the formation 
of a long-lasting immunological memory, therefore ensuring a rapid and specific 
response upon re-encounter of the same pathogen (Gourley et al., 2004). While B 
lymphocytes secrete antibodies (humoral immunity) in the plasma against specific 
antigens, T lymphocytes provide soluble factors, such as cytokines, in order to 
enhance immune responses (helper function) or to mediate cell lysis (cytotoxic 
function) (Luckheeram et al., 2012; Tscharke et al., 2015). 
 
 
1.1.2 T lymphocytes 
 
T lymphocytes are named after their maturation process, from lymphoid 
hematopoietic stem cell, in the thymus (in opposition to B lymphocytes which 







differentiation in the peripheral lymphoid organs (Luckheeram et al., 2012). T cell-
mediated immunity comprises primary responses by naive T cells, effector functions 
by activated T lymphocytes, and endurance of antigen-specific memory T cells. T 
cell-mediated immunity is part of a complex and coordinated immune response that 
includes other effector innate immune cells. T lymphocytes recognise unique 
antigenic peptides through the T cell receptor (TCR) expressed on the cell surface; 
the antigens are presented by antigen-presenting cells (APC) in association with 
major histocompatibility complex (MHC) molecules (Braciale et al., 1987).  
 
The thymus offers an adequate microenvironment, with a combination of stromal 
cells, cytokines and chemokines, to generate functional T lymphocytes from cell 
precursors called “thymocytes”. Two critical steps in antigen-specific T cell 
maturation are the TCR gene rearrangement and the thymocyte selection (reviewed 
by Starr et al., 2003).  
The classic TCR consists of αβ chains (or γδ chains in the sub-class of γδ T cells) 
associated with different cluster of differentiation 3 (CD3) subunits (the homodimers 
CD3ζζ and the heterodimers CD3γε and CD3δε). The TCR interacts with the 
antigen-MHC complex on APCs, while CD3 mediates T cell activation signals 
(Rudolph et al., 2006). TCR α-chain gene region is composed of V (variable) and J 
(joining) genes. The β-chain gene region has V, J, and D (diversity) gene segments. 
A vast repertoire of TCR αβ is generated by gene rearrangement in the variable 
domains and random insertions/deletions in the junction among gene segments 
(junctional diversity) (Rock et al., 1994).  
During the T cell differentiation process, the contact with peptide-MHC complex 
(pMHC) on distinct thymic APCs plays a key role in the shaping of the T 
lymphocytes repertoire for antigen recognition (Klein et al., 2009). Thymocytes 
expressing TCR with either negligible or very high affinity to pMHC die, while 
thymocytes with TCR of intermediate affinity to pMHC undergo positive selection 
and differentiate into mature T lymphocytes. Moreover, self-reactive T cell 
precursors are eliminated by an apoptotic process known as negative selection, thus 
avoiding aberrant recognition of self-antigens and development of autoimmune 
disorders. Immature T cells with TCR of low affinity to self-antigens escape the 







to self-antigens and develop tolerance following activation. 
Following the maturation process, naive T cells migrate to secondary lymphoid 
organs, including the spleen, lymph nodes, and the mucosa-associated lymphoid 
tissue, where they continuously scan the environment for antigen recognition 
(Drayton et al., 2006). Upon antigen encounter, TCR engagement triggers a cascade 
of intracellular signaling events, resulting in activation of transcription factors, such 
as the nuclear factor of activated T cells (NFAT), and immune gene expression 
(Woodrow et al., 1993). TCR activation is further augmented by costimulatory 
molecules, such as the receptor CD28, expressed on all naive T lymphocytes. The 
dendritic cells (DCs), expressing the CD80 (B7-1) and CD86 (B7-2) ligands for 
CD28, are the APCs with enhanced ability to stimulate naive T lymphocytes (de 
Jong et al., 2005). The activated T cells promptly proliferate (clonal expansion), 
move to the sites of antigen presence, and execute effector functions aimed at 
antigen elimination. The exact nature of effector differentiation depends on cues 
from the microenvironment, including the cytokine milieu, antigen concentration, 
type of APCs and engagement of costimulatory molecules (Tao et al., 1997). 
Cytokines are initially produced by APCs and innate immune cells, and subsequently 
by the differentiating lymphocytes. Most effector T lymphocytes disappear after the 
antigenic agent is eliminated, although a small proportion will survive and form 
memory T cells, which may reside for years in peripheral tissues and lymphoid 
organs. Therefore upon antigen re-encounter, memory T cells can perform a much 
more rapid and potent secondary immune response (Luckheeram et al., 2012). 
 
T lymphocytes with an αβ TCR are categorised into different subsets accordingly to 
their lineage markers and functionality. Two surface co-receptor molecules, CD4 and 
CD8, define two separate T cell lineages with different effector functions 













 T lymphocyte. CD4
+
 T 
cells are activated by antigenic peptides presented by MHC class II molecules (only 
expressed on “professional” APCs such as DCs, macrophages and B lymphocytes) 
and produce cytokines that can be directly toxic to the target cells or stimulate other 
immune cells, therefore they are known as effector T helper (Th) cells. CD8
+
 T cells 







nucleated cells) and perform direct granzyme B and perforin-mediated lysis of 
infected or malignant cells bearing the antigen, therefore they are so-called effector 
cytotoxic T lymphocytes (CTL). Other distinct cell subsets expressing the TCR, 
sharing some features with the innate NK cells and with cytotoxic activity, are the 
CD1d-reactive natural killer T (NKT) cells, which recognise lipidic molecules in 
association with CD1d (Bendelac et al., 2007), and the CD1d-independent NKT 
cells, comprising the CD8
+
 NKT-like cells (Wang et al., 2015).  
 
 




 T lymphocytes execute multiple effector functions, ranging from activation of 
innate immune cells, B lymphocytes, CTLs, non-immune cells, and suppression of 
immune reactions. According to their function, CD4
+
 T cells are subdivided into in 
classical subsets, including T helper cells Th1, Th2, Th17, Th9, Th22, T follicular 
helper cells (Tfh), and T regulatory cells either induced (iTreg) or type 1 (Tr1). The 
lineage differentiation is guided by complex network of cytokines signaling and 
transcription factors accompanied by epigenetic remodeling (Luckheeram et al., 
2012). 
 
Th1 cells participate in protection against intracellular pathogens, but their 
uncontrolled action is also associated with organ-specific autoimmunity (del Prete, 
1992). These cells mainly secrete interferon-γ (IFN-γ) and IL-2. IFN-γ activates 
mononuclear phagocytes, such as macrophages and microglial cells, thereby 
enhancing their phagocytic function (Murray et al., 1985). IL-2 acts as a growth 
factor particularly in CTLs proliferation (Gattinoni et al., 2005; Kim et al., 2006) 
and promotes the development of CD8
+
 memory T cells (Williams et al., 2006). Th1 
differentiation involves expression of the T-box transcription factor (T-bet), as well 
as the cytokines IFN-γ and IL-12 (Lugo-Villarino et al., 2003; Trinchieri et al., 
2003). IFN-γ and IL-12 induce two other transcription factors participating in Th1 
maturation, respectively the signal transducer and activator of transcription 1 








Th2 cells partake in the immune responses to extracellular parasites, such as 
helminths, but play also a role in the induction of asthma and allergy (del Prete, 
1992). The main effector Th2 cytokine is IL-4, which induces the secretion of 
immunoglobulin E (IgE) by B lymphocytes (Steinke and Borish, 2001), as well as 
the production of pro-inflammatory mediators, including IL-6 and granulocyte-
macrophage colony-stimulating factor (GM-CSF), and the expression of adhesion 
molecules for immune cell migration (Doucet et al., 1998). Th2 lineage 
differentiation requires the transcription factor IRF4, which activates the IL4 gene 
promoter (Rengarajan et al., 2002), and STAT6 (induced by IL-4), which 
upregulates the expression of the Th2 master regulator GATA-binding protein 3 
(GATA3) (Kaplan et al., 1996; Zhu et al., 2006). 
 
Th17 lymphocytes are involved in the defence against extracellular bacteria and 
fungi, via the activation of mononuclear phagocytes, the recruitment of neutrophils 
and the induction of epithelial antimicrobial responses. Apart from this protective 
role, hyperactive Th17 cells also participate in the development of autoimmune 
diseases (Annunziato et al., 2007). The key effector Th17 cytokines are IL-17A and 
IL-17F, which stimulate the production of pro-inflammatory cytokines (such as IL-
1β, IL-6 and TNF-α) and chemokines (in order to recruit immune cells to the 
inflamed site) (Kolls and Linden, 2004). Th17 differentiation involves the key 
transcription factor retinoic acid receptor-related orphan receptor gamma-t (ROR-γt), 
and the cytokine transforming growth factor β (TGF-β), however only at low 
concentrations and in the concurrent presence of IL-6 (Ivanov et al., 2006; Veldhoen 
et al., 2006).  
 
Other distinct subsets of CD4
+
 T helper lymphocytes are the Th9 cells, secreting 
larger amount of IL-9 and involved in the pathological process underlying asthma 
and allergic reactions (Veldhoen et al., 2008; Xing et al., 2011), the Th22 cells, 
which produce mostly IL-22 and participate in the modulation of epidermal 
immunity (Eyerich et al., 2009), and the T follicular helper (Tfh) cells, located in the 
follicular areas of the lymphoid tissue, which are critical to the development of 








T regulatory cells (Treg) play a fundamental role in maintaining the tolerance to self 
antigens: after pathogen clearance, they negatively regulate immune responses, 
thereby avoiding exaggerated inflammation and subsequent detrimental 
immunopathology in tissues (Sakaguchi et al., 2006; Fujio et al., 2010). The main 
effector Treg cytokines are IL-10 and TGF-β. IL-10 is a potent immunosuppressive 
cytokine, with the ability to inhibit pro-inflammatory responses from Th1 and innate 
immune cells, thus limiting tissue damage (Couper et al., 2008). Indeed, Treg cell 
transfer is currently considered and clinically assessed as an alternative approach to 
treat autoimmune diseases and to avoid rejection of transplanted organs (Allan et al., 
2008). Moreover, Tregs attenuate the allergic inflammation, as Tregs-derived IL-10 
and TGF-β can strongly suppress IgE production (Robinson et al., 2004).  
Among the peripheral Treg cells are the induced iTregs, differentiating from antigen-
primed naive CD4
+
 cells in a peculiar cytokine milieu; the iTreg cells are therefore 
distinct from the thymus-derived natural regulatory T cells (nTregs) (Chen et al., 
2003). Forkhead box P3 (FOXP3) is the principal nTreg lineage-specific 






 (Fontenot et 
al., 2003). TGF-β signaling plays a significant role in both Treg subgroup 
developments, apart from promoting the antagonistic Th17 cells differentiation: 
TGF-β alone, at high concentration, can divert lineage differentiation towards iTregs, 
and induce downstream FOXP3 upon TCR activation (Chen et al., 2003). Finally, 
distinct from iTregs, the regulatory Tr1 cells are other immunosuppressive IL10-
producing CD4
+
 T cells which do not express FOXP3 constitutively (Groux et al., 
1997; Roncarolo et al. 2014).  
 
 
1.1.4 CD8+ T cells 
 
The majority of CD8
+
 T lymphocytes have cytotoxic activity (hence called CTL) and 
have a principal role in the elimination of cells infected with intracellular pathogens 
(mostly viruses) and cancer cells (Tscharke et al., 2015). In analogy to Th1 cells, 
these CTLs produce large amounts of IFN-γ and TNF-α in the effector state, and 







cytokines IL-12 and IFN-γ (Carter and Murphy, 1999; Glimcher et al., 2004). 
Following activation, IL-2 and IL-15 are the key cytokines involved in the 
maintenance of CTLs effector functions and the generation of a CD8
+
 memory T 
cells pool (Mitchell et al., 2010; Mathieu et al., 2015).  
 
CTLs are highly efficient antigen-specific effector cells, as a single CD8
+
 CTL is 
able to destroy more than one target cell bearing foreign antigens, while effectively 
sparing “healthy bystander” cells. The CTL-mediated killing of selected cells is 
initiated by the generation of contacts with the target cell and antigen recognition 
(the so-called “immunological synapse”), followed by the release of cytotoxic 
granules by CTLs (Stinchcombe et al., 2001). Unlike naive T cells, the cytotoxic 
activity of effector CTLs is not dependent on costimulatory signals. Upon TCR 
activation, the two major cytotoxic pathways deployed by CTL are 1) cell lysis via 
perforin and granzymes (which is Ca
2+
-dependent) and 2) apoptosis mediated by Fas 
ligand (FasL)/Fas receptor (FasR) (Lowin et al., 1994; Esser et al., 1998).   
The first pathway requires primarily the release of lytic granules, i.e. secretory 
lysosomes bearing granzymes, perforin and the proteoglycan serglycin. These lytic 
granules mature into lysosomes containing the lysosomal-associated membrane 
protein 1 (LAMP1, also known as CD107a), which is expressed only intracellularly 
in resting cells but detectable on cell surface of activated CTLs (Sanchez-Ruiz et al., 
2011). Granzymes are serin-proteases and the most studied member is granzyme B, 
which mostly induces apoptosis via a caspase-dependent mechanism in the target 
cells (Adrain et al., 2005). Granzyme B can also directly cleave other substrates 
which facilitates apoptosis in a caspase-independent fashion, such as the Hop 
chaperone of the heath-shock proteins (HSP) 70 and 90, relieving these from 
protecting the cell from apoptosis (Bredemeyer et al., 2004), and the Rho-regulated 
kinase Rock II, which induce the membrane bleb protusions typical of apoptotic cells 
(Sebbagh et al., 2005). The intracellular release of granzymes into the target cell 
requires either the receptor-mediated endocytosis or the direct translocation from 
endocytic vesicles into the cytosol through plasma membrane pores. Perforin is the 
pore forming protein involved in this second process, and it has structural similarities 
to the complement protein C9, also participating in membrane pores assembly 







Conversely, Fas-mediated apoptosis, a general process not restricted to CTLs, is 
triggered by the recognition of FasL by FasR, respectively expressed on the cell 
surface of CTLs and target cells (Lowin et al., 1994). The FasR, a member of the 
TNF receptor superfamily, holds an intracellular “death” domain which initiates 

































1.2 The complement system 
 
1.2.1 The complement system: an overview 
 
Among the evolutionary most ancient known mechanisms involved in pathogen 
recognition is the complement system. Complement’s discovery dates back over a 
century ago, when Paul Ehrlich described a system of serum-circulating proteins that 
has the ability to “complement” the other immune responses, that are antibody-
mediated and cell-mediated (Ehrlich and Morgenroth, 1899). The complement 
system consists of over 50 blood-circulating and cell-expressed proteins, which play 
a critical role in the recognition and elimination of pathogens and other dangerous 
entities, supporting innate immune responses and initiation of inflammatory 
reactions (Kolev et al., 2014). The complement effector molecules exist largely in a 
precursor state that is activated rapidly in a cascade-like fashion following 
recognition of PAMPs and/or DAMPs molecules. Complement can be activated in 
the blood via three main routes, the classical, lectin and alternative pathways, 
triggered respectively by immune complexes, microbial surfaces, and fluid-phase 
C3b-like molecule together with specific C3-cleaving plasma proteases; all these 
pathways are commonly characterised by the sequential proteolytic cleavage of 
soluble proteins (proenzymes) by a series of proteases (Figure 1.1) (Ricklin et al., 
2010).  
The classical pathway is initiated by the C1q molecule within the C1 complex (C1q, 
C1r2, C1s2), which recognises dangerous PRMs (pattern recognition molecules, 
including both PAMPs and DAMPs) indirectly via binding to IgG- or IgM-coating 
antigens or via the C-reactive protein (CRP), or directly interacting with specific 
PRMs. This recognition induces conformational changes within C1q and subsequent 
activation of the proteases C1r and then C1s (Ricklin et al., 2010). The lectin 
pathway is triggered via the recognition of microbial carbohydrates by the mannose 
binding lectin (MBL), belonging to the collectin family of lectins, or by other 
molecules of the ficolin family, with subsequent activation of the mannose-binding 
lectin-associated serine proteases (MASPs) (Garred et al., 2009; Ricklin et al., 







danger molecules produced by stressed and dying cells (Korb and Ahearn, 1997; 
Nauta et al, 2003). Both the C1 complex and MASPs can cleave the complement 
molecules C4 and C2, which associates in the formation of the classical and lectin 
C3 convertase C4b2a (Ricklin et al., 2010). 
The alternative pathway is characterised by tonic low-level C3 hydrolysis to 
C3(H2O), exposing binding sites for the protease Factor B (fB), which is then 
cleaved by Factor D (fD) to generate the alternative C3 convertase C3bBb. Properdin 
(also known as Factor P) amplifies the alternative pathway activation, as this 
molecule is able to recognise several PAMPs and DAMPs, to attract fluid-phase C3b 
to the detected PRMs surfaces and to guide the de novo assembly of a C3 convertase 
complex C3bBbP (Fearon and Austen, 1975).  
Both the C3 convertases C4b2a and C3bBb catalyse the proteolysis of C3 into C3a 
and C3b and the subsequent cleavage of C5, either by the classical/lectin pathway C5 
convertase C4b2a3b, or the alternative C5 convertase C3bBb3b, into C5a and C5b. 
Recently, a fourth route of complement activation, known as extrinsic pathway, has 
emerged, where C3 and C5 can be cleaved by neutral proteases, such as the 
coagulation proteins thrombin, plasmin, elastase and plasma kallikrein, indicating a 
functional cross-talk between the complement and the coagulation systems (Figure 
1.1) (Sarma and Ward, 2012). 
 
The main effector molecules of complement activation are the anaphylatoxins C3a 
and C5a, the opsonin C3b and the C5b component of the membrane attack complex 
(MAC, also known as terminal complement complex, TCC) (Figure 1.1). The 
anaphylatoxins C3a, ligand of the receptor C3aR, and C5a, which binds the receptors 
C5aR1 (CD88) and C5aR2 (C5L2, GPR77), are potent chemo-attractants which 
activate principally monocyte, granulocyte and mast cell migration (and induce 
enhanced smooth muscle cells contraction and vasodilatation) and effector functions, 
including degranulation and cytokines secretion (Heeger and Kemper, 2012). C3b, 
C4b and C1q are opsonins, which facilitate the phagocytosis of coated microbes and 
damaged cells (Ricklin et al., 2010). The generation of the MAC complex is initiated 
through C5b association with the molecules C6, C7, C8, and then several molecules 
of C9, which assembly into a membrane pore-forming complex that mediates the 







Apart from the classic anaphylatoxin receptors, other receptors for the complement 
activation fragments include CR1 to 4, which mostly bind to the C3b degradation 
product iC3b, and the C1q receptors (cC1qR, gC1qR, C1qRp); commonly, activation 
of these receptors is required for normal phagocytosis of complement-opsonised 
targets by scavenger cells (Ricklin et al., 2010). 
As particularly C3b, C4b and C5b bind in a non-discriminatory fashion to pathogens 
and host cells, several soluble and cell-bound regulators control complement 
activation to prevent unwanted host tissue damage. Examples of complement 
regulators are: 1) the C1 esterase inhibitor (C1-INH), a serpin family glycoprotein 
that inhibits different proteases of the classical and lectin pathways; 2) the MBL-
associated proteins (MAP), which competes with MASP in binding to MBL (Ricklin 
et al., 2010); 3) factors that accelerate the decay of convertases, such as surface-
bound CD55 (also named “decay accelerating factor”, or DAF) or fluid-phase Factor 
H (fH, of CFH) and C4b-binding protein (C4BP) (Kolev et al., 2014); 4) Factor I 
(fI), a serin protease crucial in the inhibition of all complement pathways, which 
degrades activated C3b and C4b to generate inactive iC3b and iC4b, and which uses 
as cofactors fH, C4BP, CR1 and CD46 (known also as membrane cofactor protein, 
MCP) (Nilsson et al., 2011); 5) carboxypeptidases, enzymes that de-activate the 
complement products C3a, C4a and C5a via removal of a C-terminal arginine 
residue, generating the des-arginated complement products C3adesArg, C4adesArg 
and C5adesArg (Klos et al., 2013); 6) negative regulators of the MAC assembly, 
such as CD59, vitronectin and clusterin (Ricklin et al., 2010).  
The existence of several regulatory mechanisms aligns with the fact that, from an 
ancient mechanism of innate immune recognition and defence in invertebrates, 
complement has evolved to an effector system that bridges the innate with the 
adaptive immune responses in vertebrate species (Sunyer et al., 2003). In fact, 
although the main source of serum-circulating complement proteins and regulators is 
the liver, complement molecules are also produced locally and expressed by some 
non-immune cell types (mostly epithelial cells and astrocytes) and by both innate and 
adaptive immune cells, including monocytes, macrophages, DCs, granulocytes, NK 
cells, B and T lymphocytes; therefore, these local complement components are able 
to modulate the immune responses in the peripheral tissues (Heeger and Kemper, 










Figure 1.1 The complement cascade 
Complement can be activated via three pathways, involving the sequential 
proteolytic cleavage of soluble proteins by a series of proteases. The classical 
pathway is triggered by assembly of the proteolytic complex C1 (C1q, C1r2 and 
C1s2) after binding antigen-antibody immune complexes, while the lectin pathway 
requires the mannose binding lectin (MBL)-mediated (or ficolins) recognition of 
microbial carbohydrates followed by activation of the mannose-binding lectin 
associated serine proteases (MASPs). Both pathways lead to cleavage of C4 and C2 
and formation of the C3 convertase C4b2a, that cleaves C3 into the activation 
fragments C3a (anaphylatoxin) and C3b (opsonin). Tonic, low-level C3 activation 
occurs in plasma via the ‘tick-over’ reaction in which C3 is hydrolysed. Plasma 
circulating C3(H2O) can bind to the surface of invading pathogenic bacteria. This 
triggers the binding of Factor B to C3b, and subsequent cleavage of Factor B by 
Factor D, which generates the C3 convertase C3bBb. Both C3 convertases, after 
processing additional C3 into C3a and C3b, can bind C3b to form the C5 convertase 
of the alternative pathway, C3bBb3b, or classical/lectin pathway C4b2a3b. C5 
convertase-generated C5a is a potent anaphylatoxin and mediates the inflammatory 
reaction while C5b binds to C6, C7, C8 and several C9 molecules to form the MAC 
(membrane attack complex) that mediates pathogen/cell lysis. Finally, activated 
plasma proteases, such as thrombin, can directly cleave C3 and C5 (extrinsic 
pathway). Depicted in ‘red’ are the complement receptors for the terminal 
complement products, CD46 (receptor for C4b and C3b) and the receptors for the 
anaphylatoxins C3a (C3aR) and C5a (C5aR1 and C5aR2). 













1.2.2 Complement in adaptive immunity 
 
The best known functions of the complement system are the direct killing of 
invading pathogens and the mobilization of innate immune cells with the induction 
of a general inflammatory reaction. It is, however, now increasingly recognised that 
complement also directly modulates adaptive immune responses, both humoral and 
cell-mediated (reviewed by Kolev et al., 2014). 
 
The first evidence that complement participates in the regulation of antibody 
responses dates back to over 40 years ago in studies from Mark Pepys: his work 
showed that mice depleted of C3 by injection of cobra venom factor (which activates 
C3 and leads to almost complete C3 ‘consumption’) have diminished T cell-
dependent antibody production (Pepys, 1972; Pepys, 1974). A well-known 
complement mediated mechanism in shaping adaptive humoral immunity is the 
interaction between the complement receptors CR1 and CR2, expressed by B 
lymphocytes and follicular DCs in humans and mice, and antigen-bound by the C3 
degradation product C3d (Carroll and Isenman, 2012). It has been demonstrated that 
engagement of CR2, through C3d-coated antigen during B cell receptor (BCR) 
activation in the lymph nodes, reduces the threshold for BCR signaling and regulates 
optimal antibody production in vivo in mice (Dempsey et al., 1996). Furthermore, 
follicular B cells in the spleen’s subcapsular sinus recognise immune-complexes 
(ICs) via CR2 and these ICs are captured by macrophages (Phan et al., 2007). 
Moreover, the follicular DCs bind ICs coated with C3 activation fragments in order 
to retain the antigens and enhance B-cell memory and effector responses in the 
germinal centers (Heesters et al., 2013). Via these mechanisms, complement 
regulates antigen retention and presentation, BCR signaling and ultimately B cell 
selection, activation and memory formation.  
 
The role of complement in regulating T cell responses is now also well 
acknowledged, although experimental evidences in support were produced much 
later when compared to Pepys’ studies on humoral immunity. Originally, it was 
shown by Kopf and collaborators (Kopf et al., 2002) that complement C3-deficient 







response to pulmonary viral infection, resulting in defective viral clearance. C3-
deficient mice have also impaired anti-viral response following systemic infection 
with lymphocytic choriomeningitis virus (LCMV), the causative agent of meningitis 
(Suresh et al., 2003), associated with diminished antigen-specific CD8
+
 T cell 
expansion; conversely, mice deficient for the C3 convertase inhibitor DAF showed 
enhanced in vivo T cell immunity against LCMV, and this effect was reversed by the 
deletion of C3 or the C5aR1 (Fang et al., 2007). Different complement pathways 
shape distinct immune responses: in a West Nile virus infection model, it has been 




 T cell 
responses and trafficking to the central nervous system (CNS), while no differences 
were observed among wild type (WT) mice and the C1q-deficient counterpart, thus 
demonstrating a role specifically for the lectin and alternative complement pathways 
in regulating anti-viral T cell responses (Mehlhop and Diamond, 2006) – at least in 
these models. However, C1q binding to human T cells and opsonization of ICs with 
C1q influences clearly T cell activation and function either directly or via enhanced 
antigen uptake and presentation by APCs (Chen et al., 1994; van Montfoort et al., 
2007), indicating that the roles of complement (activation) fragments/proteins in T 
cell instruction may depend on the infectious agent and the context of infection.  
 
Studies on the roles of complement in T cell activation led in essence to an important 
new finding in the complement field. In previous models, complement receptors and 
regulators were thought to be exclusively activated via complement fragments that 
had been generated from liver-derived and serum-circulating complement. Work on 
T cells showed clearly that immune cell-produced ‘local’ complement activation 
fragments are critical drivers of T cell activation: locally produced complement 
anaphylatoxins C3a and C5a control T lymphocytes expansion and differentiation 
(demonstrated in different in vivo disease models of infection and transplantation) 
either indirectly via modulation of APCs function or via direct stimulation of 
complement receptors and regulators expressed on T cells (Christmas et al., 2006; 
Strainic et al., 2008; Lalli et al., 2008). Studies in mouse showed that C5a generated 
by the T cell and/or APC (via secretion of C3 and C5, Factors B and D and 
subsequent extracellular C3 and C5 convertase formation) binds to the C5aR1 
(expressed by CD4
+







enhancing T cell expansion (Lalli et al., 2008). In particular, the autocrine activation 
of the C3aR and C5aR1 drives the phosphatidylinositol 3-kinase (PI3K), protein 
kinase B (PKB, also known as AKT), mechanistic target of rapamycin (mTOR) and 
MAP kinases (ERK1/ERK2) pathways in APCs and T lymphocytes, connected with 
pro-inflammatory Th1 and Th17 response in vitro and in vivo (Strainic et al., 2008; 
Sarma and Ward, 2012). Conversely, absence of C3aR and C5aR1 is associated with 
activation of TGF-β1 signaling and default induction of FOXP3+ iTregs (Strainic et 
al., 2013). C5aR1 activity also affects DCs function: in the context of TLR2 
stimulation, lack of C5aR1 on DCs promotes Th17 and Tregs responses and 
simultaneously inhibits Th1 induction (Weaver et al., 2010). Local complement 
anaphylatoxins also modulate Th2 immunity, as demonstrated for both C3a and C5a 
in models of allergic asthma: for example, C3aR deficient mice showed attenuated 
airway hyperresponsiveness in a model of pulmonary allergy, associated with 
reduced Th2 cytokines production in the lung, in line with a positive role for 
C3a/C3aR signaling in Th2 induction (Drouin et al., 2002); on the other hand, 
pharmacological targeting of C5aR1 prior to allergen sensitization in a mouse model 
of allergic asthma resulted in significantly augmented Th2-polarised immune 
response and allergy inflammation, suggesting a negative role for C5a/C5aR1 
signaling in modulating Th2 effector functions (Köhl et al., 2006). 
 
 
1.2.3 CD46 and C3aR in Th1 induction 
 
Because this thesis work focuses on the role of the intracellular C5 system in human 
Th1 responses, a detailed introduction is given about the role of complement in the 
regulation of Th1 immunity, with limited excursions into Th2 and Th17 cells. Before 
starting this thesis work, the Kemper group had already established that signals 
mediated by the complement receptors C3aR and CD46, activated in an autocrine 
fashion by T cell-derived complement activation fragments are critical checkpoints 
in CD4
+
 T lymphocytes and Th1 immune responses, controlling the induction, 
effector and contraction phase (Cardone et al., 2010, Le Friec et al., 2012, Liszewski 
et al., 2013, Kolev et al., 2014).  







performed by Astier and colleagues and demonstrated that autocrine CD46 signaling 
induces proliferation and acts as a potent costimulator of human T lymphocytes 
activation (Astier et al., 2000; Zaffran et al., 2001). CD46 is a transmembrane 
glycoprotein which is expressed on all human nucleated cells and prevents 
complement deposition on the host tissues by functioning as cofactor for fI in the 
cleavage and inactivation of C3b and C4b (Yamamoto et al., 2013). CD46 possesses 
four distinct isoforms (Figure 1.2), originating from the alternative splicing of a 
single gene. These isoforms differ in their extracellular O-glycolsylation region 
compositions (termed ‘B’ and ‘C’), and also in the expression of either one of two 
possible cytoplasmic tails, termed CYT-1 and CYT-2 (Wang et al., 2000; Cardone et 
al., 2010) – thus, a combination of CD46 B-CYT-1, B-CYT-2, BC-CYT-1 and BC-
CYT-2 isoform expression is possible. Both cytoplasmic tails are able to transduce 
intracellular signals and resting CD4
+
 lymphocytes mostly express CD46-CYT-2 
(Cardone et al., 2010; Le Friec et al., 2012; Liszewski et al., 2013; Kolev et al., 
2015).  
The critical importance of C3aR and CD46 mediated signals in Th1 induction is 
exemplified by the fact that patients deficient for C3 or CD46 are unable to mount 
Th1 responses in vitro and in vivo and suffer from recurrent infections (Cardone et 
al., 2010; Cope et al., 2011). Of note, these patients have normal cell proliferation 
and Th2 responses, demonstrating that C3 and CD46 are specifically required for 
Th1 induction. Mechanistically, it was shown that CD46 is crucial in up-regulating 
the expression of CD25 (the IL-2 receptor -chain) and CD132 (the IL-2 receptor -
chain), therefore enhancing the ability of T cells to respond to IL-2, a crucial Th1 
supporting growth factor (Kolev et al., 2013). Although C3aR signaling during T 
cell activation is needed for normal Th1 induction (Liszewski et al., 2013), the 
signals driven by the C3aR during cell stimulation are currently undefined.  
Surprisingly, however it turned out that CD46 is also required for the normal 
function of more basic processes of the cell: before starting the PhD project, and 
during a MRes rotation in the Kemper laboratory, I collaborated with Dr. Martin 
Kolev, a postdoc in the lab, on a project aimed at investigating the role of CD46 in 
human T cell metabolism. This work showed that one of the critical additional 
functions of CD46 (aside from IL-2R assembly) is to modulate key metabolic events 
in human CD4
+







phosphorylation (OXPHOS) (Kolev et al., 2015). Upon TCR stimulation, which 
induces the autocrine engagement of CD46, CD46 isoforms bearing CYT-1 are 
upregulated and drive the expression of the glucose and amino acids (AA) channels, 
specifically the glucose transporter 1 (GLUT1, also known as solute carrier family 2 
member 1, gene SLC2A1) and the large neutral amino acid transporter 1 (LAT1, 
alternative name solute carrier family 7 member 5, gene SLC7A5), which promotes 
the nutrient influx necessary for T cell activation. Another gene up-regulated by 
CD46-CYT-1 is the late endosomal/lysosomal adaptor, MTOR activator 5 (gene 
LAMTOR5), which is involved in mTORC1 assembly, an event crucial for the 
induction of the high levels of glycolysis (Kolev et al., 2015), specifically needed for 
IFN- secretion and Th1 induction (Chang et al., 2013). CD46-CYT-1 also drives 
increased OXPHOS in activated T cells and NF-B signaling (Kolev et al., 2015), 
and both these events are associated with the metabolic switches required for the 
induction of T cell effector functions (Mauro et al., 2011; Marelli-Berg et al., 2012). 
The critical role for CD46 in the metabolic reprogramming of CD4
+
 T lymphocytes 
is underpinned by the observation that T cells from CD46-deficient patients have 
defective glycolysis, OXPHOS, Th1 (and Th17) induction (Kolev et al., 2015).  
These data demonstrate not only that autocrine C3-driven signals are needed for 
normal human Th1 induction but that complement, unexpectedly, participates in the 
regulation of key metabolic pathways in immune cells.  
 
 
1.2.4 CD46 in Th1 contraction and homeostasis 
 
Interestingly, C3aR and CD46 mediated signals also contribute to T cell homeostasis 
and Th1 contraction, respectively. With regards to CD46, this occurs when CD46-
mediated signals integrate signals from the IL-2R that respond to increases in high 
environmental IL-2 generated during the expansion of productive Th1 responses. 
This CD46-IL-2R crosstalk induces the coexpression of IL-10 in Th1 cells and with 
that a shift of the effector response toward a (self)regulatory T cell phenotype 
(Cardone et al., 2010), with the cells finally ‘collapsing’ into IL-10 single producing 
T cells.  This CD46-driven switch of Th1 cells (from IFN-+ IL-10– to IFN-+ IL-10+ 







(Cardone et al., 2010). IL-10 co-producing Th1 cells themselves proliferate strongly 
despite their production of this usually anti-proliferative cytokine, but suppress the 




 and  T cells via IL-10 secretion (Barchet et 
al., 2006). It is proposed that this CD46-driven molecular switch regulates the 
‘natural life-cycle’ of Th1 cells with the purpose of keeping immune responses under 
tight control and preventing the local over-production of IFN- leading to tissue 
pathologies. This notion is supported by the observation that dysregulation in this 
molecular switch towards a self-regulatory phenotype has been identified as one 
strong contributing factor to the hyperactive Th1 response in T cells from patients 
with reumathoid arthritis (RA) and multiple sclerosis (MS) (Astier et al., 2006; 
Cardone et al., 2010). The abilities to prevent or to induce this CD46-driven switch 
in Th1 cells constitute a potential therapeutic mean to stop or reduce chronic 
infection and cancer or autoimmunity and organ rejection, respectively. However, 
while there is reasonable understanding about the CD46-driven signaling pathways 
inducing Th1 responses, much less is known about the CD46 and IL-2R crosstalk 
that is vital in switching a Th1 cell into the regulatory IL-10 program. The only clue 
in this regard is the finding that CD46-mediated signals also trigger the switch from 
high glycolytic activity to steady-state glycolysis in CD4
+
 cells during IL-10 co-
production and Th1 contraction; this change from high to low glycolysis level is 
mediated by CD46-CYT-2 isoforms, which become the predominant CD46 isoforms 
in contracting T lymphocytes, similarly to the resting state (Kolev et al., 2015). The 
mechanism regulating the expression of CD46 isoforms has not yet been defined.  
Moreover, there is good evidence that the complement receptors/regulators CR1 and 
CD59 (expressed on CD4
+
 T lymphocytes) also negatively control effector T cell 
responses (Wagner et al., 2006; Longhi et al., 2005). These receptors respectively 
recognise iC3b and the MAC, generated in sequence after the activating complement 
fragment C3b and have been shown to both impact negatively on T cell IFN- and 
IL-2 production as well as cell proliferation.  
 
Surprisingly, complement receptors/regulators expressed by CD4
+
 T cells also 
modulate T cell homeostasis and this is achieved via a novel crosstalk between 
complement and the Notch system: on resting T cells, CD46 functions like a ‘brake’ 







Jagged1 from an interaction with Notch1 that would usually drive Th1 induction (Le 
Friec et al., 2012). Upon T cell and autocrine CD46 activation, the downregulation 
of CD46 on the cell surface allows Jagged1 to bind and activate the Notch1 receptor, 
and this signaling then drives IFN- production. Importantly, T cells isolated from 
patients with Alagille syndrome, that possess a mutated Jagged1, showed impaired 
Th1 (but not Th2) cytokines production in vitro, in line with the fact that these 
patients suffer from recurrent ear and respiratory infections (Le Friec et al., 2012). 
 
 
1.2.5 The concept of intracellular complement activation 
 
Work on the role of complement receptors expressed by T cells in homeostasis of 
this cell type led to the exciting new discovery of a novel location for complement 
activation – demonstrating that complement activation is not confined to the 
extracellular space but can occur within cells. Specifically, human CD4
+
 T cells 
contain intracellular stores of C3 and intracellular lysosomal C3aR and cathepsin L 
(CTSL). CTSL continuously cleaves intracellular C3 into bioactive C3a and C3b in 
resting cells and engagement of lysosomal C3aR by intracellular C3a sustains T cell 
survival via low-level mTOR induction. Upon TCR activation, the whole 
intracellular system translocates rapidly to the cell surface were C3a and C3b signal 
respectively in autocrine fashion via C3aR and CD46 on the cell surface, triggering 
IFN- production and Th1 induction (Kolev et al., 2013; Liszewski et al., 2013) 
(Figure 1.3). Thus, the location of complement activation and subsequent receptor 
engagement (intra- versus extracellular) defines the functional outcome of 
complement activation. Importantly, the intracellular C3 activation system dictates T 
cell survival and the magnitude of Th1 responses as 1. T cells in which intracellular 
C3aR expression is reduced, do not survive (Liszewski et al., 2013) and 2. T cells 
from patients with idiopathic juvenile arthritis have increased intracellular C3 
activation. This hyperactive intracellular C3 system can be normalised by a cell-
permeable CTSL inhibitor, which reverses hyperactive IFN- production in T cells 
from these patients to normal levels. Importantly, intracellular C3 activation has 







likely of broad physiological significance.  
 
Noteworthy, there are substantial differences among species in the complement-
mediated modulation of adaptive immunity. For example, a fully functional murine 
homologue of CD46 has so far not been characterised, thus there is currently no 
availability of a suitable mouse model to validate CD46 function better in vivo; thus, 
the role of the CD46 activation is mostly studied in T cells from healthy donors and 
patients either deficient for CD46 or with Th1-driven autoimmune diseases 
(Yamamoto et al., 2013). However, a critical importance of both C3aR and C5aR1-
mediated signals in Th1 induction has been confirmed in mouse models. For 
instance, studies using C3aR and C5aR1-deficient animals showed clearly that 
autocrine CD4
+
 T cell-derived, but not serum-derived, complement activation 
fragments deliver the ligands for C3aR and C5aR1, which activate the 
PI3K/AKT/mTOR pathway in T lymphocytes and drive Th1 effector responses 
(Strainic et al., 2008; Liszewski et al., 2013; Kolev et al., 2015).  
 
Although the importance of the (intracellular) ‘C3 system’ to human Th1 biology is 
now becoming increasingly acknowledged, the possible existence of an intracellular 
C5 system and its potential role in human CD4
+
 T cells was unexplored at the 





















Figure 1.2 Representative scheme illustrating the structure of CD46 and its four 
isoforms  
Alternative splicing of CD46 transcript generates four different isoforms, all 
composed by four extracellular complement control repeats for ligand binding, a 
variable O-glycosylated region (B and C), a transmembrane portion and one of two 
different cytoplasmic domains (CYT-1 and CYT-2), both able to signal 
intracellularly. These four isoforms are designated BC1, BC2, C1 and C2, with the 
letters referring to the extracellular O-glycosylated portion (B and C portions 
together or C alone) and numbered accordingly to the cytoplasmic tail, CYT-1 or 
CYT-2. 



















Figure 1.3 Complement in Th1 induction and contraction  
C3 activation fragments exert roles in T-cell homeostasis and in the induction of key 
metabolic events during Th1 responses. In resting T cells, the ‘tonic’ generation of 
intracellular C3a via cathepsin L leads to the activation of the C3aR expressed on 
lysosomes and the low level activation of mTOR which sustains T cell survival (left 
part of the cell). TCR activation and CD28 costimulation of resting T cells induces 
the local generation of the CD46 ligand C3b and increased expression of CD46 
isoforms bearing CYT-1 (1, middle part of the cell). Autocrine CD46 CYT-1-driven 
signals then lead to upregulation of genes coding for the glucose transporter GLUT1 
(SLC2A1), and the amino acid channel LAT1 (SLC7A5), allowing for increased 
influx of glucose and amino acids into the cell (2). In parallel, CD46 CYT-1 
mediated signals induce increased expression of LAMTOR5, and via this assembly of 
the lysosome-based machinery enabling amino acid sensing via mTORC1, which 
then leads the induction of glycolysis and OXPHOS required for IFN-γ production 
(3). During Th1 contraction and induction of IL-10 co-expression, CD46 isoform 
expression reverts to a CYT-2 predominant pattern (through a mechanism that is 
currently unknown) and this is accompanied by reduced expression of GLUT1 and 
LAT1, down-regulation of glycolysis and OXPHOS and re-instatement of C3a-
driven low level mTOR activity (right part of the cell).  












1.2.6 The C5a anaphylatoxin and C5a receptors 
 
The cleavage of the complement protein C5 is towards the end of the complement 
activation cascade, where the active, C5-derived products C5a and C5b execute a 
large portion of complement-effector functions (Ricklin et al., 2010). C5 is a 190 
kDa protein, composed of an alpha and a beta chain (~ 120 kDa and ~ 75 kDa, 
respectively) that are connected by disulfide bridges (Sandoval et al., 2000). C5 
cleavage from the amino-terminus of the alpha chain generates the anaphylatoxin 
C5a. Human C5a (~ 15 kDa) is composed of 74 AA, forming a globular protein with 
a four-helix core, stabilised by three disulfide bonds, and a flexible C-terminal ‘tail’ 
(AA 64 to 74) (Zuiderweg et al., 1989; Zhang et al., 1997; Huber-Lang et al., 2003). 
It was long thought that the biological activity and plasma concentration of C5a are 
controlled by the action of carboxypeptidases, enzymes that catalyse the removal of 
the C5 carboxyl-terminal arginine residue (Arg), therefore generating the less potent 
fragment C5adesArg (Bokisch and Müller-Eberhard, 1970; Manthey et al., 2009). 
Circulating C5a and C5adesArg are quickly cleared by the liver, the renal glomeruli 
secretion and the internalization after binding to C5a receptors, thus avoiding 
uncontrolled inflammatory responses due to excessive accumulation of C5a 
(Manthey et al., 2009). However, since it has now been shown that C5a and 
C5adesArg binds to both C5a receptors with similar affinity (Croker et al., 2016), it 
may be possible that des-argination only disactivates C3a.   
 
The C5a anaphylatoxin at nanomolar concentrations is a strong chemoattractant for 
myeloid cells, such as polymorphonuclear neutrophils (PMNs), basophils, 
eosinophils, monocytes and macrophages. C5a also induces other pro-inflammatory 
events, such as smooth muscle contraction, vasodilation, and apoptosis in a range of 
cells. C5adesArg has similar functions, although higher concentrations are required 
to trigger biological responses in some cases. Uncontrolled or unwanted C5a 
generation has been associated with several inflammatory, autoimmune and 
neurodegenerative disorders (Klos et al., 2009; Woodruff et al., 2011), such as 
septicaemia (Ward, 2004), autoimmune arthritis (Hashimoto et al., 2010), and MS 
(Liu et al., 2008). In addition, C5a has been implicated in cancer development, 







invasion and migration, thus preventing anti-tumor immunity (Rutkowski et al., 
2010). Furthermore, C5a is not only a potent immunomodulator, but also participates 
in (re)generative processes, for example, the regulation of embryonic development 
(Denny et al., 2013; Hawksworth et al., 2014). 
 
Aside from instructing innate immune cells, dysregulated modulation of adaptive 
immune responses by C5a participates in disease development in vivo. C5a produced 
by DCs is required for optimal CD4
+
 T cell help in vivo in allograft rejection (Vieyra 
et al., 2011), while limiting normal C5aR signaling during DC stimulation induces 
increased TGF-, and therefore a drive towards Th17 and Tregs responses (Weaver 
et al., 2010). As mentioned above, local C5a is required for the survival and effector 
functions of CD4
+ T cells (Strainic et al., 2008). However opposite effects have been 
ascribed in modulating Th17, with C5a being either a positive or a negative regulator 
in sepsis (Ma et al., 2013) and asthma (Lajoie et al., 2010). In a model of MS, the 
experimental autoimmune encephalomyelitis (EAE), autoreactive Th1 and Th17 
responses have been demonstrated to depend on local generation of C5a (Liu et al., 
2008).  
 
While there is only one C3a receptor, two distinct receptors are able to recognise 
C5a: the C5a receptor 1 (C5aR1 or CD88) and the C5a receptor 2 (C5aR2, 
alternative names C5L2 and GPR77) (Gerard and Gerard, 1991; Cain et al., 2002). 
These C5a receptors belong to the G protein-coupled receptors (GPCR) and seven 
transmembrane domains receptor superfamily (Joost and Methner, 2002): they 
possess an extracellular N-terminus, seven transmembrane domains connected by 
intra- and extra-cellular loops, and a cytoplasmic C-terminus (Findlay and Pappin, 
1986). C5aR1 and C5aR2 are known to have important functions in many 
inflammatory conditions (Monk et al., 2007). While initial studies found that C5a 
binds both receptors with the same affinity (Kd ~2.5 nm) and C5aR2 recognises 
C5adesArg with higher affinity (Kd ~12 nm) than C5aR1 (Kd ~660 nm) 
(Higginbottom et al., 2005), recent work suggests that both receptors bind C5a and 
C5adesArg with similar affinities (Reis et al., 2012; Croker et al., 2014) and the 
reasons for these discrepancies are currently unclear. C5aR1 and C5aR2 are 







granulocytes, lymphocytes, adipocytes, skin fibroblasts, neurons and astroglia of the 
central nervous system (CNS), and in different tissues, such as liver, kidney, lung, 
heart, ovary, testis, thyroid, adrenal gland and spinal cord (Klos et al., 2009; Li et al., 
2013; Klos et al., 2013). However, expression by lymphocytes remains 
controversial, with some reports showing the expression of these receptors on B and 
T cells (reviewed in Klos et al., 2009) and some not (Dunkelberger et al., 2012). 
Another matter of debate is the cellular localization of the C5aR1 and C5aR2 (Sarma 
and Ward, 2012): while studies on PMN cells detected only intracellular C5aR2 and 
both cytoplasmic and membrane surface expressed C5aR1 (Bamberg et al., 2010), 
the expression pattern of these receptors on human T lymphocytes and other immune 
cells has not been clearly defined. 
 
 
1.2.7 The C5a receptor 1 
 
The human C5aR1 was cloned 25 years ago (Boulay et al., 1991; Gerard and Gerard, 
1991) and it has a mass of ~42 kDa with 350 AA. In analogy to the other GPCR, 
ligand binding leads to a conformational change in C5aR1 and the downstream 
activation of guanine nucleotide-binding proteins (G proteins). G proteins are 
composed by three subunits, α, β, and γ, and their activation leads to the following 
events: 1) guanosine diphosphate (GDP) (bound to the Gα subunit) is exchanged for 
guanosine triphosphate (GTP); 2) Gβ and Gγ subunits dissociate from Gα, therefore 
intracellular signals are triggered by molecules such as cyclic adenosine mono-
phosphate (cAMP) and calcium mitogen-activated protein kinases (MAPK); 3) 
signaling is terminated via phosphorylation of the GPCR cytoplasmic tail by GPCR 
kinases (GRKs) and/or recruitment of β-arrestin (Rosenbaum et al., 2009). β-arrestin 
modulates receptor signaling and trafficking (Gurevich and Gurevich, 2006), in 
particular by inhibiting G protein binding (and possibly also by triggering G protein 
independent signals) therefore promoting receptor desensitisation and internalisation 
through clathrin-coated pits (Rajagopal et al., 2010). It seems that, depending on the 
agonist and the resultant conformational changes in GPCR, either the G protein or 
the β-arrestin pathways are preferentially activated (Rajagopal et al., 2010). 







al., 2003), which modulates receptor signaling. Furthermore, the C5aR1-induced 
signaling ability can be inhibited by intracellular proteases: purified neutrophil serin 
proteases, neutrophil elastase, cathepsin G and proteinase 3 cleave C5aR1 to a 26 to 
27 kDa membrane-bound fragment, thereby inactivating this receptor (van den Berg 
et al., 2014).  
 
The binding of C5a to C5aR1 triggers several signaling pathways, including PI-
3K/AKT (Wrann et al., 2007), phospholipase D (Mullmann et al., 1990), protein 
kinase C (PKC) and MAPK pathways (la Sala et al., 2005). C5aR1 signaling 
stimulates: 1) the recruitment of immune cells; 4) the production of cytokines and 
chemokines by immune cells; 3) the expression of cell adhesion molecules by 
endothelial and epithelial cells, and the vasodilatation; 4) the chemotaxis, 
phagocytosis and degranulation by neutrophils (Guo and Ward, 2005).  
Another mechanism, aside from internalisation and desensitation, which modulates 
C5aR1 function is the formation of receptor oligomeric structures: Klco et al. (2003) 
demonstrated the cross-linking of C5a receptors in membranes prepared from both 
human neutrophils and stably transfected Chinese hamster ovary (CHO) cells; the 
formation of oligomers may be linked to C5aR1 cross-modulation or rapid down-
modulation, such as in the severe condition of sepsis. Additional studies further 
demonstrated the ability of the C5aR1 to form homodimers and heterodimers (Geva 
et al., 2000; Hüttenrauch et al., 2005; Klco et al., 2003), where ligation of a 
dimerised C5aR1 can lead to phosphorylation and/or internalization of the partner 
receptor. Particular attention has been given to the ability of C5aRs heterodimers 
formation since it has been discovered that C5aR1 can form heterodimers with the 
C-C chemokine receptor 5 (CCR5), a receptor that facilitates the entry of the human 
immunodeficiency virus (HIV) into the host cells (Hüttenrauch et al., 2005). C5aR1 
can also form oligomers with the alternative C5a receptor, C5aR2, which then 












1.2.8 The C5a receptor 2 
 
The alternative C5a, receptor, C5aR2, was cloned by Ohno et al. (2000), with a 
predicted molecular weight of 37 kDa and length of 337 AA. The C5aR2 is also a 
seven transmembrane receptor and it shares a 35% sequence homology with C5aR1 
(Figure 1.4) (Woodruff et al., 2011). C5aR2 (similarly to C5aR1) contains acidic and 
tyrosine residues in the N-terminal region and hydrophobic and charged residues in 
the transmembrane portion that facilitate binding of C5a (Monk et al., 2007). As 
mentioned before, C5aR2 can under certain circumstances bind C5adesArg with 
higher affinity than C5aR1, most likely due to specific residues at the N-terminus 
(Scola et al., 2007). Further, the intracellular loop 3 of C5aR2 lacks a basic Lys-Thr-
Leu-Lys (K-T-L-K) motif, which is present in C5aR1 and required for signal 
transduction; indeed, no calcium mobilization and MAPK pathway activation have 
been observed in cells stably transfected with C5aR2 upon C5a stimulation (Okinaga 
et al., 2003). Finally, and differently from C5aR1, C5aR2 appears to be uncoupled 
from G proteins, as it lacks the Asp-Arg-Tyr (D-R-Y) motif, which in C5aR1 is Asp-
Arg-Phe (D-R-F) and in C5aR2 is Asp-Leu-Cys (D-L-C), and the Asn-Pro-X-X-Tyr 
(N-P-X-X-Y) motif in the transmembrane helix 7, both motifs required for G protein 
binding (Okinaga et al., 2003). Apart from recognising C5a and C5adesArg, C5aR2 
has also been suggested to act as receptor for C3adesArg, known also as acylation-
stimulating protein (ASP), which is involved in lipid and carbohydrate metabolism 
(Paglialunga et al., 2007). However there is some data controversy among different 
research groups (Johswich and Klos, 2007) and the prevailing opinion is currently 
that C5aR2 cannot bind C3adesArg. 
In most cells and tissues, C5aR2 is co-expressed with C5aR1 and generally at a level 
lower than C5aR1 (Okinaga et al., 2003; Lee et al., 2008; Bamberg et al., 2010). The 
exact C5aR2 expression profile, specifically in human myeloid cells, has been a 
matter of discussion for a long time, and it is now suggested that there is a wide 
variation in C5aR2 surface expression among human cells, possibly due to the cell 
activation status and the cell type, where C5aR2 expression level may modulate 
cellular functions and immune responses (Scola et al., 2009). 
 







role of C5aR2 is still enigmatic, with three main different function hypothesised 
(Figure 1.5): 1) C5aR2 may act as non-signaling decoy receptor, which antagonises 
the pro-inflammatory signals usually triggered by the C5aR1 (Scola et al., 2009); 2) 
C5aR2 can bind to β-arrestins, by which it modulates C5aR1 signaling (Van Lith et 
al 2009; Bamberg et al., 2010); 3) C5aR2 can independently and actively transduce 
either pro- or anti-inflammatory signals, with effects varying in respect to the cell 
type and disease setting (Bamberg et al., 2010; Li et al., 2013).  
The “decoy” hypothesis suggests that C5aR2 may compete with the C5aR1 for C5a 
and C5adesArg bioavailability by sequestering these ligands from the extracellular 
environment and targeting them for intracellular degradation (Figure 1.5, panel A) 
(Okinaga et al., 2003; Scola et al., 2009). This hypothesis is corroborated by the 
observation that C5aR2 is uncoupled from G proteins and that C5aR2 ligands are 
constitutively internalised (via a clathrin-dependent mechanism) and degraded in 
human PMN cells (Klos et al., 2009; Scola et al., 2009; Li et al., 2013). Several 
groups reported that in vitro binding of C5a, C3a, C4a, or their desArg derivatives to 
C5aR2 does not trigger G protein-mediated responses such as degranulation, 
chemotaxis, Ca
2+
 mobilization and MAPK pathway activation, in contrast to C5aR1 
activation (Cain and Monk, 2002; Kalant et al., 2003; Okinaga et al., 2003; Johswich 
et al., 2006; Scola et al., 2009). On the basis of these observations, it has been 
proposed that C5aR2 plays a fundamental role in removing the more abundant 
C5adesArg form from circulation, as ligand internalisation seems more efficient for 
C5adesArg than for C5a (Scola et al., 2009). 
An emerging alternative idea is that C5aR2 engages G protein-independent 
signaling, such as -arrestin mediated pathways (Figure 1.5, panel B) (Defea, 2008): 
C5a-induced translocation of -arrestin 2 has been observed in cells stably 
transfected with C5aR2, where upon C5a binding, the C5aR2 physically interacts 
with both β-arrestin and the C5aR1 to prevent C5aR1-mediated signals, in particular 
ERK1/2 phosphorylation (Cui et al., 2009; Van Lith et al., 2009; Bamberg et al., 
2010). Specifically, in human monocyte-derived macrophages (HMDM), C5a, but 
not C5adesArg, induces heterodimer formation of C5aR1 and C5aR2 (Croker et al., 
2013), where C5aR2 recruits β−arrestin and down-modulates the ERK1/2 signaling 
triggered by C5aR1 (Croker et al., 2014). 







(Figure 1.5, panel C), it has been shown that in vitro stimulation using C5a leads to 
diminished activation of MAPK pathways in neutrophils and macrophages from 
C5aR2
-/-
 animals (Chen et al., 2007), and that, during sepsis, C5aR2 stimulates the 
release of high mobility group 1 box proteins (HMGB1) (Rittirsch et al., 2008), the 
latter playing an important role in the pathogenesis of autoimmune arthritis 
(Andersson and Harris, 2010). 
 
To make the situation even more complex, aside from differences in the signaling 
pathways induced, both anti- and pro-inflammatory effects have been ascribed to 
C5aR2 in vivo in disease models. Both the decoy and -arrestin mediated functions 
are in line with an anti-inflammatory role for C5aR2, where C5aR2 negatively 
regulates C5aR1-mediated responses (Scola et al., 2009). Congruent with this, mice 
deficient for the C5aR2 mounted an exaggerated inflammatory reaction, with 
increased neutrophils influx into the lung and higher levels of IL-6 and TNF- in a 
model of ovalbumin (OVA)-induced pulmonary injury (Gerard et al., 2005). Further, 
increased C5aR2 expression in rat astrocytes is associated with suppression of pro-
inflammatory genes (Gavrilyuk et al., 2005). In a rat model of sepsis-induced by 
cecal ligation and puncture (CLP), C5aR2 protein expression is increased in the liver 
and lung, and blocking C5aR2 via specific antibodies leads to elevated IL-6 levels in 
serum, while rat neutrophils pretreated with a C5aR2-blocking antibody produced 
higher amounts of IL-6 compared to untreated cells in presence of C5a and 
lipopolysaccharide (LPS) (Gao et al., 2005). Similarly, a study of human septic 
patients reported that low C5aR2 expression on PMN cells correlated with sepsis-
induced multi-organ failure and reduced survival, and similar results were observed 
in rats subjected to CLP-induced sepsis (Huber-Lang et al., 2005). In support for an 
anti-inflammatory role in adaptive immunity, C5aR2 was found to be upregulated by 
TGF-β, in turn increasing the induction of anti-inflammatory iTregs (Strainic et al., 
2013). 
In contrast to these experimental evidences, C5aR2 was also shown to support 
C5aR1 activity in neutrophils, macrophages and fibroblasts, therefore having a pro-
inflammatory role in models of sepsis (Gao et al., 2005; Chen et al., 2007; Rittirsch 
et al., 2008) and allergic asthma (Zhang et al., 2010). Specifically, C5aR2-deficient 







cell infiltration, although these mice were more susceptible to LPS-induced shock, 
associated with elevated IL-1 serum levels and high mortality (Chen et al., 2007). 
The same group has also reported attenuated immune complex-induced lung injury 
in C5aR2
-/-
 mice, in contrast with the study from Gerard and collaborators (Gerard et 
al., 2005). Regarding a function in sepsis, it seems that only a combined 
pretreatment with both anti-C5aR1 and anti-C5aR2 antibodies reduce lethality, with 
C5aR2 causing sepsis via release of HMGB1 (Rittirsch et al., 2008). Further, the 
C5aR2 plays a complex role in the pathogenesis of experimental allergic asthma, 
also in regulating adaptive immune responses: C5aR2 acts at the DC/T cell interface 
to suppress Th1 and Th17 polarization and concomitantly drives Th2 cytokine 
production (Zhang et al., 2010).  
 
In conclusion, although it is now broadly acknowledged that C5aR2 activation 
participates in key immunological processes (Li et al., 2013) the exact physiological 
roles of the C5aR2 under both normal and pathological conditions remain a matter of 
debate and likely depend on the cell type that expresses this receptor and the context 























Figure 1.4 C5aR1 and C5aR2 structure  
P-blast alignment of the FASTA protein sequences for human C5aR1 and C5aR2 
(NCBI website), with the conserved C5a binding sites green (extracted from Klos et 
al., 2013) highlighted in and G protein-coupled receptor (GPR) binding sites 


















Figure 1.5 Models for possible C5aR1/C5aR2 interactions and cross-regulations  
The biological role of C5aR2 is not fully explored yet and a matter of controversy in 
the field. Shown are the three current models for its potential function. (A) The 
decoy receptor model states that C5aR2 on the cell surface prevents C5a (generated 
locally or in serum) from binding C5aR1 and thereby inhibits the normally pro-
inflammatory role of C5aR1-driven signals. (B) In the ‘-arrestin-coupling’ model, 
C5aR2 is only expressed intracellularly. When surface C5aR1 binds C5a, this 
complex is internalised and pairs then with the C5aR2 receptor. This complex 
recruits -arrestin, which prevents the usual induction of ERK1/2 phosphorylation 
driven by C5aR1 activation. In the model shown in (C), C5aR2 has an active 
signaling function independent of C5aR1-mediated signals. C5aR2 activation has 
been demonstrated to stimulate the release of HMGB1 (high mobility group box 1) 
protein through MAP kinases phosphorylation and activation.  












1.2.9 Therapeutic targeting of the C5a system  
 
Modulation of the C5a/C5a receptors axis is crucial for elimination of 
pathogens/dangers and equally important in cell homeostasis and disease prevention. 
However, unwanted or uncontrolled C5a generation has been linked to several 
pathologies, including asthma, sepsis, acute lung injury, ischemia-reperfusion injury, 
atherosclerosis, glomerulonephritis, dementia, MS and RA. Thus, approaches 
targeting C5a/C5aRs signaling have been at the center of interest for complement-
targeted therapeutic intervention (Sarma and Ward, 2012).  
A valuable therapeutic strategy is the direct targeting of C5a generation: Eculizumab 
(also known as Soliris) is a humanised monoclonal antibody, developed by Alexion 
Pharmaceuticals (Cheshire, CT), that binds to C5 and prevents generation of C5a and 
C5b and with this also the assembly of the MAC (Thomas et al., 1996). Eculizumab 
is currently approved for the treatment of paroxysmal nocturnal hemoglobinuria, a 
disease characterised by frequent red blood cell lysis, severe anemia and venous 
thrombosis (Hill et al., 2005; Woodruff et al., 2011).  
On the other hand, efforts in targeting the C5aR1 have been concentrated on anti-
C5aR1 antibodies, peptides, and small molecule inhibitors (Monk et al., 2007). A 
selective potent C5aR1 antagonist, with no measurable effects on C5aR2, is PMX53 
(or 3D53), a cyclic hexapeptide derived from the C-terminus of C5a, AcF-
[OPdChaWR], with pIC50 = 7.05 assessed on human neutrophil membranes 
(Strachan et al., 2000, Scola et al., 2007). PMX53 is currently produced by Teva 
Pharmaceutical Industries Ltd (Petah Tikva, Israel) and has completed clinical Phase 
II trials for treatment of psoriasis and RA, unfortunately, without demonstrating 
substantial beneficial effects (Woodruff et al., 2011). In addition, pharmacokinetics 
characteristics limit the therapeutic usage of PMX53, because this compound is 
characterised by a short half-life and is rapidly degraded in the intestinal mucosa 
(Woodruff et al., 2005; Morgan et al., 2008).  
Based on the numbers of studies reporting an anti-inflammatory role for C5aR2, in 
preventing C5aR1 pro-inflammatory signaling, treatments that increase C5aR2 
expression or activity could be used as anti-inflammatory therapeutic intervention 







therefore C5aR2-specific activity has until now been studied in vitro and in vivo by 
using C5aR2 deficient animals, C5aR2 knockdown or blocking antibodies (Croker et 
al., 2016). While several blocking antibodies targeting the mouse, rat, or human 
C5aR2 have been developed and tested in vitro and in vivo (Gao et al., 2005; Cui et 
al., 2007; Lee et al., 2008; Bamberg et al., 2010), the only published antagonists for 
the human C5aR2 is the large molecule C5a antagonist A8
Δ71–73
, which does inhibit 
ligand binding to both the C5aR1 and C5aR2, and therefore it is a double receptor 
antagonist (dRA) (Heller et al., 1999; Otto et al., 2004). However, very recently, 
functional selective C5aR2 ligands have been described, which can recruit β-arrestin 
2, inhibit IL-6 release and C5a-induced neutrophil mobilization in vivo, and 
modulate C5a-induced ERK1/2 activation in HMDMs (Croker et al., 2016). These 
two peptides (P32, Ac-RHYPYWR-OH, and P59, Ac-LIRLWR-OH) at 100M 
concentration showed significant inhibition of 
125I
C5a binding to C5aR2 in 
radioactive binding studies but do not interact with the C5aR1. These ligands 
provide an effective tool for complement researchers to selectively probe C5aR2 
function and deliver a medicinal chemistry template for development of higher 
selective and more potent C5aR2 ligands - that may have potential as treatments for 





















1.3 The NLRP3 inflammasome  
 
1.3.1 A brief introduction to inflammasomes 
 
The execution of the immune system effector functions requires initially appropriate 
PAMPs and DAMPs recognition by PRRs expressed by immune cells. Among the 
key effector functions triggered by PRRs, in particular NLRs, is the induction of the 
assembly and activation of a macromolecular protein complex called 
“inflammasome”. This complex triggers the maturation and production of the key 
host pro-inflammatory cytokines IL-1β and IL-18, fundamental in regulating 
pathogen and danger clearance (Dowling and O’Neill, 2012). Recently, experimental 
evidences demonstrate a role for the complement system (aside from the TLRs as 
‘classic’ inflammasome inducers), particularly engagement of complement receptors 
and regulators on immune cells, either independently or in conjunction with 
incoming signals from other PRRs, in the activation and regulation of inflammasome 
function (Asgari et al., 2013; Samstad et al., 2014).  
 
 
1.3.2 The inflammasome: complex regulating IL-1β and IL-18 
secretion 
 
The inflammasome was first discovered and defined as a functional multiprotein 
complex in the last decade by Martinon (Tschopp et al., 2003). As mentioned above, 
this innate immune sensor regulates the production of the mature pro-inflammatory 
cytokines IL-1β and IL-18, both belonging to the IL-1 cytokine family. These 
cytokines are synthesised as the inactive precursors pro-IL-1β (31 kDa) and pro-IL-
18 (24 kDa) which require proteolytic cleavage mediated by caspases (cysteine-
dependent aspartate-directed proteases), mostly caspase-1, to become mature and 
bioactive IL-1β and IL-18 (both 17 kDa) (Dinarello, 2005; Dinarello et al., 2013). 
Caspase-1 also exists as an inactive preform in cells and it is proteolytically activated 







18, and the active cytokines are then secreted outside of the cell. IL-1 and IL-18 are 
mostly produced by myeloid cells, such as monocytes, macrophages and neutrophils, 
and facilitate their effector functions during the clearance of pathogens and dying or 
damaged self cell (van de Veerdonk et al., 2011).  
 
IL-1β can bind to two receptors expressed on immune cells, the IL-1 receptor 1 (IL-
1R1), whose signal transduction is mediated by the MyD88 adaptor protein, and the 
IL-1 receptor 2 (IL-1R2), that has currently no defined signal transduction function 
(Arend et al., 2008). Other endogenous immune and non-immune cells derived 
ligands for IL-1 receptors are the pro-inflammatory IL-1α cytokine, which is usually 
not activated by inflammasomes, and the natural IL-1 receptor antagonist (IL1RA), 
which does not possess agonistic activity and therefore acts as an antagonist for the 
binding of IL-1α and IL-1β to the IL-1Rs (Dinarello, 1996). IL-1 receptor 1 signals 
via several intracellular adaptor molecules but principally through MyD88, and 
activates different signal transduction pathways, such as NF-B, AP-1 (activator 
protein-1) and p38 MAPK pathways (Arend et al., 2008). Interleukin-1β exerts many 
fundamental function in innate immunity (Sims and Smith, 2010, Di Virgilio, 2013), 
such as: 1) stimulation of immune cells to release other pro-inflammatory cytokines, 
including TNF-α, IL-6, IL-1α and IL-1β itself, 2) induction of release of growth and 
differentiation factors crucial for immune cells, like GM-CSF and granulocyte 
colony-stimulating factor (G-CSF), 3) secretion of vascular endothelial growth factor 
(VEGF) and expression of adhesion molecules on vascular endothelial cells, 
fundamental for cell migration during inflammation, and 4) DCs activation. 
Moreover, IL-1β participates in adaptive immunity and lymphocytes activation, via 
modulation of T cell priming and T helper effector function (Zielinski et al., 2012), 
specifically supporting the differentiation into Th1 and Th17 effector cells (Rao et 
al., 2007) and the generation of memory T cells (Schenten et al., 2014). 
The ‘other’ IL-1 family cytokine that needs to be processed by the inflammasome to 
become fully active is IL-18. This cytokine was originally defined as IFN-γ inducing 
factor, for its ability to stimulate IFN-γ secretion in the serum of mice after 
intraperitoneal injection of endotoxin (Nakamura et al., 1989). The IL-18 receptor 
(IL-18R) has a structure similar to IL-1R1, recruits the same adaptor molecules and 







also secrete a soluble form of the IL-18 receptor, the IL-18 binding protein (IL-
18BP), which sequesters IL-18 therefore inhibiting IL-18 binding to the IL-18 
receptor (Arend et al., 2008). Similar to IL-1β, IL-18 has many functions in the 
regulation of both innate and adaptive immune responses such as: 1) enhancement of 
functional cytokines secretion by NK cells, basophils and mast cells, 2) induction of 
IFN-γ production by T lymphocytes, and 3) sustainance of Th1 and CTLs function 
(Okamura et al., 1995; Smith, 2011; Dinarello et al. 2013). 
Considering the broad range of effector functions triggered by IL-1β and IL-18, it is 
not surprising that dysregulated secretion of these cytokines is a key pathological 
feature of chronic inflammatory, metabolic and autoimmune diseases. 
 
Different inflammasomes, once activated, can assemble and drive IL-1β and IL-18 
maturation. The inflammasome is a multiprotein complex, composed of 
PAMPs/DAMPs sensor molecules, either of the Nod-like receptor (NLR) or the 
PYHIN (pyrin and HIN domain-containing protein) family, caspase-1 and eventually 
adaptor molecules for the interaction among the sensor protein and the caspase 
(Figure 1.6) (Dowling and O’Neill, 2012). 
Over twenty human NLRs have been identified on the basis of their molecular 
structure and phylogeny (Ting et al., 2008; Schroder and Tschopp, 2010), and the 
currently best characterised are NLRP1, NLRP3, NLRP6, NLRP7, NLRP12, all 
composed of the NOD (nucleotide binding and oligomerization domain), LRR 
(leucine rich repeat) and pyrin domains, and NLRC4 (known also as IPAF), 
containing the domains NOD, LRR and CARD (caspase recruitment domain) 
(Figure 1.6). The NLR proteins contain three main domains: 1) an amino-terminal 
death-fold domain involved in the formation of the multiprotein complex, where 
NLRPs contain a pyrin domain, which binds indirectly to caspase-1 through the 
adaptor ASC (apoptosis speck protein, also possessing a pyrin domain), while 
NLRC4 contains a CARD, that can directly bind caspase-1 without need for an 
adaptor molecule; 2) a central NACHT (NAIP (neuronal apoptosis inhibitor protein), 
C2TA (class 2 transcription activator, of the MHC), HET-E (heterokaryon 
incompatibility) and TP1 (telomerase-associated protein 1)) domain, involved in 
nucleotide-binding and oligomerization; 3) carboxy-terminal repeat LRRs that most 







the NLRPs proteins is represented through NLRP1, which has two additional 
domains at the C-termini, a FIIND (function-to-find) domain involved in autolytic 
proteolysis (Finger et al., 2012) and a CARD domain. Both NLRP1 and NLRC4 can 
interact and activate caspase-1 through their CARD domain without recruiting the 
adaptor ASC; despite this, the recruitment of ASC in the case of NLRP1 strongly 
enhances the formation of a functional inflammasome complex (Proell et al., 2013). 
 
The first NLRP inflammasome identified was NLRP1 (previously known as NALP1) 
(Martinon et al., 2002), and it has been found expressed by both immune and non-
immune cells (Kummer et al., 2007). One of the main functions of NLRP1 is the 
protection against infection by Bacillus anthracis via detection of the anthrax lethal 
toxin (LT) (Levinsohn et al., 2012). NLRP1 can also be activated by the bacterial 
wall muramyl dipeptide (MDP) (Hsu et al., 2008). However, the mechanism 
involved in LT and MDP recognition by NLRP1 has not yet been elucidated, and no 
direct binding of these factors to NLRP1 has so far been demonstrated. It has 
therefore been proposed that an indirect mechanism of activation, possibly involving 
K
+
 efflux or cathepsin B release into the cytoplasm may be involved in NLRP1 
activation via these bacterial entities (Ali et al., 2011).  
The activation of NLRP6 inflammasome has surprisingly revealed a protective role 
in preserving host-microbiota homeostasis in the gastro-intestinal tract (Kempster et 
al., 2011) as in vivo studies using models of intraperitoneal microbial infection in 
mice demonstrated that the NLRP6 inflammasome acts as negative regulator of 
innate immunity in pathogens clearance (Anand et al., 2012). In contrast, NLRP7 has 
a ‘classic’ pro-inflammatory role: this inflammasome is involved in microbial 
lipopeptide recognition by macrophages, with subsequent systemic IL-1β release and 
induction of septic shock in a mouse model (Khare et al., 2012). The NLRP12 
inflammasome is among the least characterised inflammasomes, although a recent 
study by Vladimer et al. (2012) demonstrated a specific role for this inflammasome 
in the recognition of Yersinia pestis via promoting the release of both IL-1β and IL-
18, as well as supporting lymphocyte activation and IFN-γ secretion. Another innate 
immune function of NLRP12 is that as a positive regulator of DC stimulation and 
myeloid cells migration during inflammation, as demonstrated in vivo in models of 







In addition to the NLRP inflammasomes, the NLR inflammasome NLRC4 plays a 
key protective role against Salmonella, Shigella, Pseudomonas, and Legionella 
infections (Schroder and Tschopp, 2010). The most characterised NLRC4 
inflammasome activator is the bacterial flagellin, but it has been suggested that also 
endogenous cell components can bind and activate NLRC4 (Mayor et al., 2007). 
Moreover, there is evidence that K
+
 efflux triggers NLRC4 inflammasome activation 
(Arlehamn et al., 2010). However, is has been proposed that NLRC4 acts mostly as 
scaffolding protein and not as direct functional receptor: NLRC4 associates with 
various NAIP (NLR family-apoptosis inhibitory) proteins, and these NAIPs, rather 
than NLRC4, are involved in PAMPs ligand bindings, therefore they can oligomerise 
with NLRC4 to constitute a NAIP/NLRC4 inflammasome (Vance, 2015).  
 
A second key inflammasome family is represented by the PYHIN members, 
annoverating the two inflammasomes absent in melanoma 2 (AIM2) and IFNγ-
inducible protein 16 (IFI16) (Dowling and O’Neill, 2012). AIM2 consists of a pyrin 
domain that recruits ASC and a DNA-binding HIN domain, whereas IFI16 has one 
pyrin domain and two HIN domains for DNA binding (Di Virgilio, 2013). The main 
function of these inflammasomes is the recognition of bacterial and viral dsDNA 
(Hornung et al., 2009). The AIM2 protein possesses an N-terminal pyrin domain and 
a C-terminal HIN200 domain that recognises cytosolic dsDNA. DNA binding drives 
AIM2 heteroduplex formation, displacing the PYD domain (Jin et al., 2012), and 
induces subsequent recruitment of ASC and caspase-1 into the complex (Hornung et 
al., 2009). Activation of the AIM2 inflammasome also involves K
+
 efflux, as 
demonstrated in macrophage activation during Mycobacterium bovis infection (Yang 
et al., 2013). The IFI16 inflammasome has been named based on its ability to be 
induced by interferons. Similar to AIM2, it contains an N-terminal PYD domain, but 
it differs from AIM2 by two HIN domains with the consensus motifs A and B 
(Ludlow et al., 2005). IFI16 has mostly a role in innate responses to nucleic acids 
(Unterholzner et al., 2010), both double-stranded and single-stranded microbial 
DNA (Dowling and O’Neill, 2012). 
 
The best characterised inflammasome, which recognises many different exogenous 







specifically focussed on investigating a role for complement-regulated NLRP3 
inflammasome activity in T cell responses, the following sections in this chapter 
contain an in-depth description of NLRP3 activation, function and involvement in 
human diseases, with a final summarising look at the published evidences of 
complement-mediated NLRP3 regulation.  
 
 
1.3.3 NLRP3 inflammasome structure and activation 
 
Due to the plethora of activating signals and also disease conditions in which it is 
involved, the majority of currently published inflammasome studies focus on the 
NLRP3 inflammasome (Dowling and O’Neill 2012). The NLRP3 gene (alternative 
names NALP3, CIAS1, PYPAF1 or cryopyrin), coding for the NOD-like receptor 
NLRP3, has been identified originally by Hal Hoffman and collaborators (2001): 
they observed that mutations in this gene is associated with the development of 
severe auto-inflammayory conditions, specifically the familial cold 
autoinflammatory syndrome (FCAS) and the Muckle–Wells syndrome (MWS).  
Similar to other NLRs, NLRP3 is composed of an amino-terminal pyrin domain, a 
central NACHT nucleotide-binding and oligomerization domain and carboxy-
terminal LRRs (Figure 1.6) (Dowling and O’Neill, 2012). This discovery was 
followed few years later by the further characterisation of the NLRP3 inflammasome 
complex components: the NLRP3 molecule, the ASC adaptor protein and pro-
caspase-1 (Agostini et al., 2004). ASC is composed of a pyrin domain, which can 
recognise the pyrin domain of NLRP3 and a CARD domain that can interact with the 
CARD domain of pro-caspase-1 (Dowling and O’Neill, 2012).  
 
In homeostatic conditions and resting cells, thus in absence of danger, the NLRP3 
protein (as shown for other NLRs) is normally present in the cytoplasm in an 
inactive state in association with the heath shock protein 90 (HSP90) and the 
ubiquitin-ligase suppressor of the G2 allele of skp1 (SGT1) (Mayor et al., 2007). 
NLRP3 inflammasome activation is induced upon sensing of specific danger signal 







and SGT1 release the NLRP3 protein, which then binds the Pyrin domain of ASC, 
leading to pro-caspase-1 binding to the CARD domain of ASC, via CARD–CARD 
homotypic interactions (Figure 1.7) (Mayor et al., 2007; Dowling O’Neill, 2012). 
Once bound to this complex, ASC is converted to a prion-like shape with generation 
of long molecular filaments, crucial for inflammasome activation (Guo et al., 2015). 
This binding cascade triggers the formation of oligomers (known as “speck” 
complexes) of many molecules of NLRP3, ASC and pro-caspase-1, resulting in pro-
caspase-1 autocatalysis and release the functional caspase-1 fragments p20 and p10; 
therefore, active caspase-1 is able to cleave the pro-inflammatory cytokines pro-IL-
1β and pro-IL18 into their respective mature forms (Figure 1.7) (Dowling and 
O’Neill 2012).  
Importantly, as part of a non-canonical inflammasome ‘platform’, NLRP3 can also 
bind to and activate other caspases aside from caspase-1, such as the human 
caspases-4 and caspase-5 (Schmid-Burgk et al., 2015; Baker et al., 2015) and their 
mouse homolog caspase-11 (Rühl and Broz, 2015), in addition to caspase-8 (Gurung 
et al., 2014). Moreover, the NLRP3 inflammasome can also induce the secretion of 
IL-1α, which lacks the recognition sequence for the protease activity of caspases, via 
a yet unidentified mechanism that does not require the proteolytic cleavage of IL-1α 
cytokine from a precursor form (Yazdi et al., 2013).  
 
The canonical NLRP3 inflammasome-driven caspase-1 activation and subsequent 
maturation of IL-1β and IL-18 has been mostly described both in human and in mice 
in myeloid innate immune cells, such as monocytes and macrophages which 
constitute the main source of IL-1β (Dinarello, 1996, Rao et al., 2007). Furthermore 
a functional NLRP3 inflammasome has been observed recently in several non-
immune cell types, such as microglia (Heneka et al., 2013), endothelial cells 
(Shahzad et al., 2015) and retinal pigment epithelial cells (Cao et al., 2016). NLRP3 
protein expression has been detected also in adaptive immune cells, such as in B and 
T lymphocytes (Kummer et al., 2007) and more recently, a functional role for 
NLRP3 has been investigated in CD4
+
 T lymphocytes in different studies: in a first 
study by Doitsh and collaborators (2014), where NLRP3 has been found expressed 
by CD4
+
 cells were inflammasome activity was connected with pathogen clearance 







1 dependent process required an inflammasome containing ASC but not NLRP3 per 
se and the exact mechanistic function of NLRP3 was not defined in this study.  
Subsequently, Bruchard et al. (2015) found that NLRP3 in the nucleus of mouse 
CD4
+
 T cells can directly bind the DNA via the IRF4 transcription factor, therefore 
modulating expression of the genes associated with Th2 differentiation, including 
Gata3. Noteworthy, these two studies also did not describe a canonical functional 
NLRP3 inflammasome in T lymphocytes. Finally, a very recent work (published 
after this PhD thesis work was finalised) showed the presence of a functional non-
canonical NLRP3/ASC/caspase-8 inflammasome in T cells, which regulates Th17 
response in the murine model of MS, called experimental autoimmune 
encephalomyelitis (EAE) (Martin et al., 2016). Noteworthy, before this experimental 
thesis work, a role for functional inflammasome in Th1 response had not been 
defined. 
 
The NLRP3 inflammasome is activated by two main signals: 1) an upstream priming 
event (Signal 1), consisting of the engagement either of other PRRs, such as the Toll-
like receptor 4 (TLR4) (whose principal ligands are lipopolysaccharides (LPS) 
derived from bacterial walls), or of cytokine receptors, such as the tumor necrosis 
factor receptor (TNFR), thus leading to NF-B activation, nuclear translocation of 
this transcription factor and activation of the transcription of the NLRP3 and IL1B 
genes, followed by their translation into proteins (Bauernfeind et al., 2009); 2) a 
secondary signal (Signal 2) required for functional inflammasome assembly and 
speck formation, driven by several exogenous or endogenous activators (Dowling 
and O’Neill, 2012). Exogenous stimuli driving Signal 2 and NLRP3 inflammasome 
assembly include many different microbial, fungal, viral and parasitic products 
(Dowling and O’Neill, 2012) such as the glycan MDP (Martinon et al., 2004), toxins 
(Mariathasan et al., 2006) and viral nucleic acid (Franchi et al., 2014) and 
environmental polluters such as silica and asbestos (Yazdi et al., 2010), in addition 
to other nanoparticles that can cause sterile inflammation (Di Virgilio, 2013), 
polyester (Demento et al., 2009), titanium oxide (Yazdi et al., 2010; Winter et al., 
2011), carbon (Reisetter et al., 2011), polystyrene (Lunov et al., 2011), gold 







Moreover, the NLRP3 inflammasome can be activated by endogenous molecules 
that accumulate into complexes and cause severe diseases, for example cholesterol 
crystals in atherosclerosis (Samstad et al., 2014), amyloid-β in Alzheimer disease 
(AD) (Heneka et al., 2013), and monosodium urate (MSU) in gout (Cumpelik et al., 
2015). Other endogenous sources of Signal 2 are provided by events occurring 
during cell activation, including increased production of reactive oxygen species 
(ROS) (Zhou et al., 2011), lysosomal damage and release of cathepsin B (Hornung et 




 efflux (Yaron et al., 2015), changes in 
adenosine triphosphate (ATP) production or influx via P2X purinoreceptor 7 (P2X7) 
(Asgari et al., 2013), and also products of glucose and lipid metabolism (reviewed in 
Arbore and Kemper, 2016).  
 
Because many of these endogenous signals are derived from metabolic changes 
accompanying cell (hyper)activation, the NLRP3 inflammasome has now been 
recognised as a cellular sensor for metabolic activity and stress. This notion is much 
in line with the increasing understanding that the ancient PRRs (including 
complement and the TLRs) have all initially been identified as pathogen-fighting 
systems but clearly serve also in sensing self-derived danger and particularly 
metabolic and nutritional imbalances within cells and tissues (Schroder et al., 2010). 
In line with a pro-inflammatory role, NLRP3 inflammasome priming and activation 
is driven by heightened glucose concentration, glucose metabolism and ATP 
production in several cells. Indeed, NLRP3 activity has been associated with type 2 
diabetes, where the higher concentration of circulating glucose activates NLRP3 
inflammasome; in this case activated NLRP3 cooperates with the thioredoxin-
interacting protein (TXNIP), a protein linked to insulin resistance (Zhou et al., 
2010). Further, enzymes and products of both glycolysis and the Krebs cycle partake 
in NLRP3 inflammasome regulation. Beginning with the first glycolytic enzyme 
hexokinase, Moon and colleagues (2015) have recently demonstrated that mTORC1 
driven hexokinase 1 (HK1)-dependent glycolysis is a potent NLRP3 inflammasome 
inducer in macrophages. In addition, another key glycolytic enzyme, the pyruvate 
kinase M2, is involved in LPS-induced NLRP3 activation in macrophages by 
regulating the hypoxia-inducible factor 1 (HIF-1α), a transcription factor that binds 







McDermott et al., 2015). Furthermore, the Krebs cycle product succinate stabilises 
HIF-1α thus enhancing inflammasome function in macrophages (Tannahill et al., 
2013). As product of glycolysis and of increased cellular stress, ATP release is a 
strong driver of inflammasome assembly by activating the P2X7 receptor, therefore 
stimulating IL-1 and IL-18 cytokines release (Asgari et al., 2013; Carta et al., 
2015). Also adenosine on its own is able to sustain NLRP3 inflammasome activation 
induced by LPS, where stimulation of the adenosin A(2A) receptor triggers the 
cAMP/PKA/CREB/HIF-1α pathway, then acting as a priming signal for IL1B 
transcription (Ouyang et al., 2013).  
Importantly, active NLRP3 has been found to colocalise with mitochondria in human 
monocytic cells, and mitochondrial activity (with increased metabolism and 
mitochondrial damage) produce ROS that sustain NLRP3 inflammasome function 
(Schroder et al., 2010). In resting cells, homeostatic metabolism produces low 
intracellular ROS levels, however the oxidative stress associated with cellular 
infection or augmented metabolic demand to execute cell effector function causes 
intracellular accumulation of ROS. All known NLRP3 activators induce ROS and in 
vitro treatment with ROS scavengers blocks NLRP3 activation, therefore ROS are a 
more general indicator of cellular stress (Schroder et al., 2010).  
In addition to ROS production, mitochondrial damage leads also to diminished 
production of the co-enzyme NAD
+
, and this further amplifies inflammasome 
activation. Reduced NAD
+
 co-enzyme also affects the activity of the NAD
+
-
dependent deacetylase sirtuin 2 (SIRT2) involved in de-acetylation of α-tubulin: 
acetylated α-tubulin enhances microtubule polymerization in the cytosol and NLRP3 
trafficking to mitochondria and inflammasome activation, as showed in macrophages 
in response to various inflammasome triggering stimuli (Misawa et al., 2013). 
Conversely, several cell metabolites – and mostly those connected with resting, 
anergic or contracting immune cells – also inhibit NLRP3 inflammasome activity. 
For example, increased lactate, the main product of anaerobic glycolysis, is 
associated with reduced TLR4-mediated inflammasome induction in monocytes and 
macrophages, through a pathway dependent on the lactate receptor G protein-
coupled receptor 81 (GPR81) and arrestin-β 2 (ARRB2) (Hoque et al., 2014). Lipids 
and amino acids also inhibit inflammasome activity:  AMP-dependent protein kinase 







promotes the switch from energy-consuming processes to oxidative metabolism, 
associated with anti-inflammatory and homeostatic states, and favours mitochondrial 
biogenesis (O’Neill and Hardie, 2013). In line with a role for AMPK in negatively 
regulating the NLRP3 inflammasome, it has also been observed that AMPK 
activation driven by mono-unsatured fatty acids attenuate inflammasome function 
and IL-1β secretion in vivo in models of obesity (Finucane et al., 2015). Other 
negative inflammasome regulators include: 1) the ketogenic metabolite β-
hydroxybutyrate (an alternative source of ATP during energy-deficit status) prevents 
K
+
 efflux, ASC oligomerization and specifically NLRP3 inflammasome speck 
formation, but not NLRC4 or AIM2 inflammasome activity (Youm et al., 2015); 2) 
the activation of the N-methyl-d-aspartate (NMDA) receptor (that recognised 
polyunsaturated fatty acids and the amino acids aspartate and glutamate) which 
downregulates inflammasome activity in monocytes, macrophages and Kupffer cells 
via a β-arrestin dependent pathway (Farooq et al., 2014); 3) the prostaglandin E2 
(PGE2), a potent lipid mediator (Sokolowska et al., 2015), which activates the PGE2 
receptor subtype 4 (EP4) which increases intracellular cAMP and mediates blockage 
of  NLRP3 activation (Lee et al., 2013). Indeed cAMP can negatively regulate 
NLRP3 inflammasome via promoting NLRP3 ubiquitination by the E3 ubiquitin 
ligase MARCH7 (Membrane-Associated Ring Finger (C3HC4) 7) and subsequent 
NLRP3 degradation via the proteasome (Yan et al., 2015). 
 
Apart from cell metabolites, specific additional regulatory proteins modulate NLRP3 
inflammasome function. The formation of the NLRP3 inflammasome in response to 
pathogenic microbes and other non-crystalline activators can be promoted by 
guanylate-binding protein 5 (GBP5) (Shenoy et al., 2012). In addition, regulatory 
proteins can also disrupt the inflammasome speck formation. Belonging to the 
CARD-containing proteins that control caspase activity during cell death, CARD8 is 
a binding partner of NLRP3 (Agostini et al., 2004), and proteins with a card domain 
can sequester pro-caspase-1 from its recruitment to a functional inflammasome 
complex. Moreover, the pyrin domain- only proteins POP1 and POP2 interfere with 
the pyrin–pyrin interaction among inflammasome components, such as NLRP3 and 
ASCs (Stehlik et al., 2003; Dorfleutner et al., 2007; Bedoya et al., 2007). 







humans, as genes encoding for COPs (CARD only proteins) and POPs have not yet 
been identified in the mouse (Di Virgilio, 2013). The inflammasome specks 
formation also requires the switch of ASC shape onto long filaments, and that has 
been shown to be regulated also by phosphorylation: upon NLRP3 inflammasome 
activation, ASC is phosphorylated specifically the kinases Syk and JNK (which have 
many different activating stimuli and many downstream targets apart from ASC), 
and inhibition of these kinases blocked speck formation and caspase-1 activation 
(Hara et al., 2013).  
Finally, recent evidences suggest the possibility that inflammasome activation is 
transmitted from cell to cell: dying cells were reported to release ASC specks, 
resulting in the cleavage of extracellular pro-IL-1β and in activation of pro-caspase-1 
in the macrophages internalising the specks. This mechanism of transmission of 
inflammation has serious implications for inflammatory diseases, as inflammasome 
ASC specks injected in vivo into mice are able to propagate the inflammation 



























Figure 1.6 Schematic representation of the most characterised inflammasomes 
Illustration of the structure of the main inflammasomes of the NLR family (NLRP1, 
NLRP3, NLRP6, NLRP7, NLRP12 and NLRC4) and PYHIN family (AIM2, IFI16), 
with respective activating ligands (see text for details). 
Abbreviations: PYD (pyrin domain), NACHT ((NAIP (neuronal apoptosis inhibitor 
protein), C2TA (class 2 transcription activator, of the MHC), HET-E (heterokaryon 
incompatibility) and TP1 (telomerase-associated protein 1)), LRR (leucine rich 
repeats), CARD (caspase recruitment domain), FIIND (function to find domain), 
HIN (hematopoietic interferon-inducible nuclear protein domain), LT (antrax lethal 












Figure 1.7 NLRP3 inflammasome structure and activation 
Inflammasome activation requires two signals, a priming Signal 1 and an ‘assembly’ 
Signal 2.  Signal 1: TLR ligands binds TLRs, leading to NF-kB nuclear translocation 
and activation of both NLRP3 and pro-IL1β transcription. Signal 2: exogenous 
microbial products (PAMPs) and endogenous DAMPs, and intracellular mechanisms 
such as ROS, K
+
 efflux and lysosomal damage, activate NLRP3 (LLRs + NACHT + 
PYRIN domains), that interact with pro-caspase-1 (CARD + p10/p20) via the 
adaptor ASC (PYRIN + CARD), olygomerises and catalises the release of active 
caspase-1. Active caspase-1 cleaves the proteins pro-IL-1β and pro-IL-18 (the latter 
cytokine constitutively expressed), and mediates release of the active cytokines IL-
1β and IL-18. Inflammasome regulates also the secretion of IL-1α from the cell, via 
a yet-unidentified caspase independent mechanism. More details are present above in 
the text.  











1.3.4  NLRP3 inflammasome and human diseases 
 
Apart from the important function as pathogen sensor, NLRP3 is a major sensor for 
cell metabolic activity and stress, and therefore not surprisingly, dysregulation of the 
NLRP3 inflammasome contributes to several metabolic diseases, such as type 2 
diabetes (T2D), obesity, atherosclerosis, gout, colitis and cancer (reviewed in Menu 
and Vince, 2011), all conditions in which chronic inflammation plays a pivotal role. 
T2D is a chronic inflammatory disease characterised by insulin resistance, elevated 
circulating levels of TNF, interleukins and adipokines, cytokine-like proteins 
released from the adipose tissue (Donath and Schoelson, 2011). IL-1β is involved in 
the pathogenesis of T2D via induction of insulin resistance and cellular functional 
impairments including dysregulation of mechanism that control apoptosis (Wen et 
al., 2011). Neutralization of this cytokine by either the IL-1 receptor antagonist (IL-
1RA) or anti-IL-1β antibodies improved control of glucose levels and cell function 
in clinical trials (Larsen et al., 2007; Mandrup-poulsen et al., 2010). Moreover, Lee 
and collaborators observed heightened NLRP3 inflammasome activity in myeloid 
cells from T2D patients when compared to those from unaffected individuals (Lee et 
al., 2013), while mice lacking Nlrp3, Asc or caspase-1 showed improved insulin 
sensitivity and glucose tolerance upon high fat diet (Zhou et al., 2010; Wen et al., 
2011; Stienstra et al., 2011; Vandanmagsar et al., 2011; Stienstra et al., 2012). 
NLRP3 inflammasome in T2D is activated by the increased levels of circulating 
glucose, thus stimulating IL-1β expression by pancreatic β-cells (Zhou et al., 2010), 
and by saturated fatty acids such as palmitate increased through a high-fat diet, as 
palmitate inhibits the inflammasome negative regulator AMPK (Wen et al., 2011). 
Thus, a diet rich in unsaturated fatty acids might ameliorate T2D, as these molecules 
are negative regulators of the NLRP3 inflammasome in vitro (L’homme et al., 2013) 
and in vivo, including the polyunsaturated omega-3 fatty acids (Yan et al., 2013).  
 
Atherosclerosis is a pathology characterised by the progressive narrowing of the 
arterial vessels, due to altered lipid metabolism and accumulation of cholesterol 
crystals and white blood cells on the arterial wall, resulting in reduced flow of 
oxygen-rich blood to the organs (Weber and Noels, 2011). Low-density lipoproteins 







atherosclerosis patients, can induce TLRs therefore providing a priming signal for 
inflammasome activation (Masters et al., 2011). Moreover the cholesterol crystals, 
which accumulate in atherosclerotic plaques, can activate the NLRP3 inflammasome 
through phagolysosomal damage and release of both cathepsin B and cathepsin L 
(Duewell et al., 2010), and recent studies also associate cholesterol crystals with 
direct NLRP3 activation (Samstad et al., 2014, Niyonzima et al., 2015).  
 
Gout is an inflammatory disease where MSU crystals accumulate in various tissues, 
specifically in the joints, inducing acute arthritis (So, 2008). Similarly, pseudogout is 
a pathology characterised by intra-articular deposition of calcium pyrophosphate 
dehydrate (CPPD) crystals (Martinon et al., 2006). Both MSU and CPPD strongly 
induce the NLRP3 inflammasome, in fact mice deficient for Nlrp3, Asc, and 
caspase-1 have diminished release of IL-1β and IL-18 and are protected from 
inflammation in response to intraperitoneal injection of MSU or CPPD (Martinon et 
al., 2006). Clinical trials on gout patients treated with drugs targeting IL-1β, such as 
Anakinra or Rilonacept, demonstrated high efficacy without substantial side effects 
(So et al., 2007; Terkeltaub et al., 2009), therefore therapies tackling also the NLRP3 
inflammasome might be helpful to treat patients for which the use of colchicine, the 
standard gout therapy, is ineffective or contraindicated (Sundy, 2010). 
 
Very recently, the NLRP3 inflammasome has also been associated with 
inflammatory bowel disease (IBD). IBD is a set of chronic inflammatory, relapsing-
remitting conditions characterised by damage of the bowel wall, including ulcerative 
colitis (UC), a superficial colonic inflammation, and Crohn’s disease (CD), a 
transmural inflammation that might affect any part of the gastro-intestinal tract 
(Neurath, 2014). SNPs in the NLRP3 gene in humans have been associated with CD 
(Villani et al., 2009), while increased IL‑1β production by lamina propria cells from 
CD patients has been detected (Youngman et al., 1993). However, using mouse 
models of colitis induced with dextran sulphate (DSS) application, different groups 
found opposing results: NLRP3 knockout (KO) mice are either more susceptible to 
(Hirota et al., 2011) or protected from (Bauer et al., 2010) colitis. The underlying 
reason for these discrepancies may depend in large parts on differences in the gut 







UC and CD predispose to colorectal cancer, where an excessive inflammatory 
response to commensal bacteria appears as the main cause of the neoplastic 
transformation of the intestinal epithelial cells (Menu and Vince, 2011). In line with 
a role for the NLRP3 inflammasome in the modulation of immune responses to 
bacteria and intestinal homeostasis, in vivo studies of colitis-associated cancer, 
induced by DSS and azoxymethane, demonstrated that NLRP3 inflammasome acts 
as negative regulator of tumorigenesis (Allen et al., 2010). In any form of cancer, the 
inflammatory microenvironment is a key factor determining tumor progression. The 
contribution of dysregulated inflammasome activity to cancer is supported by the 
observation that several cancers are characterised by high release of IL-1β (Krelin et 
al., 2007; Reed et al., 2009; Dunn et al., 2012) and concentration in biologic fluids 
of this cytokine is considered a negative prognostic indicator (Zitvogel et al., 2012). 
NLRP3 inflammasome hyperactivation has been observed in the interstitium of solid 
tumors, in concomitance with high concentration of extracellular ATP and 
expression of P2X7 receptor by tumor and infiltrating inflammatory cells (Okamoto 
et al., 2010; Adinolfi et al., 2012). Targeting IL-1β has been considered also a 
therapeutic strategy to fight cancer, however the IL-1β cytokine is also crucial in 
modulating anticancer-specific immunity. Moreover, NLRP3 has a detrimental role 
in tumor development that is independent from its canonical function as part of the 
inflammasome: Bruchard and collaborators (2015) observed that Nlrp3 KO mice are 
protected from metastatic melanoma, where NLRP3 acts as transcription factor that 
facilitates the Th2 response, the latter favouring tumor progression. Thus, 
understanding the circumstances in which the NLRP3 inflammasome is protective or 
detrimental in the specific disease context will help to design specific therapeutic 
approaches to modulate NLRP3 activity in CD and colonic cancer. 
 
Furthermore, NLRP3 inflammasome activity has been associated with diseases 
caused by particulate deposits, such as the neurological disorders MS, Alzheimer’s 
diseases (AD), and age-related macular degeneration (AMD). MS is a pathology of 
the central nervous system (CNS) with currently no effective therapy. In MS, 
myelin-reactive CD4
+
 T lymphocytes attack the oligodendrocytes and induce 
demyelination, with subsequent damage of neurotransmission, resulting in serious 







key role for the NLRP3 inflammasome in MS pathogenesis, because the NLRP3 
inflammasome is known to participate in skewing human CD4
+
 T cells toward the 
proinflammatory Th17 phenotype, driving inflammation in the CNS. Further, in 
clinical studies, higher levels of NLRP3, caspase-1 and IL-1β have been detected in 
peripheral blood mononuclear cells (PBMCs) from MS patients when compared with 
healthy controls (Peelen et al., 2015). However, the role of the NLRP3 
inflammasome in MS is still controversial, as different studies using the EAE in vivo 
model of MS, where disease is induced by immunization with CNS auto-antigens, 
showed opposing results: work by Gris and collaborators demonstrated a detrimental 
role for NLRP3 inflammasome in EAE, as Nlrp3
-/-
 mice have a reduced disease 
severity and Th1 and Th17 responses to brain autoantigens (Gris et al., 2010). 
Notwithstanding, it seems that the role of inflammasome in EAE is not intrinsic to T 
cells, as other researchers observed that CD4
+
 T cells from EAE-induced WT and 
Nlrp3
−/−
 mice delivered into the brain and spinal cord of Rag2
−/−
 mice (which lack 
mature T cells) resulted in a similar degree of disease (Inoue et al., 2012). Another 
study using Nlrp3
-/-
 mice also failed to demonstrate a direct role for the NLRP3 
inflammasome in EAE, while ASC participated in EAE progression by sustaining 
CD4
+
 T cell survival (Shaw et al., 2010). Most recently, a NLRP3-ASC 
inflammasome within CD4
+
 lymphocytes has been found to regulate Th17 response 
in EAE model, via a pathway involving caspase-8 activation (Martin et al., 2016), in 
opposition with the results from Inoue and colleagues (Inoue et al, 2012), where 
intrinsic NLRP3 inflammasome activity was not observed. Even though there are 
conflicting results, it seems that targeting the NLRP3 inflammasome with a specific 
small molecular inhibitor, the MCC950, strongly ameliorates EAE in vivo (Coll et 
al., 2015, see below), although further studies are needed to translate these 
observations into clinical practice.  
Alzheimer’s disease (AD) is characterised by the accumulation of plaques of 
amyloid- in the cerebrum (Heneka et al., 2015). Amyloid- was the first molecule 
found to be able to activate the NLRP3 inflammasome and IL-1 production in vivo 
in a mouse neurodegenerative disease model (Halle et al., 2008). Heneka and 
collaborators also demonstrated that APP/PS1 mice (transgenic mice that develop 







AD-like pathogenesis with diminished amyloid- secretion, neuronal inflammation 
and cognitive damage (Heneka et al., 2013).  
Another disease that affects neurotransmission, specifically of vision, and that has 
been correlated with NLRP3 activity, is AMD (Gao et al., 2015). The loss of vision 
in AMD is partially caused by the accumulation under the retina of molecular 
aggregates known as “drusen”, composed by many components including protein, 
lipids, glycation products and complement, which are able to activate the 
inflammasome (Gao et al., 2015). Some in vivo work has associated NLRP3 
inflammasome activity with retinal epithelial cell degeneration and AMD 
progression (Tarallo et al., 2012). However, another study has shown that NLRP3 
inflammasome, activated by drusen components, might protect from the pathologic 
choroidal neovascularization typical of AMD (Doyle et al., 2012). An in-depth 
understanding of the molecular mechanisms underlying the retinal cell death and the 
neoangiogenesis associated with AMD might allow to design therapies to modulate 
NLRP3 inflammasome function in AMD. 
 
Importantly, the NLRP3 inflammasome has been implicated in the pathogenesis of 
several additional autoinflammatory syndromes, a group of genetically transmitted 
diseases characterised by recurrent fever attacks and systemic inflammation 
(Chitkara et al., 2007). In contrast to autoimmune diseases, autoinflammatory 
disorders lack high-titre autoantibodies or increase in antigen-specific T cells 
(McDermott and Tschopp, 2007). The association of these diseases, including for 
example Behcet’s disease (Bilginer et al., 2010), TNF receptor-associated periodic 
syndrome and systemic juvenile idiopathic arthritis (Kalliolias and Liossis, 2008), 
with inflammasome activity is based by their favourable response to anti-IL-1 
therapy (Menu and Vince, 2011; Masters et al., 2009).  
In addition to these diseases, a specific set of hereditary autoinflammatory disorders, 
known as cryopyrin associated periodic syndrome (CAPS), are caused by over-active 
NLRP3 inflammasome due to a gain-of function mutation in the NLRP3 gene 
(Lachmann et al., 2009). Because this thesis contains work on T cell isolated 
specifically from these patients, a more detailed description of this specific direct 








1.3.5 Cryopyrin associated periodic syndrome 
 
The discovery of the NLRP3 gene by Hal Hoffman (Hoffman et al., 2001) came as 
result of a mapping analysis of the genetic loci associated with a set of inherited 
aseptic autoinflammatory disorders known as “cryopyrinopathies” or “cryopyrin 
associated periodic syndromes” (CAPS). CAPS include the familial cold-induced 
autoinflammatory syndrome (FCAS, early on know as familial cold-induced 
urticaria), the Muckle-Wells syndrome (MWS, or also known as urticaria-deafness-
amyloidosis syndrome, UDA), and neonatal onset multisystem inflammatory 
disorder (NOMID, also known as chronic infantile neurologic cutaneous and 
articular syndrome, CINCA) (Rigante et al., 2016). These three rare diseases of 
childhood onset share clinical manifestations and are likely to represent a continuum 
of increasing severity during time/aging, where FCAS is the mildest and NOMID the 
most severe pathology (Kastner, 2005; Savic et al., 2012). CAPS conditions can be 
traced to at least 170 different autosomal dominant mutations in the NLRP3 gene 
(Rigante et al., 2016) and, in some cases, to somatic mutations appearing during fetal 
development (somatic mosaicism) (Tanaka et al., 2011). All these mutations modify 
the normal structure of the NLRP3 protein, therefore increasing the tendency of 
NLRP3 towards spontaneous protein oligomerization and enhanced inflammasome 
activation resulting in uncontrolled and heightened IL-1 release (Savic et al., 2012). 
The pathologically increased systemic production of this cytokine clinically 
manifests in recurrent outbreaks of periodic fever, skin rashes, fatigue, arthralgia, 
cold sensitivity, conjunctivitis and aseptic meningitis (Rigante et al., 2016). Current 
therapies involve blockage of IL-1β via Anakinra, a soluble form of IL-1 receptor 
antagonist (IL-1RA), or Canakinumab, a monoclonal antibody against IL-1β (Menu 
and Vince, 2011; Lachmann et al., 2009). The human disease can be replicated in 
two knock-in mouse models harboring two mutations associated with MWS and 
FCAS (Brydges et al., 2009; Meng et al., 2009). In particular the mouse model of 
MWS was generated by expression of the mutation Nlrp3A350VneoR 
(NLRP3A352V in the human NLRP3) in the myeloid lineage (crossed with 
LysMCre – meaning mice with the cre cDNA inserted onto the M lysozyme locus 







neonatal period and have heightened amount of circulating IL-1β and IL-18 
(Brydges et al., 2009). Using this MWS in vivo model, it has been recently 
demonstrated that targeting the NLRP3 inflammasome with the specific inhibitor 
MCC950 strongly ameliorates disease in mice (Coll et al., 2015, see below). 
Moreover the same group demonstrated that MCC950 treatment resulted in lower in 
vitro inflammasome activation in PBMCs from CAPS patients. This latter study 
could be the basis for an alternative specific treatment of CAPS diseases via 
targeting directly the NLRP3 mutated protein and the overactive inflammasome 




1.3.6 Inflammasome inhibitors and NLRP3 therapeutic targeting 
 
The NLRP3 inflammasome is an attractive therapeutic target for ar range of diseases, 
including CAPS and the other examples mentioned above, where inappropriate 
NLRP3 activation contributes to the pathogenesis. However, effective activation of 
the NLRP3 inflammasome is fundamental in the host response to pathogens and 
likely also in enhancing the action of vaccine adjuvants, as the resulting products, 
IL-1β and IL-18 cytokines, modulate both innate and adaptive immune responses (Di 
Virgilio, 2013). A better understanding of the mechanism regulating the balance 
between beneficial and harmful NLRP3 inflammasome activity will help to design 
therapeutic approaches that target the deleterious effect of the inflammasome and 
simultaneously preserve its physiological protective functions in the host. To date, 
the mainstream therapies for CAPS and other chronic inflammatory pathologies aim 
at targeting IL-1β, including the drugs Anakinra, Canakinumab and Rilonacept 
(soluble decoy IL-1 receptor), while currently no therapies are in use that target IL-
18 (Dinarello and van der Meer, 2013). The necessity of developing drugs that 
inhibit specifically the NLRP3 inflammasome rises from two main considerations: 1) 
targeting the inflammasome partly preserves the beneficial role of IL-1β in the 
protective responses to pathogen and endogenous danger; 2) another function of 
NLRP3 inflammasome, independent from IL-1β and IL-18 maturation, is the 







release therefore amplifying the inflammatory process, which plays also a key role in 
pathology of CAPS and other autoinflammatory diseases (Brydges et al., 2013). 
Therefore, the possibility to specifically inhibit the NLRP3 inflammasome activation 
offers therapeutic promises. 
Several small-molecule inhibitors targeting specifically NLRP3 have been described, 
such as parthenolide (Juliana et al., 2010), CRID3 (Coll et al., 2011), auranofin 
(Isakov et al., 2014), isoliquiritigenin (Honda et al., 2014), 3,4-methylenedioxy-β-
nitrostyrene (He et al., 2014), cyclopentenone prostaglandin 15d-PGJ2 (Maier et al., 
2015) and 25-hydroxycholesterol (Reboldi et al., 2014), although their mechanism of 
action is not specific for NLRP3 and they do not exhibit substantial potency for in 
vivo usage. Even dimethylsulphoxide (DMSO) itself non-specifically inhibits 
inflammasome activation (Ahn et al., 2014). A small-molecule inhibitor, glyburide, 
which is commonly used for treatment of T2D, was the first compound identified to 
be able to inhibit NLRP3 - but not NLRC4 and NLRP1 – inflammasome dependent 
IL-1β production; glyburide acts downstream of the P2X7 receptor and upstream of 
NLRP3 although via a yet unidentified mechanism (Lamkanfi et al., 2009).  
Most recently, a highly selective inhibitor of the NLRP3 inflammasome, the 
MCC950, has been reported (Coll et al., 2015). MCC950 blocked both canonical 
(ATP, nigericin and MSU) and non-canonical (cytosolic LPS) NLRP3-dependent 
inflammasome activation at nanomolar concentrations, with no effect on NLRC4, 
NLRP1 or AIM2 inflammasomes. As mentioned above, in vivo MCC950 has been 
shown to reduce IL-1β production and to attenuate the severity of the EAE model of 
MS disease. MCC950 administration also rescued the neonatal lethality in a mouse 
model of CAPS (Coll et al., 2015). The mechanism of action of MCC950 is not fully 
understood, although its inhibition of inflammasome activity has been observed in 
association with reduced NLRP3/ASC speck formation. MCC950 is a small 
diarylsulfonylurea molecule, much cheaper to synthesise when compared to the 
recombinant antibodies and proteins currently used as therapeutics, therefore clinical 
trials are warranted to define whether this compound can be used as a more effective 
and cost-efficient therapy for NLRP3 inflammasome-associated inflammatory 









1.3.7 Complement-mediated NLRP3 inflammasome regulation 
 
The involvement of complement in inflammasome modulation is not surprising, as 
these systems share a ‘mutual interest’ in protecting the host against danger: the 
complement system is evolutionarily among the most ancient PRR system (Köhl, 
2006) and there is an acknowledged strong cross-talk between complement and other 
PRRs such as TLRs (Zhang et al., 2007). Recently, complement activators, receptors 
and/or regulatory molecules, either independently or in conjunction with incoming 
signals from TLRs or RIG-Is, have emerged as additional key modulators of NLRP3 
inflammasome function (reviewed in Arbore and Kemper, 2016). Complement-
derived inflammasome modulators include molecules at the beginning of the 
complement cascade, such as C1q, terminal complement activation products such as 
the MAC complex, the receptors for the anaphylatoxins C3a and C5a and possibly 
also the co-stimulatory molecule CD46 (the receptor for C3b) (Figure 1.8).  
 
A functional connection between complement and inflammasome activity had been 
suggested before the inflammasome machinery was discovered: studies already in 
the 1980s by Haeffner-Cavallion and colleagues observed that the anaphylatoxin C3a 
induces IL-1β production by human monocytes (Haeffner-Cavallion et al., 1987). 
More recently, it has been demonstrated that locally produced C3a, which binds in 
an autocrine fashion to the C3aR expressed by human monocytes, increases ATP 
efflux from the monocyte cytosol (through ERK1/ERK2 phosphorylation and 
modulation of a yet-unidentified channel) (Asgari et al., 2013). Therefore, the 
NLRP3 inflammasome, primed by LPS binding TLR4 in vitro in monocytes, is 
activated via this C3a-driven ATP efflux through activation of the ATP receptor 
P2X7, a potent Signal 2 for NLRP3 inflammasome activation (Mariathasan et al., 
2006), and contributes to substantially increased mature IL-1β production by 
monocytes (Asgari et al., 2013).  
Also, signaling through the anaphylatoxin C5a drives both Signal 1 and Signal 2 for 
NLRP3 inflammasome activation (Arbore and Kemper, 2016). Regarding a role for 
C5a in NLRP3 priming, Samstad et al. (2014) showed that C5a generated by human 
monocytes exposed to cholesterol crystals (CC) (which activate both the classical - 







the NLRP3 inflammasome by increasing IL1B transcription in PBMCs. Importantly, 
the C5a-regulated NLRP3 activity has impact on the development of human 
diseases, such as atherosclerosis, where high density lipoproteins might be beneficial 
as they reduce CC-induced complement activation and subsequently diminish 
NLRP3 inflammasome activity in human monocytes and granulocytes (Niyonzima et 
al., 2015). C5a signaling seems to regulate IL1B gene expression via induction of 
NF-B, as demonstrated in non-immune retinal pigment epithelial cells in the 
context of AMD, another disease in which both complement and inflammasome 
activation have been implicated (Cao et al., 2016). C5a delivers not only a priming 
Signal 1 but also the Signal 2 for NLRP3 inflammasome activation. In models of 
gout disease, C5aR1 activation on monocytes potentiates NLRP3 inflammasome 





, lysosomal damage and cathepsin B release (An et al., 2014); this role for C5a 
has been also observed in neutrophils, using a mouse model of peritonitis with 
injection of MSU to induce gout, and in human exudates from the articular joints of 
gout patients (Cumpelik et al., 2015). C5a may activate the NLRP3 inflammasome 
by increasing ROS generation, a general danger signal triggering the inflammasome 
(Schroder et al., 2010): ROS production has been linked tightly with C5a 
anaphylatoxin receptor activation in granulocytes and monocytes (Guo et al., 2003; 
Daniel et al., 2006), and this C5a-mediated ROS release drives the NLRP3 
inflammasome function in PBMCs (Samstad, et al., 2014). A role for C5aR1 in ROS 
generation and subsequent induction of the NLRP3 inflammasome is further 
supported by the fact that C5aR1 activation drives PI3K signaling (Strainic et al., 
2008), which also acts upstream of mitochondrial ROS production and NLRP3 
inflammasome activation (Ives et al., 2015).  
 
In analogy with pore forming toxins which are strong inflammasome inducers 
(Mariathasan et al., 2006), sublytic deposition of the membrane pore-forming MAC 
is also able to activate the NLRP3 inflammasome: in murine DCs, sublytic MAC 
elicits the caspase-1 dependent secretion of IL-1β and IL-18 (Laudisi et al., 2013); 
similarly, in human lung epithelial cells, MAC formation results in increased 
intracellular Ca
2+







transmembrane potential due to Ca
2+
 accumulation in the mitochondrial matrix, and 
this process triggers NLRP3 inflammasome activation (Triantafilou et al., 2013). 
In line with the fact that the complement system is involved in both initiation and 
contraction of immune responses (Yamamoto et al., 2013), another complement 
component, the classic pathway molecule C1q, appears to negatively regulate 
NLRP3 inflammasome activity. This effect has been demonstrated in human 
macrophages where C1q suppresses caspase-1 activation and mature IL-1β 
production during the phagocytosis of apoptotic lymphocytes (Benoit et al., 2012). 
The authors suggest that C1q may indirectly inhibit the inflammasome via positively 
regulating NLRP12 mRNA expression and IL-10 secretion, and both NLRP12 (via 
NF-kB suppression) and IL-10 (through JAK signaling activation) negatively 
modulates NLRP3 inflammasome activation (Kim et al., 2004a; Williams et al., 
2005). Thus, presumably C1q acts as a rheostat in controlling the excessive NLRP3 
inflammasome activation caused by the DAMPs derived from late apoptotic cells 
(Benoit et al., 2012). 
In sum, a picture emerges were complement activation (at distinct locations) clearly 
intersects with the activation and also control of the NLRP3 inflammasome – albeit 
the exact molecular mechanisms underlying this functional crosstalk remain yet to be 















Figure 1.8 Complement-mediated NLRP3 inflammasome regulation  
NLRP3 inflammasome activation requires two distinct signals. The ‘priming’ Signal 
1 is triggered by PAMP/DAMP recognition by PPRs (for example TLRs) and certain 
cytokines (TNF-α) and drives NF-κB nuclear translocation and NLRP3 and IL1B 
gene transcription. Signal 2 induces the assembly of NLRP3, ASC and caspase-1 
supracomplex to form an active NLRP3 inflammasome, where active caspase-1 
processes pro-IL-1β into mature IL-1β. The complement components C1q and 
C5aR1 (together with TNFR and/or TLR signaling) potentiate Signal 1. C5aR1 act 
as a priming signal to sustain inflammasome activation during the uptake of DAMPs, 
with a mechanism involving increased lysosomal damage and cathepsin B release. 
C5aR1 activation directly delivers Signal 2 for NLRP3 inflammasome activation, via 
induction of mitochondrial damage and intracellular accumulation of ROS. The 
C3aR regulates ATP efflux (via a not yet identified channel, denoted by a question 
mark) and subsequent autocrine P2X7 engagement, and sublytic MAC formation 
increases intracellular Ca
2+
 levels and mitochondrial membrane potential. Of note, 
C1q can increase canonical NLRP3 inflammasome activation in epithelial cells 
(Doyle et al., 2012) through a not yet defined mechanism (denoted by a question 
mark) but can also function as a negative regulator of NLRP3 inflammasome 
activation by sequestering DAMPs (such as cholesterol crystals) and inhibiting PPRs 
signaling.  












1.4 Hypothesis and aims of the thesis 
 
The intracellular activation of C3 into C3a and C3b by CTSL and the subsequent 
engagement of C3 activation fragment receptors C3aR and CD46 in an autocrine 
fashion are critical events in normal human Th1 response induction and contraction 
(Cardone et al., 2010; Liszewski et al., 2013). Similary, the role of C5 activation 
products as key drivers in immunological responses is undisputed (Woodruff et al., 
2011). Although there is some literature published that indicates a direct role of 
C5aR signaling on mouse CD4
+
 T cells, the data obtained so far are still 
controversial. Further, the existence of an ‘intracellular C5 system’ and its potential 
role in the regulation of human Th1 immunity has not yet been defined.  
Based on the preliminary observation that exogenous addition of C5a and 
C5adesArg to in vitro activated human CD4
+
 lymphocytes affects IFN- production 
severely and these cells indeed express both C5aR1 and C5aR2 (Claudia Kemper 
and Antonella Fara), the overarching aim of this thesis work was to address the 
initial hypothesis that:  
 
‘Human CD4+ T cells harbor (aside from an intracellular C3 system) also an 
‘intracellular C5 system’ and this system contributes to normal Th1 effector 
responses.’  
 
The initial set of experiments herein reported demonstrated that this hypothesis was 
correct and that intracellular C5a generation and autocrine C5aR1 and C5R2 activity 
are indeed also required for normal human Th1 induction (IFN- secretion) and 
contraction. Further experimental work addressed the molecular mechanism 
underlying C5-driven support of IFN-γ production in human CD4+ T cells. Based on 
data derived from gene arrays using human CD4
+
 T cells that had been activated in 
the presence of C5aR-modulating agents, the following second aim/hypothesis was 
developed: 
 
‘Normal human Th1 immunity requires the intrinsic activity of a C5-regulated 
canonical NLRP3 inflammasome.’ 
  











Results and Discussion Part 1:  
T helper 1 immunity requires complement-



























2.1 Summary of results  
 
As outlined above, and based on preliminary data generated in the Kemper 
laboratory, the initial hypothesis of this thesis work was that:  
 
1. ‘Human CD4+ T cells harbor (aside from an intracellular C3 system) also an 
‘intracellular C5 system’ and this system contributes to normal Th1 effector 
responses’  
and  
2. ‘Normal human Th1 immunity requires the intrinsic activity of a C5-regulated 
canonical NLRP3 inflammasome’  
 
The experiments reported in this thesis, which I performed also in collaboration with 
researchers coming from different institutions (section 2.5), demonstrated the 
validity of these two hypotheses and the work has been published in 2016 in Science 
as a research article entitled “T helper 1 immunity requires complement-driven 
NLRP3 inflammasome activity in CD4
+
 T cells” (Arbore et al., 2016).  
 
The published paper (sections 2.2, 2.3 and 2.4) is incorporated into the pages 83 to 
116 of this thesis. The following points summarise the key findings of the paper: 
 
1. C5 storages and constitutive C5a generation in resting and activated human 
CD4
+
 T cells was demonstrated in vitro by means of flow cytometry staining 
and confocal microscopy. The expression levels and (sub)cellular localization of 
the C5aR1 and C5aR2 were confirmed via RT-PCR, immunoblotting, flow 
cytometry staining, confocal analysis and binding assays using radioactively 
labelled C5a, the latter in collaboration with Professor Andreas Klos (University 
of Hannover, Germany), and demonstrated that resting and activated CD4
+
 T 
cells express the C5aR1 exclusively intracellularly while the C5aR2 is expressed 
both intracellularly and on the cell surface.  
  





2. Using siRNA technique to reduce intracellular C5aR1 expression, a cell non-
permeable C5aR1/C5aR2 double antagonist (which blocked only C5aR2 activity 
on the T cell surface as the C5aR1 is only expressed intracellularly), and a 
specific cell non-permeable C5aR2 agonist (provided by Professor Jörg Köhl, 
University of Lübeck, Germany; Dr. Trent Woodruff, University of Queensland, 
Australia; and Dr. Peter Monk, University of Sheffield, UK), it has been  
demonstrated that the engagement of intracellular C5aR1 by intracellular C5a 
(driven by TCR activation and CD46 co-stimulation) is required for induction of 
normal levels of IFN- (but not IL-4) and that the cell surface expressed C5aR2 
(engaged by secreted C5a/C5adesArg in an autocrine fashion) negatively 
regulates IFN- production in human CD4+ T cells. 
3. Subsequent gene array analyses (in collaboration with Dr. Paul Lavender and 
Dr. Behdad Afzali at KCL) using α-CD3 + α-CD46 versus α-CD3 + α-CD46 + 
dRA activated human CD4
+
 T cells revealed unexpected NLRP3 and IL1B gene 
expression upon in vitro activation, which was further increased for IL1B by 
dRA treatment. Subsequent work using CD4
+
 T cells from healthy donors and a 
range of methods (immunoblotting, mRNA PCR, confocal microscopy and 
FACS analyses) revealed the activation of a canonical NLRP3 inflammasome in 
T cells with subsequent activation of caspase-1 cleavage and generation of 
mature IL-1 (but not IL-18). Further, NLRP3-driven autocrine IL-1 is 
required for normal levels of IFN- secretion, hence Th1 induction.  
4. In collaboration with Dr Helen Lachmann from the National Amyloidosis 
Centre (Royal Free Hospital, UCL, London) and Professor Andy Cope (King’s 
College London), which provided blood specimens of CAPS patients, it has also 
been shown that intrinsic NLRP3 inflammasome activity and thus Th1 responses 
are hyperactive in CD4
+
 lymphocytes isolated from these patients but that these 
can be normalised in vitro by specific inhibition of the NLRP3 inflammasome 
with MCC950 (provided by Professors Matthew Cooper and Luke O’Neill). 
5. Mechanistically, CD46 co-stimulation during TCR activation increases NLRP3 
and IL1B gene expression (Signal 1), while intracellular C5aR1 activation drives 
mitochondrial ROS production (Signal 2) that leads to the assembly of the 
NLRP3 inflammasome and IL-1 secretion supporting Th1 induction. The 
  





mechanism by which surface C5aR2 negatively regulates this process is not yet 
clear but could include a direct negative effect on intracellular C5aR1 signaling 
or a separate, yet undefined regulative pathway.  
6. In collaboration with Dr. Erin West, Professor Warren Leonard, Dr. Katrin 
Mayer-Barber  and Professor Alan Sher (all NIH, USA, MD), the in vivo 
significance of this novel ‘C5-NLRP3-inflammasome’ axis in CD4+ T cells for 
normal Th1 responses was proved: T cells isolated from Nlrp3
–/–
 mice had 
significantly reduced anti-viral CD4
+ 
T cell IFN-γ responses in a model of 
lymphocytic choriomeningitis virus (LCMV) infection and also led to more 
severe disease in T cell transfer models of colitis and graft versus host disease 
(GvHD), as the reduction in Th1 responses induced unrestrained Th17 activity 
in these animals.  
 
In sum, this thesis work demonstrated that ‘the regulated crosstalk between 
intracellularly activated complement components (‘complosome’) and the NLRP3 





























Figure 2.1 An intrinsic complement-NLRP3 axis regulates human Th1 
responses 
T cell receptor activation and CD46 costimulation trigger NLRP3 expression and 
intracellular C5a generation. Subsequent intracellular C5aR1 engagement induces 
ROS production (and possibly IL1B gene transcription) and NLRP3 assembly, which 
in turn mediates IL-1 maturation. Autocrine IL-1 promotes Th1 induction (IFN-γ 
production) but restricts Th1 contraction (IL-10 coexpression). C5aR2 cell surface 
activation by secreted C5a negatively controls these events via undefined 
mechanisms. Dysfunction of this system contributes to impaired Th1 responses in 
infection or increased Th17 responses during intestinal inflammation. 























2.2 Research article summary  






































2.3 Research article main text  
(Arbore et al., Science, 2016) 
 
  



































          
  
























































2.4 Research article supplement 
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Materials and Methods 
 
Antibodies, proteins, agonists and antagonists  
Cell-stimulating mAbs to human CD4
+
 T cells were bought from BD Biosciences, 
San Diego, CA (anti-hCD28, CD28.2), purified from a specific hybridoma (anti-
hCD3; OKT-3) or generated in-house (anti-CD46; TRA-2-10) (3). Mouse T cells 
were activated with anti-CD3 (145-2C11) and anti-CD28 (37.51) from Bio X Cell 
(West Lebanon, NH). The anti-human/mouse NLRP3 (ab4207), anti-human C5 
(ab66850) and C5a (ab11878), anti-human/mouse IL1-β (ab9722) and anti-human β-
actin (ab8226) antibodies were purchased from Abcam (Cambridge, UK). The anti-
human C5a antibody was also biotinylated in house using the APEX™ Biotin-XX 
Antibody Labeling Kit (Life Technologies Ltd, Paisley, UK). Alternative antibodies 
to human/mouse NLRP3/NALP3 (Clone 768319) and human/mouse IL-1β (3A6, 
used for Western blotting and FACS experiments) were purchased from R&D 
Systems (Minneapolis, MN) and Cell Signalling Technology (Beverly, MA), 
respectively. Additional antibodies used include anti-human NLRP3/NALP3 (AG-
20B-0014-C100) and ASC (AL177) from Adipogen (Liestal, Switerland), anti-
hC5aR1 (sc-53795) and anti-hNLRP3 (sc-34408) from Santa Cruz (Dallas, TX), 
anti-hC5aR2 (ID9-M12) and anti-hCD45RA from Biolegend, anti-hIL-1β (12-7018-
81) and anti-hCD4 from eBioscience (San Diego, CA), anti-hC5aR1 (MCA2059; 
AbD Serotec, Oxford, UK), anti-hC5aR2 (PA1-41397; Thermo Scientific 
(Leicestershire, UK)), and anti-hcaspase-1 (3019-100; Biovision (Milpitas, CA)). 
The antibodies recognizing anti-human-CD25, CD45RA (555488), and CD45RO 
(559865) were purchased from BD Biosciences. The following mouse antibodies 
were purchased from Biolegend: Mouse Trustain (Fc-Block), anti-CD44 FITC, PE-
cy7 or BV421, anti-mouse IFN-γ PE, anti-mouse CD4 (APC-cy7, BV 421 or 
BV605), anti-mouse CD45.1 FITC and CD45.2 PerCP, anti-mouse CD45RB FITC, 
anti-mouse CD25 APC. Anti-mouse/human Ki67 was purchased from BD 
Biosciences. The secondary antibodies anti-rabbit IgG H+L chain Alexa Fluor 594 
(ab150076), anti-goat IgG H+L chain PE (ab7004) and anti-goat IgG H+L chain 
Alexa Fluor 488 (ab150129) were from Abcam, while anti-mouse IgG Alexa Fluor 
488 (A11001), anti-rabbit IgG H+L chain Alexa Fluor 594 (A11037) and anti-rat 
IgG H+L chain Alexa Fluor 488 (A11006) were obtained from Molecular 
Probes/Life Sciences (Paisley, UK). APC streptavidin was purchased from 
Biolegend.  
Recombinant active human IL-1β was bought from Abcam and used at 20 ng/ml in 
cultures, recombinant human IL18BPa (Sino Biologicals Inc.) was used at 50 μM, 
human IL-2 was provided by C. Pham (Washington University in Saint Louis, MO) 
and lipopolysaccharide (LPS) was purchased from Sigma Aldrich (Saint Louis, MO). 
Recombinant C5 and C5adesArg were purchased from CompTech (Tyler, TX). The 
specific C5aR1 antagonist (PMX53) (17) was provided by T. Woodruff (University 
of Queensland, AU) and used at 10 μM, the C5aR1/C5aR2 double antagonist a gift 
from J. Köhl (University of Lübeck, Germany) (18) and used at 7 μM, and the 
specific C5aR2 agonist (RHYPYWR) was generated by T. Woodruff and P. Monk 
(Sheffield University, UK) (19) and used at 100 μM. The specific NLRP3 inhibitor 
MCC950 (36) was used at 10 μM, the specific caspase-1 inhibitor Z-YVAD-FMK 
(Abcam) was used at 20 μM and  the reactive oxygen species (ROS) inhibitor 
Diphenyleneiodonium (DPI) (Sigma Aldrich) was added at 750 nM. In all 
experiments, cells were incubated in media for 15 minutes including the compound 
  





of choice (incubation with the corresponding vehicle buffer was used as control) 




Figure legends  
 
Suppl. Fig. 1. Autocrine activation of C5a receptors regulates IFN-γ production 
by human CD4
+
 T cells. (A) C5aR1 and C5aR2 Western blot analyses on 
cytoplasmic (Cyt.) and membrane (Mem.) fractions of resting human CD4
+
 cells 
(representative of n=3). (B and C) Representative flow cytometry histograms for 
intracellular staining (B) and immunoblot with cytoplasmic (Cyt.) and membrane 
(Mem.) fractions (C) on C5aR1 and C5aR2 in HEK293 cells (HEK) transfected with 
a vector expressing either C5aR1, or C5aR2, or an empty control vector (Ctrl. Vec.). 
(D) Binding of radioactively-labelled 
125
I-C5a to HEK293 cells expressing either 
C5aR1, C5aR2 or no C5a receptor in the absence or presence of non-labelled ‘cold’ 
C5a as competitor (n=3). (E) IFN-γ production in CD4+ T cells activated for 36 
hours with α-CD3 + α-CD46 in presence of increasing concentrations of exogenous 
C5a or C5adesArg (n=3), with significance assessed between untreated cells (0 
ng/mL C5a or C5adesArg) and cells treated with indicated amounts of either C5a or 
C5adesArg. (F) IL-17 and IL-4 production by non-activated (NA) and activated (36 
hours) CD4
+
 T cells in the absence or presence of either a C5aR1/C5aR2 double 
receptor antagonist (n=9), a C5aR2 agonist (n=8) or a C5aR1 antagonist (n=7). (G) 
Cell viability of T cells either resting or activated for 36 hours as indicated in the 
absence or presence of the C5aR1/C5aR2 double antagonist or C5aR2 agonist (n=2). 
(H) Reduction of C5AR1 mRNA levels in T cells transfected with either a C5AR1-
specific siRNA or a scrambled control siRNA (Ctrl. siRNA) 48 hours post 
transfection. Left panel shows a representative mRNA expression sample and the 
right sample statistically significant reduction in C5AR1 mRNA expression in 
C5AR1-specific siRNA-treated CD4
+
 T cells (n=6). Error bar graphs represent mean 
± SEM. *p <0.05, **p <0.01, ***p <0.001 (D to G, two-way analysis of variance 
(ANOVA) with Bonferroni’s multiple comparison test; H, paired t-test). 
 
  





Suppl. Fig. 2. NLRP3 inflammasome activation occurs in CD4+ T cells and 
enhances IFN- production. (A) Volcano plot showing transcripts differentially 
regulated in CD4+ T cells from 3 donors after α-CD3 + α-CD46 activation (2 hours) 
with or without addition of the C5aR1/C5aR2 antagonist to cultures. (B) Quantitative 
RT-PCR to measure NLRP3 and IL1B mRNA in non-activated (NA) or α-CD3 + α-
CD46 activated human CD4+ T cells at 36 hours post activation (n=3, expression 
normalized to ACTB). (C and D) Representative NLRP3 expression assessed by flow 
cytometry (C) and by immunofluorescence (D) in non-activated naïve and memory 
human CD4+ T cells (n=3). (E and F) Representative caspase-1 and IL-1β 
immunoblot analyses (with lower arrows depicting the activated protein forms), 
performed on resting and α-CD3 + α-CD46 activated CD4+ T cells (36 hours) and 
resting and LPS activated monocytes (50 ng/ml, 18 hours) (representative of n=4) 
with densitometric analyses on activated caspase-1 and IL-1in T cells. The 
corresponding quantitative data shown below the immunoblots do not depict 
absolute amounts of proteins in monocytes versus T cells. They depict the ratio 
(percentage) of non-cleaved (non-activated) versus cleaved (activated) protein in 
either T cells or in monocytes. (G) IL-17 and IL-4 secretion in CD4+ cells non-
activated (NA) or activated as indicated with or without the NLRP3 inhibitor 
MCC950 at 36 hours post activation (n=7). (H) Cell viability of CD4+ cells either 
resting or activated for 36 hours as indicated in the absence or presence of the 
NLRP3-specific inhibitor MCC950 (n=2). (I) IL-1β secretion by resting (NA) and 
activated CD4
+
 T cells (36 hours) with or without addition of the caspase-1 inhibitor 
Z-YVAD-FMK (n=4). (J) IL-18 production in α-CD3 + α-CD46 activated CD4+ T 
cells (36 hours) from three HDs (left panel) and IFN-γ production in CD4+ T cells 
from HDs 1 and 2 by T cells activated with α-CD3 + α-CD46 for 36 hours in full 
media and for 72 hours in serum free media, in the presence of 50 μM of rIL18BP 
(right panel). Error bar graphs represent mean ± SEM. *p <0.05, **p <0.01 (E and F, 
paired t-test; G to I, two-way analysis of variance (ANOVA) with Bonferroni’s 
multiple comparison test). 
 
Suppl. Fig. 3. T cells from CAPS patients have increased caspase-1 activity and 
IL-1 secretion upon in vitro stimulation. (A) Percentages of naïve and memory 
CD4+ T cell subpopulations in the blood of a second cohort of CAPS patients P8 to 
  





P14 and of three sex- and age-matched healthy donors (HD5-HD7). (B) Correlation 
between active caspase-1 and IL-1β production in T cells from patients P8-P14 upon 
CD3 + CD46 activation (Spearman’s correlation analysis).  
 
Suppl. Fig. 4. C5a receptors regulate NLRP3 activation to modulate IFN-γ 
responses. (A and B) Quantitative RT-PCR to measure IL1B (A) and NLRP3 mRNA 
(B) in resting or α-CD3 + α-CD46 activated (2 hours) human CD4+ T cells in the 
absence or presence of the C5aR1/C5aR2 antagonist with the respective 
corresponding bar graphs (panel below) showing relative expression in activated 
versus non-activated cells with or without C5aR1/C5aR2 antagonist-treated T cells 
(n=3, expression normalized on ACTB). (C) IL-17 and IL-4 production in resting or 
activated T cells in presence or absence of MCC950 and/or the C5aR1/C5aR2 
double antagonist at 36 hours (n=4). (D) NLRP3 expression in CD4+ T lymphocytes 
either left non-activated or activated with α-CD3, α-CD3 + α-CD28 or α-CD3 + α-
CD46 for 36 hours with or without addition of the C5aR1/C5aR2 antagonist (upper 
row) or the C5aR2 agonist (lower row) to cultures (data representative of n=3). (E) 
NLRP3 expression after α-CD3 + α-CD46 activation (36 hours) in T cells transfected 
with either C5aR1-specific siRNA or scrambled control (Ctrl.) siRNA (data 
representative of n=3). Error bar graphs represent mean ± SEM. *p <0.05 (A and B, 
paired t-test; C, two-way analysis of variance (ANOVA) with Bonferroni’s multiple 
comparison test).  
 
Suppl. Fig. 5. Effect of ROS inhibition on IL-17 and IL-4 production by CD4+ T 
cells. IL-17 and IL-4 secretion (shown as % normalized to respective untreated 
conditions) from CD4+ T cells left non-activated (NA) or activated as indicated with 
or without a specific ROS inhibitor and/or the C5aR1/C5aR2 antagonist at 36 hours 
post activation (n=3). Error bar graphs represent mean ± SEM. *p <0.05, **p <0.01, 
***p <0.001 (two-way analysis of variance (ANOVA) with Bonferroni’s multiple 
comparison test). 
 
Suppl. Fig. 6. NLRP3 function in CD4
+
 T cells is required for optimal IFN-γ 
response in vivo. (A) Representative immunofluorescence analysis for NLRP3 and 
IL-1β protein expression on CD4+ T cells isolated from wild type (WT), Nlrp3–/– and 
  











) mice. (B) Percentages of naïve and memory 
CD4
+











 mice (n=3). (C) Cell viability of 
sorted CD4
+
 T cells from WT and knock out mice 96 hours post CD3 + CD28 
activation (n=3). (D) IL-10, IL-4 and IL-17 secretion from CD4
+
 T cells isolated 
from WT and knock out mice activated 96 hours with antibodies to CD3 and CD28 
(n=3). (E) Cell viability of sorted CD4
+
 T cells from WT and Nlrp3
–/–
 mice assessed 
with or without MCC950 addition (right panel) during activation (96 hours post -
CD3 + -CD28 activation, n=4). (F) IL-10, IL-4 and IL-17 secretion from CD4+ T 
cells activated 96 hours with antibodies to CD3 and CD28 from WT and Nlrp3
–/–
mice with or without addition of MCC950 (n=4). (G and H) IFN-γ, IL-10, IL-4 and 
IL-17 secretion from sorted naïve (G) and memory (H) CD4
+







 mice 96 hours post -CD3 + -CD28 activation 
(n=3). Error bar graphs represent mean ± SEM. *p <0.05 (B, E and F, two-way 
analysis of variance (ANOVA) with Bonferroni’s multiple comparison test; C, D, G 
and H, one-way analysis of variance (ANOVA) with Tukey’s multiple comparison 
test). 
 
Suppl. Fig. 7. Lack of intrinsic NLRP3 inflammasome function in CD4
+
 T cells 
impacts on GvHD disease. (A-D) Disease scores and Th1 and Th17 T cell 
populations. T cell-depleted C57BL/6 bone marrow was transferred into lethally 





 T cell from either C57BL/6 or Nlpr3
–/–
 mice. (A) Colon length at study 
endpoint (12 days post-cell transfer). (B-D) Intracellular IFN-γ and IL-17A staining of 
mesenteric lymph node CD4+ T cells at the study endpoint after overnight -CD3 and -
CD28 stimulation and brefeldin A and monensin addition for 5 hours (Gated on live 
CD4+ Thy1.2+ C57BL/6 (H-2KdDd+) T cells). Percent (B) and mean fluorescence 
intensity (MFI) of IFN-γ+ cells (C) and percent IL-17A+ cells (D). For (A-D) n=4 WT, 5 
KO, 2 controls. Error bar graphs represent mean ± SEM. *p <0.05, **p <0.01, ***p 









Suppl. Fig. 8. The C5aR2-NLRP3-IL-1β axis may regulate ‘IL-10 switching’ in 
human Th1 cells. (A) IFN-γ to IL-10 ratio in α-CD3 + α-CD28 or α-CD3 + α-CD46 
activated (36 hours) CD4+ T cells in the absence or presence of either a 
C5aR1/C5aR2 double receptor antagonist (n=9), a C5aR2 agonist (n=8) or a C5aR1 
antagonist (n=7). (B) IL-10 production by resting and activated CD4+ T cells, in 
presence or absence of MCC950 and/or rhIL-1β measured at 36 hours post activation 
(n=3). (C) IL-10 secretion at 36 hours post indicated activation by CD4+ cells from 
the patients with CAPS P8-P14 and seven sex- and age-matched healthy donors 
(HD5-11) with data represented as mean ± SEM. *p <0.05, **p <0.01 (two-way 
analysis of variance (ANOVA) with Bonferroni’s multiple comparison test). 
 
Suppl. Fig. 9. Cytokine production of T cells from C5ar2–/– mice in the presence 
and absence of NLRP3 inhibition. In vitro cytokine production of CD4
+
 T cells 
from wild type and C5ar2
–/– 
mice with or without addition of MCC950 at 48 hours 
post -CD3 + -CD28 activation. Error bar graphs represent mean ± SEM. *p 
<0.05, **p <0.01 (two-way analysis of variance (ANOVA) with Bonferroni’s 











Normalized read values from microarrays for Fig. 2A and B  
Table is provided in Other Supplementary Material as an Excel file.  
 
 
ID p-value Fold change 
C15orf48 0.0118739 2.08331 
C3orf14 0.0327513 2.13952 
CXCL2 0.0330927 5.59906 
DDX60 0.00208813 2.38253 
DTX3L 0.0101958 2.02692 
EIF2AK2 0.00659247 3.45509 
EREG 0.00093681 2.50735 
FAM45B 0.035722 2.16729 
HERC6 0.00197424 2.8311 
HSH2D 0.0219705 2.13182 
IFI44 0.00790994 2.89407 
IFI44L 0.0204978 4.5496 
IFIH1 0.00489751 2.63568 
IFIT1 0.0250406 3.36767 
IFIT3 0.0192085 4.57257 
IFIT5 0.00982865 2.10946 
IL1A 0.0137544 3.52362 
IL1B 0.0053077 2.36807 
IL6 0.0145825 3.11426 
IL8 0.00751255 3.61565 
LAMP3 0.0046064 2.25455 
MX1 0.032786 4.21644 
NM_001199779 
// PSMB2  0.0148295 -2.09297 
OAS2 0.010885 4.16812 
OR4N2 0.0348681 -2.69263 
PARP9 0.0314253 3.3435 
PTGS2 0.00566655 3.80875 
SAMD9 0.0116602 2.07468 
SAMD9L 0.0364514 3.18497 
SERPINB2 0.0268882 3.68178 
TNFAIP6 0.0045844 2.61021 
Table S2. 
Genes differentially regulated by the C5aR1/C5aR2 double antagonist  
Reported the p-value and the fold change (α-CD3 + α-CD46 + C5aR1/C5aR2 double 
antagonist vs α-CD3 + α-CD46) 
  










Age/gender  NLRP3 Mutation Treatment 
1 59 y./female V198M Canakinumab 
2 29 y./female V198M Canakinumab 
3 45 y./male T436I Anakinra 
4 53 y./male 
mut neg (mosaic c.1699G>A, E567K, 
in 5.2% of cells) 
Anakinra 
5 72 y./male A439V Canakinumab 
6 22 y./male R260W Canakinumab 
7 16 y./male R260W Canakinumab 
 
Table S3. 









Age/gender  NLRP3 Mutation Treatment 
8 31 y./female A439V Canakinumab 
9 52 y./female A439V Canakinumab 
10 29 y./female A439V Canakinumab 
11 55 y./female A439V Canakinumab 
12 27 y./female A439V Starting canakinumab 
13 60 y./female A439V Starting canakinumab 
14 67 y./female somatic mosaicism (none in germline) On anakinra for 3 weeks 
Table S4. 
Details of seven patients (8 to 14) with cryopyrin-associated periodic syndrome 














Gene Primer Forward Primer Reverse 
 
C5AR1 5'-CACTAGGGCCCAGAAGAC-3’ 5'-AAGAGTCCCGCTGGAAAAGG-3’ 
 
C5AR2 5’-GCTCTTCCTGTATTTTGGGAGGG-3’ 5’-GCTGGTGGATTTCTTGCTGTCC-3’ 
 
NLRP3 5’-GGCAACACTCTCGGAGACAAG-3’ 5’-GCTCTGGCTGGAGGTCAGAA-3’ 
 
IL1B 5'-CTCGCCAGTGAAATGATGGCT-3' 5'-GTCGGAGATTCGTAGCTGGAT-3' 
 
ACTB 5'-ACGGCCAGGTCATCACCATTG-3' 5'-AGTTTCGTGGATGCCACAGGAC-3' 
 
Nlrp3 5’-AGCCAGAGTGGAATGACACG-3’ 5’-CGTGTAGCGACTGTTGAGGT-3’ 
 
Il1b 5’-ATCAACCAACAAGTGATATTCTCCAT-3’ 5’-GGGTGTGCCGTCTTTCATTAC-3’ 
 
Il1r1 5’-ATGGAAGTCTTGTGTGCCCT-3’ 5’-TCCGAAGAAGCTCACGTTGT-3’ 
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2.5 Individual authors contributions (Arbore et al., Science, 
2016) 
 
I have performed the large majority of the experiments using cells from healthy 
donors and patients and several mouse strains (see below), while Dr. Erin West from 
The National Heart, Lung and Blood Institute at the National Institutes of Health in 
Bethesda, MD (NHLBI, NIH) has performed all key mouse in vivo work and we thus 
shared the first authorship. Professor Claudia Kemper co-ordinated the whole study, 
gave substantial advice in experimental design and data interpretation and helped in 
writing and revising the manuscript. Below, the contributions of all co-authors are 
listed for any single main and supplementary figure of the manuscript. 
 
Figure 1: 
A to F - Giuseppina Arbore 
G - Andreas Klos, Pavel Dutow, Claudia Rheinheimer 
H - Giuseppina Arbore and Claudia Kemper 
I - Giuseppina Arbore 
(Additional input in form of reagents, experimental design and/or data interpretation: 
Jörg Köhl, Trent Woodruff and Pete Monk) 
 
Figure 2: 
A - Behdad Afzali 
B - Behdad Afzali, Matthew Arno 
C to H - Giuseppina Arbore 
(Additional input in form of reagents, experimental design and/or data interpretation: 
Matthew Cooper, Luke O’Neill, Rebecca Coll, Avril Robertson) 
 
Figure 3: 
A - Giuseppina Arbore and Claudia Kemper 
B to F - Giuseppina Arbore 
(Additional input in form of experimental design and data interpretation: Helen 
Lachmann, Andrew Cope) 
  






A to G - Giuseppina Arbore  
 
Figure 5: 
A - Giuseppina Arbore  
B - Claudia Kemper 
C - Giuseppina Arbore 
 
Figure 6: 
A - Giuseppina Arbore 
B and C - Erin West, Claudia Kemper, Katrin Mayer-Barber 
D - Giuseppina Arbore and Erin West 
E to H - Erin West and Katrin Mayer-Barber 
(Additional input in form of reagents, experimental design and/or data interpretation: 
Warren Leonard, Alan Sher, Luke O’Neill, Matthew Cooper) 
 
Figure 7: 
A and B - Erin West and Rosanne Spolski 
C - Zu Xi Yu 
D and E - Erin West and Rosanne Spolski 
 
Supplementary Figure 1: 
A - Giuseppina Arbore  
B - Giuseppina Arbore, Andreas Klos, Pavel Dutow, Claudia Rheinheimer 
C - Giuseppina Arbore 
D - Andreas Klos, Pavel Dutow, Claudia Rheinheimer 
E - Claudia Kemper 
F - Giuseppina Arbore and Claudia Kemper 
G and H - Giuseppina Arbore 
 
Supplementary Figure 2: 
A - Behdad Afzali  
B to J - Giuseppina Arbore 
  





Supplementary Figure 3: 
A - Giuseppina Arbore and Claudia Kemper 
B - Giuseppina Arbore 
 
Supplementary Figure 4: 
A to E – Giuseppina Arbore 
 
Supplementary Figure 5: 
Claudia Kemper 
 
Supplementary Figure 6: 
A - Giuseppina Arbore  
B - Erin West and Katrin Mayer-Barber 
C and D - Erin West and Claudia Kemper 
E and F - Erin West  
G - Erin West and Claudia Kemper 
H - Erin West 
 
Supplementary Figure 7: 
A to C - Erin West and Rosanne Spolski 
D - Erin West 
 
Supplementary Figure 8: 
A to C - Giuseppina Arbore  
 
Supplementary Figure 9: 













2.6 Discussion  
 
The novel findings that came out of this thesis work are that: 1) C5 activation can 
occur intracellularly: 2) a canonical NLRP3 inflammasome is operative in CD4
+
 T 
cells and required for normal Th1 responses; 3) the regulated crosstalk between 
intracellular C5 activity and the NLRP3 inflammasome is needed for the induction 
but also regulation of IFN- secretion by CD4+ T cells.  
 
Because a ‘C3 system’ in CD4+ T cells had been described as key regulator of T cell 
effector functions previously (Cardone et al., 2010; Liszewski et al., 2013), the 
existence of an intracellular C5 activation system was likely. However, the 
expression of the C5aRs on mouse and human T lymphocytes is a matter of 
controversy in the field: work with green fluorescent protein (GFP) reporter mice 




 T cells 
(Dunkelberger et al., 2012; Karsten et al., 2015). However, the insertion of 
fluorescent reporter proteins can transcriptionally destabilise the mRNA of the 
targeted gene (Reinhardt et al., 2015) and, moreover several published papers 
endorse C5aR1 expression in mouse and human T lymphocytes (Nataf et al., 1999; 
Strainic et al., 2008; Lalli et al., 2008; Strainic et al., 2013; Kwan et al., 2013). Thus, 
for the purposes of this thesis, particular emphasis was put on thoroughly and 
conclusively assessing the expression/presence of C5, C5a and the C5aRs on human 
T cells together with the help of leading experts and a solid range of technical 
approaches. C5 expression and low-level C5a generation were indeed observed in 
the resting state of T cells, while C5a intracellular generation increases upon in vitro 
activation (Figure 1 and supplementary Figure 1, Arbore et al., 2016). Importantly, 
the mechanism mediating intracellular C5 cleavage in activated T lymphocytes has 
not been pursued in this study and warrants further investigations. As the Kemper 
laboratory has previously ruled out that cathepsin L (which activates C3 
intracellularly) cleaves C5 (Liszewski et al., 2013), candidates could include other 
proteases or possibly even an intracellular C5 convertase. The latter may be a real 
possibility as ongoing work in the laboratory by other members has indeed detected 
the generation of the Factor B neo-epitope (Bb), which is indicative of the alternative 
  





pathway C3 convertase formation within T cells. Further, the data published 
demonstrate that at least in human CD4
+
 T cells, the C5aR1 is expressed only 
intracellularly while the C5aR2 is found within cells and on the cell surface. Thus, 
this work provides the first conclusive description of intracellular C5 expression and 
activation as well as the C5a receptors expression pattern in human CD4
+
 T cells – 
findings supporting a paradigm shift centralised around the notion that complement 
activation is not only confined to the extracellular space but occurs intracellularly 
and that CD4
+
 T lymphocytes contain indeed a full intracellular complement system, 
the ‘complosome’ (Kolev et al., 2014). 
There is a long list of yet unanswered questions. Some key questions surrounding the 
C5aRs system that need to be addresses are: 1) the variations in protein expression 
and cellular localization of C5aR1 and C5aR2 (to assess by flow cytometry and 
confocal microscopy); 2) a possible C5aR1/C5aR2 interaction (to investigate by 
super-resolution microscopy and immunoprecipitation/immunoblotting techniques);  
3) how the surface expressed C5aR2 negatively regulates Th1 immunity (see below); 
4) the potential functions of  the C5aR2 localised into the cytoplasm. 
 
The subsequent functional analysis of the role of the intracellular C5aR1 and 
extracellular C5aR2 then demonstrated that the engagement of intracellular C5aR1 
by C5a is required for induction of normal levels of IFN- (but not IL-4) and that the 
cell surface expressed C5aR2 (engaged by secreted C5a/C5adesArg in an autocrine 
fashion) negatively regulates IFN- production in human CD4+ T cells (Figure 1 and 
supplementary Figure 1, Arbore et al., 2016). Interestingly, the fact that modulation 
of the T cell ‘C5 system’ did not affect IL-4 secretion (Th2 responses) aligns well 
with our current understanding that autocrine C3 activity is particularly important in 
the regulation of IFN-secretion (Liszewski et al., 2013; Kolev et al., 2014) – and 
indicates that both the autocrine C3 and the C5 system are needed for optimal Th1 
immunity.  
Gene array analyses using α-CD3 + α-CD46 versus α-CD3 + α-CD46 + dRA 
activated human CD4
+
 T cells, which were supposed to give a hint about the 
pathways regulated by the C5 system that is driving IFN- revealed NLRP3 and 
IL1B gene expression by activated human CD4+ T lymphocytes (Figure 2, Arbore et 
  





al., 2016). This observation was unexpected because so far canonical NLRP3 
inflammasome activity has not been described in adaptive immune cells. Myeloid 
and particularly monocytes and macrophages were thought to be major NLRP3 
inflammasome-operative cells as they are also the largest producers of IL-1 
(Dinarello, 1996, Rao et al., 2007). Although there was indication that NLRP3 
expression may be more ubiquitous as it was also later found in endothelial cells, 
epithelial cells and neurons (Heneka et al., 2013; Shahzad et al., 2015; Cao et al., 
2016), early reports on potential presence of NLRP3 in T cells were dismissed and 
thought to be contaminations with monocytes.  
 
However, in vitro and ex vivo work carefully performed with T cells from healthy 
donors and from CAPS patients showed then clearly the ‘classical’ function of an 
NLRP3 inflammasome in human CD4
+
 T cells with the secretion of mature IL-1 as 
‘end product’ (Figure 2 to 4 and supplementary Figure 2 to 4, Arbore et al., 2016). 
Further, full activation of the NLRP3 inflammasome requires C5aR1-driven ROS 
activation (Figure 5 and supplementary Figure 5, Arbore et al., 2016). These 
observations align with the previous knowledge that the C5aR1 is a key ROS inducer 
in monocytes and neutrophils (Guo et al., 2003; Daniel et al., 2006). It was, 
however, always assumed that cell surface C5aR1 activation drives ROS production 
in these cells – and the data observed during this thesis work suggest that it may be 
worthy to assess if ROS production in monocytes and neutrophils may also be (at 
least in part) dependent on intracellular C5a activity. This may be important for 
sterile inflammation as C5aR1 triggers augmented ROS generation upon cholesterol 
crystal uptake and induced the inflammasome in myeloid cells (Samstad et al., 2014) 
- and there is now indeed indication that the intracellular C5aR1 is instrumental in 
these cells (Kemper laboratory, unpublished data).  
 
Nonetheless, is also likely that other complement-mediated pathways (aside from 
ROS) contribute to the modulation of the NLRP3 inflammasome function in T cells. 
A candidate initially considered as potential C5a-driven inflammasome activator in T 
cells was the S100A8/S100A9 (calprotectin), a TLR4 ligand (Ehrchen et al., 2009), 
because S100A8/S100A9 expression was also modulated in T cells from individuals 
with complement dysregulation (data not shown). This was indeed an attractive 
  





candidate initially because a mechanistic interplay between complement and S100A8 
has previously been reported, where C5a can stimulate the release of S100A8 from 
PBMCs (Hetland et al., 1998), while with regards to inflammasome activity S100A8 
is also a molecular marker of CAPS disease progression (Wittkowski et al., 2011) 
and a driver NF-kB activation and ROS production, thus activating the NLRP3 
inflammasome (Simard et al., 2013). Following these considerations, immunoblot 
and immunostaining analysis on human CD4
+
 T cells proved indeed S100A8 protein 
expression, which is higher in the activated status and increased by C5aR2 
antagonism (dRA) but not by MCC950 addition (data not shown), in support of the 
hypothesis that this ligand is regulated by autocrine C5a-mediated pathways 
upstream of inflammasome activation. However, additional experiments performed 
in the course of this thesis project were unable to reduce S100A8/S100A9 protein 
expression by silencing RNA technique and could, thus, not assess its function 
within the C5/NLRP3 inflammasome axis in T cells.  
A second protein of interest is the inflammasome assembly regulator GBP5 (Shenoy 
et al., 2012), as GBP5 is among the most up-regulated genes by CD4
+
 T cells 
activated upon C5aR2 antagonism (data not shown). Although GBP5 expression has 
not yet been shown in T cells, it has recently been identified as a ‘rheostat’ of 
NLRP3 inflammasome activation in mouse monocytes (Shenoy et al., 2012). Thus, 
the functional connection between C5a and GBP5 expression may be fruitful area of 
research for the future.  
Of course, the definition of how C5aR2 may negatively regulate these events is of 
critical importance as it would possibly deliver the means for new therapeutic 
interventions for T cell-mediated diseases: extracellular engagement of 
C5a/C5adesArg to C5aR2 down-modulates the NLRP3 inflammasome either directly 
via a yet unidentified mechanism or indirectly by inhibiting intracellular C5aR1. 
C5aR2 is likely to achieves this inhibitory effect via engagement of -arrestins: 
noteworthy, ARRB2 can interact with other GPCRs, such as GPR40 and GPR120 
activated by omega-3 fatty acids (Yan et al., 2013) and the lactate receptor GPR81 
(Hoque et al., 2014) to dampen NLRP3 inflammasome activation; in addition, 
ARRB2 can associate with C5aR2 to inhibit C5aR1-driven ERK1/2 signaling 
(Croker et al., 2014). Thus, it would be interesting to assess in the future if these 
pathways are engaged in T cells upon C5aR2 stimulation and regulate Th1 activity. 
  





Regarding a role for autocrine C5 system in mouse, higher in vitro IFN-γ secretion 
has been observed in C5aR2 deficient CD4
+
 cells, which is normalised by the 
inflammasome inhibitor MCC950, demonstrating an anti-inflammatory role for this 
receptor (supplementary Figure 9, Arbore et al., 2016). Conversely, the notion that 
autocrine C5a-driven C5aR1 positively regulates Th1 responses is supported by 
other studies showing a clear defect in IFN-γ production by CD4+ T lymphocytes 
from C5
-/-
 (Mashruwala et al., 2011) or C5ar1
-/-
 mice (Strainic et al., 2008). 
However, there are differences among the mouse and human species in expression of 
complement receptors and regulators (see Chapter 1) and this is most clearly 
demonstrated for CD46 (Kolev et al., 2014), therefore making difficult to compare 
the complement contribution to inflammasome activity in T cells among the mouse 
and human species. 
 
Another surprising observation coming out of this work is that autocrine IL-1 
production by CD4
+ 
T cells is critical for normal in vivo Th1 induction (Figure 6 and 
7 and supplementary Figure 6 and 7, Arbore et al., 2016). CD4
+
 T lymphocytes from 







) showed reduced IFN-γ production upon in 
vitro activation, without an effect on IL-4, IL-17 and IL-10 cytokines and on cell 
viability. But importantly, in all three in vivo experiments (the LCMV infection, the 
colitis and the GvHD models), Nlrp3 KO T cells (or T cells deficient in Il1b or 
Il1r1) (Mayer-Barber et al., 2014) were injected into animals in which all other cells 
were fully capable of making IL-1 in normal amounts. Nonetheless, IFN- 
production was decreased by about half in all models - and neither the expression of 
the key Th1 lineage transcription factor T-bet (Lugo-Villarino et al., 2003) nor cell 
viability were affected (unpublished data and Arbore et al., Science, 2016).  
Although in the experiments for this thesis it has been observed basically no direct 
intrinsic effect of the canonical NLRP3 inflammasome on Th2 and Th17 cytokines 
production in vitro and in vivo (supplementary Figure 2 and 6, Arbore et al., 2016), it 
should be noted that exogenous IL-1β is known to boost also Th2 and Th17 
responses apart from Th1 (Ben-Sasson et al., 2009). Thus, IL-1β effects in general 
on T cell responses may be context dependent. In fact, intrinsic NLRP3 protein (but 
not inflammasome) activity in CD4
+
 T cells has been shown to act as transcriptional 
  





activator of Th2 differentiation (Bruchard et al., 2015) and to drive Th17 response in 
vivo in EAE as part of an inflammasome complex (Martin et al., 2016). Noteworthy, 
both these studies investigated Th1, Th2 and Th17 in vitro responses under 
exogenous skewing stimuli, while in the work here reported, for both human and 
mouse in vitro data, the experimental set-up throughout is not traditional in vitro Th1 
skewing with IL-12 and anti-IL-4 (to avoid ‘masking’ any observations by addition 
of non-physiological levels of cytokines) but activation of CD4
+
 T cells with anti-
CD3 and co-stimulation under non-polarising conditions. Furthermore, in many 
published studies using mouse systems, NLRP3 inflammasome-driven IL-18 
production also contributes heavily to Th1 responses while our data indicate that at 
least human CD4
+
 T cells do not produce IL-18 and do not rely on an intrinsic 
function of this cytokine (supplementary Figure 2J, Arbore et al., 2016). 
Given that APCs provide generally ample amounts of IL-1 during the cognate 
APC/T cell interaction, the finding that normal IFN- production requires also T cell 
autocrine IL-1 production was unexpected. The exact reasons for this are not yet 
clear but it is likely that, while APC-derived NLRP3-activated IL-1β supports initial 
Th1 priming, successful ‘imprinting’ or maintenance of the Th1 phenotype during 
differentiation and migration into the periphery may require autocrine NLRP3 
activity. It would therefore be a valuable experiment to assess if autocrine IL-1 may 
impact on epigenetic changes in the DNA landscape.  
IL-1β production by T cells, in comparison to myeloid cells, is relatively low and 
tightly regulated by an autocrine C5aR1 versus C5aR2 activation balance. The 
probable reason for this is that rapid control of local IL-1β is critical to normal 
termination of Th1 responses: human Th1 cells co-induce IL-10 secretion in a CD46-
dependent fashion (section 1.2.4 of this thesis) during their contraction phase and 
failure of this ‘IL-10 switch’ underlies hyperactive Th1 responses observed in 
rheumatoid arthritis and multiple sclerosis (Astier et al., 2006; Cardone et al., 2010). 
IL-1β strongly suppresses IL-10 production by effector Th17 cells (Zielinski et al., 
2012) and, accordingly, it has been observed that blockade of C5aR2 increases the 
IFN-γ:IL-10 ratio in CD4+ T cells while IL-1β addition to the activated cells 
increases IFN-γ but blocked proportional IL-10 secretion. Fully in line with this, T 
  





cells from CAPS patients have significantly reduced IFN-γ to IL-10 switching 
(supplementary Figure 8C, Arbore et al., 2016).  
 
The adoptive T cell transfer models using Nlrp3 deficient CD4
+
 T cells, to induce 
colitis and acute GvHD disease in mice (Figure 7 and supplementary Figure 7, 
Arbore et al., 2016), gave also a very surprising finding. It was initially expected that 
mice injected with the Nlrp3 deficient CD4
+
 T cells would have less severe disease 
or later onset because of reduced Th1 responses, which are acknowledged to play a 
role in these settings (Powrie et al., 1994; Nikolic et al., 2000). However, the mice 
injected with the Nlrp3 deficient CD4
+
 T cells had clearly more severe disease in 
both models when compared to animals injected with WT cells. Assessment of other 
cytokines affected in these models then showed that the reduced in vivo Th1 
induction (due to lack of intrinsic NLRP3 inflammasome activity in CD4
+
 T 
lymphocytes) tips the balance towards Th17 responses and via this causes more 
severe disease. In full concordance with the finding that Th1 and Th17 responses 
counter-regulate each other, activated CD4
+
 T cells from CAPS patients (overactive 
NLRP3) produce higher IFN- and lower IL-17 in vitro (Figure 3E, Arbore et al., 
2016). This may also explain why many patients fail to have obvious T cell-mediated 
autoimmune symptoms. My findings also explain why the role of NLRP3 was 
discussed so controversial in the field of IBD: Th17 response is associated with 
colitis (Coccia et al., 2012) and regulated by paracrine IL-1 from APCs and in one 
study, lack of Nlrp3 indeed reduced disease severity (Bauer et al., 2010). However, 
similarly to the data herein shown, Hirota and colleagues (2011) observed higher 
susceptibility to colitis in Nlrp3 KO mice (however colitis was induced by DSS 
exposure and not CD4
+
 cell transfer, not discriminating the role for NLRP3 in 
different myeloid and lymphoid cell subsets), although discordant studies have been 
reported (Bauer et al., 2010). Thus, it is now clear that it is important in which cell 
type NLRP3 activity is modulated and there are obvious different effects of paracrine 
and autocrine IL-1 functions in the intestine. These considerations led to the start of 
a follow-up project in collaboration with the clinicians Dr. Nick Powell and 
Polychronis Pavlidis (from King’s College London) to investigate whether the 
intrinsic CD4
+
 T cells complement/inflammasome axis partakes also in colitis 
  





pathogenesis in humans, specifically in patients with Crohn’s disease, with the 
possibility to modulate this system therapeutically – this work is currently ongoing.  
Of note, additional attempts were made to address an in vivo role for hyper-active 
NLRP3 inflammasome activity of CD4
+
 T cells in humans, performing a GvHD 
experiment with the adoptive transfer of naïve CD4
+
 cells isolated from patients with 
CAPS into Rag2
-/-
 mice in collaboration with Dr Nick Powell and Dr Adam Laing 
(King’s College London). Although engraftment of human CD4+ T cells was 
effective with detection in mouse serum of human IFN-, with a trend toward higher 
cytokine over percentage of engraftment in recipients of patients T cells when 
compared to recipients of HDs cells, mice did not show weight loss after two months 
from T cell transfer (data not shown). Given the fact that T cells from CAPS patients 
produce less IL-17 (Figure 3E, Arbore et al., 2016) and that IL-17 production is 
critical in GvHD, the mice may have not developed disease because of reduced 
production of this cytokine by human CD4
+
 T cells.  
 
During my MSc studies in the Kemper laboratory, I participated in a project that 
ultimately led to the finding that autocrine CD46 activation during T cell stimulation 
is required for metabolic reprogramming during Th1 cell responses (Kolev et al., 
2015). Upon TCR activation, CD46 is engaged via T cell autocrine C3b production 
and induces (aside from IL1B and NLRP3 gene expression) also the increased 
expression of the glucose and AA channels, GLUT1 and LAT1, respectively, thereby 
mediating the nutrient influx needed for T cell activation (Kolev et al., 2015) 
Moreover, CD46 also up-regulates the late endosomal/lysosomal adaptor, MAPK 
and MTOR activator 5 (LAMTOR5), which then drives mTORC1 assembly and 
activation with subsequent increased glycolysis (Kolev et al., 2015), in line with 
previous work that has linked augmented glycolysis in human CD4
+
 T cells with 
IFN- production (Marelli-Berg et al., 2012). Thus, this work demonstrates that the 
autocrine C3 system in T cells participates in key cell metabolic pathways.  
Now, the published work on the functional interplay between the ‘cellular 
complosome and the inflammasome’ (Arbore et al., Science, 2016) brings together 
the ‘intracellular C5/C5a/C5aR/NLRP3-inflammasome axis’ and the already 
described ‘CD46/C3/C3a/C3aR-metabolism axis’ in T cells (Kolev et al., 2013). 
CD46 participates in NLRP3 inflammasome priming: CD3 and CD46 co-stimulation 
  





leads to upregulation of inflammasome genes, and in addition previous work in 
Kemper lab demonstrated that CD46 engagement potentiates NF-kB activation in 
stimulated human CD4
+
 T cells (Kolev et al., 2015). Moreover, CD46 activation 
drives mTORC1 activity, nutrient influx and augmented glycolysis (Kolev et al., 
2015), a metabolic change fundamental for T cell effector functions (Marelli-Berg et 
al., 2012), while mTORC1 activity and glycolysis have been recently shown as 
NLRP3 inflammasome inducers in macrophages (Moon et al., 2015). Accordingly, 
treatment of T cells with the mTORC1 inhibitor rapamycin (Kolev et al., 2015) 
during CD46-activation abolishes caspase-1 activation, IL-1β and IFN-γ secretion 
(data not shown), therefore providing other signals for inflammasome induction 
(Figure 2.2). Thus, the cross-talk between intracellularly activated complement 
components, the ‘complosome’ (Kolev et al., 2014), key metabolic changes and the 
NLRP3 inflammasome emerge as fundamental to human Th1 induction and 
modulation. Detailed background information and an in-depth discussion on the 
potential significance for health and disease of this novel ‘Complement-metabolism-
inflammasome axis’ is included in a recent Mini-Review in the European Journal of 
Immunology of which I am the 1
st
 author (Arbore and Kemper, 2016). 
 
In summary, two quintessential innate pathways, the intracellular complosome and 
the inflammasome, are fundamental contributors to the adaptive immune system. 
That established innate immune pathways previously unpostulated to be operative in 
adaptive immune cells are not only present but also key in directing immunological 
responses is of great significance to our understanding of the immunobiology and 
why targeting just one arm of the immune system is often insufficient for the 
treatment of human diseases. This complement/metabolism/inflammasome axis may 
constitute a bull’s eye therapeutic approach for the treatment of autoimmune and 
autoinflammatory conditions, metabolic disorders and cancer – as it is possible that 
this axis is also operative in a wide range of other immune cells.  
 
Finally, it is worth to explore whether autocrine complement-NLRP3 inflammasome 
activity is also required for optimal IFN-γ production by other immune cell subsets, 
such as CD8
+
 T lymphocytes, natural killer T (NKT) cells and innate lymphoid type 
1 (ILC1) cells. Within the PhD project, after work on CD4
+
 T cells, preliminary data 
  





were generated on human CD8
+
 cytotoxic T cells with regards to C5 system and 
NLRP3 on IFN-γ production and effector functions, which constitute the Chapter 3 






























Figure 2.2 A complement-metabolism-inflammasome axis regulates human Th1 
response induction and contraction 
TCR stimulation of human CD4+ T cells induces the autocrine activation of CD46 and 
the C3aR via the ‘C3 system’ that cumulates in nutrient influx, mTORC1 activation 
(which is a NLRP3 inflammasome activator) and induction of key metabolic events. In 
addition, CD46 stimulation simultaneously induces gene expression of NLRP3 and IL1B 
to prime the NLRP3 inflammasome as well as increased intracellular C5 activation and 
C5a generation (of note, the enzyme cleaving intracellular C5 into C5a and C5b has not 
yet been identified and is denoted by a question mark). Intracellularly generated C5a 
then engages the intracellular C5aR1 to amplify ROS production. Increased ROS levels, 
together with the indicated metabolic changes, induce the assembly of the NLRP3 
inflammasome and subsequent IL-1β (but not IL-18) production required for optimal 
Th1 induction. Cell surface expressed C5aR2 (engaged via secreted C5a/C5adesArg) 
negatively regulates C5aR1 signaling via a yet-unidentified mechanism - and therefore 
controls the Th1 responses. 




















Results and Discussion Part 2:  
Autocrine complement and NLRP3 
inflammasome in human CD8
+




























3.1.1 Complement-mediated regulation of CD8
+
 T cells responses 
 
Although the larger body of work about the complement’s role in T cell immunity 
has been performed on CD4
+ 
T cells, there are also a number of studies showing that 
local complement modulates the cytotoxic activity of CD8
+
 T lymphocytes in vitro 
and in vivo in response to infection and during anti-cancer responses. 
 
Their ability to respond to complement products is demonstrated by the fact that 
CD8
+
 T cells express the complement receptors and regulators, such as CD46, DAF 
and CD59 whilst the expression of CR1 has not been reported (Christmas et al. 
2006). Further, in vitro stimulation of human CD8
+
 T lymphocytes with 
phytohaemagglutinin leads to upregulation of surface-expressed CD46 and DAF, 
thus suggesting that these two molecules may also play a role in shaping CD8
+
 T 
lymphocytes immune responses. 
 
The first studies which showed a role for CD46 costimulation in promoting CD8
+
 T 
cell proliferation, and in induction of morphological changes associated with 
activation, analysed total CD3
+





 subpopulations (Astier et al., 2000, Zaffran et al., 2001), therefore 
indicating that CD46 may also promote CD8
+
 T cells effector functions aside from 
CD4
+
 T cells.  
Several experimental observations demonstrate that indeed CD46 co-activation 
modulates T cell mediated cytotoxicity. Firstly, in a mouse model of contact 
hypersensitivity reaction in mice either expressing human CD46 CYT-1 or CYT-2 
tail bearing isoforms, CD46 engagement controls total splenocytes cytotoxicity, with 
CYT-1 bearing isoform having a negative and CYT-2 a positive effect (Marie et al, 
2002). This observation is in opposition with human data on CD4
+
 T cells where 
CYT-1 promotes pro-inflammatory response and CYT-2 activity allows Th1 
contraction (Cardone et al., 2010, Kolev et al., 2015), however this discrepancy 
might be explained by the fact that mouse T cells lack the exactly similar signaling 
  





machinery required for normal human CD46 function and hence distinct signaling 
events are induced by hCD46 in mouse T cells and in human T cells (Yamamoto et 
al., 2013). Secondly, CD46 co-stimulation on human CD4
+
 T cells leads surprisingly 
to granzyme B and perforin overexpression, an event which allows the contact-
dependent cytotoxic elimination of autologous activated T lymphocytes by CD4
+
 T 
cells (Grossman et al., 2004). Thirdly, CD46 ligation by anti-CD46 coated beads 
leads to microtubule polarization and reduced IFN-γ production in CD8+ cytotoxic T 
lymphocytes, in addition to altered perforin polarization and cytotoxicity to the target 
cell (Oliaro et al., 2006), although in contrast to the positive effect ascribed for CD3 
and CD46 co-ligation on a solid surface in T cells (Astier et al., 2000, Kemper et al., 
2003). 
Apart from a general effect on T cell cytotoxicity, most recently CD3 and CD46 
costimulation of CD8
+
 T cells has been demonstrated to increase cell proliferation 
and induce the expression of several T cell activation markers, such as CD25, CD28, 
OX40 and PD-1 (Kickler et al., 2012). Importantly, this latter study did not 
demonstrate a significant effect of CD46 co-stimulation on IFN-γ production by 
CD8
+
 T cells, albeit a thorough analysis of the effects of CD46 activation on 
different T cell subsets and level of TCR stimulation as controls had not been 
performed in that study. Thus, further studies are needed to better elucidate the 
potential role of CD46 on human CD8
+
 T lymphocytes function. 
 
In addition to CD46, signaling mediated by the anaphylatoxins C3a and C5a appears 
to shape CD8
+
 T cell migration and effector function.  
Expression of the C3aR has been detected not only in human CD4
+
, but also in CD8
+
 
T cells (Werfel et al., 2000). Further studies also demonstrated the ability of 
cytotoxic T cells to respond to complement C3 activation: local C3 generation and 
activation was required for T cell-mediated control of influenza virus infection in a 
mouse model, where C3 gene KO mice showed reduced cytotoxic T lymphocytes 
priming in the draining lymph nodes and impaired recruitment in the lung of virus-
specific IFN-γ producing T cells, independently from CR2 expression (Kopf et al., 
2002). A similar C3-dependent, CR2-independent, mechanism in anti-viral immune 
response has also been observed in a model of acute LCMV infection, where it has 
been demonstrated that complement C3 activity regulates epitope selection and is 
  





needed for optimal expansion of LCMV-specific mouse effector CD8
+
 T 
lymphocytes (Suresh et al, 2003).  
The current opinion is that complement-mediated regulation of CD8
+
 T cells effector 
functions is rather operating via C5 complement activation products, as C3 activation 
generates the C3b component of C5 convertase (which cleaves C5 into C5a and C5b) 
and Cr2
-/-
 mice did not show defective anti-viral CD8
+
 T cell response (Suresh et al, 
2003). Such notion is in line with other studies indicating the importance of local 
C5a in shaping CD8
+
 T cell immunity in vivo. In a model of flu infection, mice 
treated systemically with the C5aR1 antagonist PMX53, which blocks C5a binding 
to this receptor, showed diminished frequency of flu-specific CD8
+
 T cells (Kim et 
al., 2004b). Further, CD55 (DAF) expression increases in human CD8+ lymphocytes 
upon in vitro stimulation (Christmas et al., 2006), and mice deficient for Daf1, which 
leads to reduced formation of complement convertases on the T cell surface, 
demonstrated heightened CD8
+
 T cell immunity to LCMV infection, which is 
reversed by co-deletion of either C3 or C5aR1 (Fang et al., 2007). Several 
mechanisms by which C5a can modulate the priming of CD8
+
 T cells have been 
proposed, such as indirect T cell activation by paracrine downstream inflammation 
products, via increased recruitment and stimulation of antigen presenting cells, or 
direct enhancement of T cell trafficking or CD8
+
 TCR antigen sensitivity (Kim et al. 
2004b). The effects of locally produced C5a on CD8
+
 T lymphocytes also affects the 
outcome of T cell-mediated graft injury in vivo: Daf1
-/-
 mice which receive a heart 
transplant undergo increased CD8
+
 T cell-dependent CD4
+
 T cell-independent graft 
rejection compared to WT recipients. This enhanced CD8
+
 T cell reactivity may be 
due to the augmented stimulation by APCs, as locally produced C3a and C5a up-
regulate the expression of CD80 and CD86 by APC (thus facilitating antigen 
presentation) and increase IL-12 production (Vieyra et al., 2011). Further studies in 
mice showed that paracrine-derived C5a from endothelial cells stimulates cytotoxic 
T cell expansion, IFN-γ and perforin production (Raedler et al., 2009), while CD8+ T 
cells lacking C3aR and C5aR1 proliferate weakly to allogeneic dendritic cells (which 
produce C3a and C5a) (Vieyra et al., 2011). Of note, these latter two studies suggest 
an effect of C3a and the C3aR and indicate that C3 activation products (and not just 
C5 activation products) also contribute to CD8
+
 T cell immunity.  
 
  





Interestingly (and somewhat similar to the CD4
+
 T cell situation), local complement 
can also have negative impact on CD8
+
 T cell responses: C5a appears to indirectly 
inhibit CD8
+
 T cell anti-tumor responses. In a syngeneic mouse model of cervical 
cancer, blockade of C5aR1 via subcutaneously injected PMX53 results in reduced 
tumor growth, while locally produced C5a favours the recruitment of myeloid-
derived suppressor cells (MDSC), which suppress T cell immunity (Markiewski et 
al., 2008). This C5a-mediated MDSC suppression of anti-tumor CD8
+
 T cell 
responses is also associated with augmented formation of cancer metastases: in a 
mouse model of breast cancer, mice either deficient for C5aR1 or treated with the 
C5aR1 antagonist PMX53 show reduced metastasis formation and higher frequency 
of IFN-γ producing ex vivo restimulated CD4+ and CD8+ T cells isolated from the 
lung (Vadrevu et al., 2014). It seems that the concentration of C5a within the tumor 
microenvironment determines the anti-tumor T cell responses and cancer 
progression: tumor-bearing mice with high C5a-producing syngeneic lymphoma 





 T lymphocytes in the tumor, tumor-draining lymph 
nodes, and spleen, while mice recipient of low C5a-producing lymphoma cells had 





 T cells in the draining lymph nodes (Gunn et al, 2012). Finally, 
recent evidence suggests a role for local C3a and C5a in inhibiting intrinsic IL-10 
production and anti-tumor activity by CD8
+
 tumor infiltrating lymphocytes in a 
breast cancer mouse model, therefore anaphylatoxin receptor signaling can dampen 
anti-tumor T cell immunity, favouring disease progression (Wang et al., 2016). 
 
The mechanism by which C5a anaphylatoxin regulates CD8
+
 effector functions in 
vivo, with opposing and different effects in anti-viral and anti-tumor immunity, have 
not yet been fully elucidated. Particularly, if C5a acts directly through C5aR1 
expressed by CD8
+
 T cells or indirectly on APCs or myeloid cells expressed C5aR1 
to shape T cell immunity is still a matter of controversy.  





peripheral blood T lymphocytes (Nataf et al., 1999) and by mouse CD8
+
 cytotoxic T 
cells (Raedler et al., 2009). C5aR1 protein expression has been detected only in 
effector (not resting) human CD8
+
 T cells: while T cell stimulation with 
  









 cell population (Nataf 
et al., 1999), tumor infiltrating CD8
+
 T lymphocytes from patients with melanoma, 
but not from the peripheral blood, show cell-surface expressed C5aR1 (Wang et al., 
2016). This is in line with work from Vadrevu and collaborators, which did not 
detect any C5aR1 protein expression from the peripheral blood mouse CD8
+
 T cells 
(Vadrevu et al., 2014). 
Moreover, an effect for the alternative C5a receptor C5aR2 in shaping CD8
+
 T cell 
immunity has not been investigated by any of these studies. 
A better understanding of C5a mechanism of action, either paracrine or autocrine, on 
C5a receptors expressed by either APCs or CD8
+
 lymphocytes, may elucidate the 
role of local complement in modulating the antigen-specific killing of infected or 
tumor cells. 
Thus although the exact molecular pathways driving the effects of C5a are not 
defined yet, there is strong indication that cytotoxic anti-viral T cell responses can be 
modulated via targeting C5a mediated signaling in mice and humans.  
 
 
3.1.2 Inflammasome-mediated regulation of CD8
+
 T cells responses 
 
Apart from signals derived from complement activation products, it is now 
acknowledged that signals coming from APCs and myeloid cells-derived pro-
inflammatory IL-1β and IL-18 cytokines, produced as result of inflammasome 
activation, are critical regulators of CD8
+
 T cells cytotoxicity (Kupz et al., 2012, 
Ben-Sasson et al., 2013). 
In recent years, IL-1β has been defined as a strong enhancer of antigen-specific 
CD8
+
 T cell responses in vivo. IL-1 facilitates their expansion, tissue migration, 
effector functions and memory responses (Ben-Sasson, et al., 2013): 1) mice 
receiving ovalbumin-specific transgenic CD8
+
 T cells and then immunised with 
ovalbumin and LPS, showed increased accumulation of antigen-specific CD8
+
 T 
cells in the peripheral tissues (spleen, liver and lung) in the presence of exogenous 
IL-1β and this effect is not observed upon transfer of ovalbumin-specific CD8+ T 
lymphocytes deficient for the IL-1R1, 2) IL-1β administration results in heightened 
IFN-γ and granzyme B production by antigen-specific CD8+ T cells both upon 
  





primary immunization and antigen re-challenge (memory response); 3) IL-1β co-
administration favours in vivo T cell cytotoxicity to inoculated splenocytes loaded 
with ovalbumin-tetramers. It is likely that IL-1β/IL1R1 signaling enhances antigen-
stimulated CD8
+
 T cell expansion via suppression of apoptosis, a mechanism which 
seems operative in IL-1β-driven increase of CD4+ T cell responses (Ben-Sasson et 
al., 2009). 
At least in the models assessed, the IL-1β-mediated effect on in vivo CD8+ T cell 
responses is thought to depend on paracrine activation of the NLRP3 inflammasome 
in APCs and subsequent production of IL-1 and this aligns with data reporting that 
the NLRP3 inflammasome activity and the IL-1β production promote anti-tumor T 
cell cytotoxicity in a mouse model of thymoma (Ghiringhelli et al., 2009). However, 
an NLRP3-independent and IL-1β-dependent CD8+ protective T cell response has 
been demonstrated in vivo in flu models and an intrinsic activity for the NLRP3 
inflammasome in CD8
+
 T cells has so far not been assessed (Ichinohe et al., 2009). 
 
The inflammasome-derived cytokine IL-18 can also enhance IFN-γ production by T 
lymphocytes (Okamura et al., 1995). Again, published work suggests that APCs-
derived IL-18 is critical for CD8
+
 T cell responses, and particularly effector memory 
function (Soudja et al., 2012, Kupz et al., 2012). Soudja and collaborators showed 
that the canonical NLRP3 inflammasome pathway contributes to in vitro and in vivo 
IFN-γ production by memory CD8+ T cells: while exogenous IL-18 enhances ex-
vivo IFN-γ response by CD8+ T lymphocytes (possessing an ovalbumin-specific 
TCR and isolated from mice pre-challenged with ovalbumin) in absence of antigen 
stimuli, bone-marrow caspase-1 deficient mice (which lack full canonical 
inflammasome activity) showed a significantly diminished proportion of IFN-γ+ 
CD8
+
 T antigen-specific memory cells upon antigen immunization when compared 
with WT animals. The authors demonstrated further that a subset of inflammatory 
monocytes represents the source of IL-18 which initiates CD8
+
 T cells differentiation 
and effector responses to bacterial, viral and parasitic infections (Soudja et al., 
2012). NLRC4 inflammasome driven IL-18 production by DCs can also support 
antigen-independent IFN-γ production by memory CD8+ T cells (Kupz et al., 2012).  
Overall, the in vitro and in vivo studies published so far support a clear role for 
paracrine NLRP3 (and NLRC4) inflammasome activation in APCs that drives IL-1β 
  





and IL-18 production which in turn supports CD8
+
 T lymphocyte effector function 
and memory development. The possibility of an intrinsic functional NLRP3 
inflammasome machinery (possibly regulated by intracellular complement) that is 
required for normal CD8
+
 T cell function (as herein demonstrated for CD4
+
 T cells) 




























3.2 Hypothesis and aims  
 
As main part of this thesis project, data have been generated which demonstrated that 
complement C5-regulated canonical NLRP3 inflammasome activity within CD4
+
 T 
lymphocytes is required for optimal IFN-γ production and Th1 responses in vitro and 
in vivo (Chapter 2). As CD8
+
 T cells, like CD4
+
 T cells, also produce IFN- and 
granzyme B and can respond to CD46 engagement and C5aR1 stimulation but the 
downstream events of the engagement of these regulators/receptors is not defined, 
the further  hypothesis has been developed and investigated:  
 
‘Human CD8+ T cells, similar to CD4+ T cells, harbour an intracellular C3 and C5 
system and this system contributes to effector responses in direct cross-talk with an 






















3.3 Materials and methods  
 
3.3.1 Cells isolation, culture and stimulation  
 
Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of 
healthy donors (HDs) (in accordance with the guidelines of the Wandsworth 
Research Ethics Committee, REC number 09/H0803/154) by centrifugation with 
Ficoll-Paque PLUS (GE Healthcare).   
All the in vitro activation assays were performed with cells isolated by FACS 




 T cells sorting, PBMCs 
isolated from the blood of HDs were treated for 10 minutes with human FcR 
blocking reagent (Miltenyi Biotec), then stained with mouse anti-human CD4 eFluor 
450 (clone OKT4, eBioscience), mouse anti-human-CD8a PE-Cy7 (clone RPA-T8, 
Biolegend), mouse anti-human-CD56 APC (clone MEM188, eBioscience). Cell-
Sorting was performed with a BD FACSAriaTM II Cell Sorter (Flow Core facility, 









 cells (Figure 3.1). The cells purity was ≥ 99%.  
For the cytotoxic assays optimization on cancer cells, which were requiring an 
higher amount of CD8
+ 
cells than what usually obtained by FACS, CD8
+
 T 
lymphocytes were isolated with magnetic beads. CD56
+
 cells were depleted by 
positive selection using the CD56
+
 Cell Isolation Kit (Miltenyi Biotec), following 
manufacturer’s instructions. After CD56+ cells depletion, CD8+ T cells were purified 
with CD8
+
 Cell Isolation Kit-II (Miltenyi Biotec), following manufacturer’s 
instruction. The purity of cell populations was assessed by flow cytometry co-stain 
for CD8 and CD56 and it was ≥ 95%. 
For cell stimulation, 48-well plates were coated overnight at 4°C with 2 μg/ml of 
anti-CD3 (clone OKT-3), anti-CD28 (BD Biosciences), and anti-CD46 (GB24, 
generated in house) antibodies; the antibodies were diluted in modified dPBS with 
calcium and magnesium (Hyclone) to improve their stability. T cells were 
resuspended and cultured in RPMI 1640 (Gibco), with 1% penicillin-streptomycin 
and L-glutammine (both from Sigma), and activated in presence of 10U/ml 
recombinant human IL-2 (a gift from Dr. Pham, Washington University, Saint 
  









 cells were plated at a density of 1x10
6
 cells/ml (250 μl 
cells/well, for a total of 2.5x10
5
 cells/well), and soon after plating cells were spun 
down for 2 minutes at 500 rpm to allow them to deposit to the bottom of the plate 
and to bind to the coated antibodies. Primary T cells were left in incubator at 37
o
C 
and 5% CO2, and stimulated for 60 hours.  
The NLRP3 inflammasome antagonist MCC950 (Coll et al., 2015) was provided by 
Professor Matthew Cooper (University of Queensland, Australia) and Professor Luke 
O’Neill (Trinity College, Dublin, Ireland), and used at a concentration of 10 μM in 
PBS. The C5aR2 agonist P32 (Croker et al., 2016) was provided by Dr. Peter Monk 
(University of Sheffield, UK) and used at 100 μM, with sterile dH2O (Hyclone) as 
vehicle control. Cells were left for 15 minutes in media with the compounds, then 
directly plated for stimulation.  
 
 
3.3.2 Flow cytometry analysis 
 
Extracellular stainings were performed in a buffer containing PBS supplemented 
with 0.5% BSA and 2 mM EDTA (both from Sigma). For intracellular stainings, 
cells were fixed and permeabilised with Cytofix/Cytoperm kit (BD Biosciences). 
Before the stainings cells were pre-incubated 10 minutes with human FcR blocking 
reagent (Miltenyi Biotec). Cells were contemporarily stained for extracellular CD4, 
CD8 and CD56 expression and gated as shown in Figure 3.1. Stainings were 
performed with mouse anti-human CD46 PE (clone 8E2, eBioscience), mouse anti-
human CD107a FITC (eBioscience), mouse anti-human-granzyme B FITC (BD 
Pharmigen), mouse anti-human-C5aR1 FITC (clone S5/1, Santa Cruz), mouse anti-
human-C5aR2 PE (Biolegend), rabbit anti-human-C5 and goat anti-human NLRP3 
(both from Abcam). Secondary antibodies were goat anti-rabbit-PE and donkey anti-
goat PE (both from Molecular Probes).  
Cleaved caspase-1 staining was performed using the Green FLICA Caspase-1 Assay 
kit (Immunochemistry Technologies), following manufacturer’s instructions.  
Data were acquired with a Fortessa LSRIII supported by FACS diva software (BD 
Biosciences), and analysed by FlowJo 10.0.8 software (Ashland, OR).  
  







Figure 3.1 Gating strategy used for cell sorting and flow cytometry stainings 
Following PBMCs staining, cells were gated accordingly to their size to exclude the 
debris and myeloid cells, with respectively lower and bigger forward scatter area 
(FSC-A) and side scatter area (SSC-A) when compared to lymphoid cells. Then 
doublets of bigger size were excluded for their increased side scatter width (SSC-W) 
and CD56
-
 cells were selected accordingly to their expression of CD4 and CD8 for 




3.3.3 RNA extraction, cDNA synthesis and RT-PCR for CD46 tails  
 
RNA extraction and RT-PCR for CD46 tails were performed by Dr. Gaelle Le Friec, 








 cells from 3 HDs 
fresh blood.  
RNA was extracted using the RNeasy Mini kit and the on-column DNAse digestion 
(both from QIAGEN), following manufacturer’s instructions. RNA concentration 
(A260) and purity (A260/A280 ≈ 2.0) was checked with the spectrophotometer 
NanoDrop 1000 (Thermo Scientific).  
Reverse transcription to cDNA was performed with 200 ng of input RNA using 
RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Scientific).  The 
mastermix was generated using 100 pmol random hexamer primers, 1 X reaction 
buffer, 40 U RiboLock RNase inhibitor, 1 mM dNTP mix, 200 U RevertAid H 
Minus reverse transcriptase from Moloney Murine Leukemia Virus (M‐MuLV) and 
100 ng of RNA sample diluted in RNAse-free dH2O. The reverse transcription 
reaction was carried out by incubating the samples at 25°C for 5 minutes, followed 
by a step of 60 minutes at 42°C and a final incubation of 5 minutes at 70°C for 
enzyme inactivation. Real-Time PCR was performed in 384 wells  plate with 
  





7900HT Fast Real-Time PCR System (Thermo Fisher) with the following 
conditions: 1 X Taqman universal mastermix II with Uracil-DNA Glycosylase 
(UNG), 100 nM of each primers, 250 nM probe 5' 6-FAM, 3' Iowa Black FQ, 250 
nM Eukaryotic 18S rRNA Endogenous Control (VIC®/MGB probe) (all products 
from Applied Biosystems), 0.5 μl RNase Free water, 2 μl cDNA template (final 
reaction volume = 10 μl). 
CYT1 primers: forward 5’- TTGTCCCGTACAGATATCTTC – 3’ 
reverse 5’- CTTCTCAGAGAGAAGTAAATTTT - 3’ 
CYT-1 antisense probe: 5’- AGTTAGGTATGTGCCTTTCTTCTTCCTCC - 3’ 
CYT2 primers: forward 5’- GGAGGAAGAAGAAAGGGAAAGC - 3’ 
                         reverse 5’- TCAGCCTCTCTGCTCTGC - 3’ 
CYT-2 sense probe: 5’- AGATGGTGGAGCTGAATATGCCACTT - 3’ 
PCR amplification was performed in an ABI Prism 7900HT thermocycler (Applied 
Biosystems) for 2 min at 50°C, 10 min at 95°C, followed by 40 cycles of combined 
15 s at 95°C and 1 min at 60°C. The sequence detector SDS 2.4 software (Applied 
Biosystems) was used to export the threshold cycles (Ct) values. 
Expression of the target gene was normalised using the endogenous gene 18S 
ribosomal RNA (18S rRNA). 
The relative quantification (RQ) of the CYT-1 and CYT-2 expression in CD8
+
 cells 
was performed using the ΔΔCt method (Livak and Schmittgen, 2001), where: 
ΔCT = Ct (CYT-1 or CYT-2) – Ct (18S rRNA) 






3.3.4 Prostate cancer cells culture and cytotoxicity assay 
 
The primary prostate cancer cell line DU145 (a gift from Dr. Hide Yamamoto, 
King’s College London) was used as APCs source for cytotoxic assay in co-culture 
with CD8
+
 cells. Similarly to T cells, DU145 cells were cultured in RPMI 1640 
(Gibco), with 1% penicillin-streptomycin and L-glutammine (all from Sigma) and, 
once confluent, trypsinised with 0.05% trypsin EDTA (Gibco) and passaged to a new 
flask with fresh media (approximately every 48 hours). The doubling time of DU145 
  





cell line is about 16 hours.  
For the cytotoxic assay to measure the cell viability (apoptosis and necrosis), DU145 
cells were plated at 1.0x10
4
 cells/well and left to grow in incubator at 37
o
C and 5% 
CO2, for 24 hours (approximately reaching 2.5x10
4










 cells were marked with carboxyfluorescein succinimidyl 
ester (CFSE) to further distinguish them from the DU145 cells in the co-culture. 
CD8
+
 cells were stained at a density of 1x10
7
 cells/mL in PBS, at room temperature 
(RT), with 2.5 μM of CFSE (Thermo Fisher) for 2 minutes, and 5 volumes of culture 
media were added to wash the unbound CFSE. Cells were then resuspended in fresh 
media at 1x10
6
 cells/mL and activated as described above (section 3.3.1) in 48 well 
plates for 24 hours. Following activation, T cells were harvested and added on top of 
the DU145 cells, the 48 well plate was spun at 500 rpm for 2 minutes to allow the 
CD8
+
 cells to deposit to the bottom in co-culture with the cancer cells, and the plate 
was left to incubate for other 12 hours.  
After this overnight incubation, the co-culture of DU145/CD8
+
 cells was harvested 
from the single wells into separate eppendorf tubes, the media was washed out by 5 
minutes centrifugation at 300g, at RT, the supernatants were collected to check for 
cytokine production. PBS was added immediately after cell collection for 1 minute 
to wash the wells in the 48 well plate and remove the rest of media from the DU145 
cells still adhering to the plate. After PBS removal, detachment of the adherent cells 
was performed by addition of 100 μl/well of 0.05% trypsin EDTA (Gibco) for 2 
minutes, then the detached cells were collected in the corresponding eppendorf tubes 
where non-adherent cells were previously collected. 
Trypsin was removed by centrigugation at 300 g for 5 minutes at RT, then the cells 
were resuspended in 100 μl of Annexin V binding buffer (BD Biosciences) and 
transferred to minitubes for flow cytometry. Annexin V staining was carried out at 
RT for 15 minutes with 3 microL/test of Annexin V-APC, following addition of 0.5 
μg/ml propidium iodide (PI) (both from BD Biosciences) 2 minutes before flow 
cytometry acquisition. Cells were analysed on a FACS Calibur cytometer, supported 
by CellQuest Pro software (both from BD Biosciences). The DU145 cells were gated 
as FL1-H negative (no green stain), because CD8
+
 cells were marked with the green 
CFSE dye. Annexin V single positive cells, Annexin V/PI double positive cells and 
  





PI single positive cells were considered respectively as early apoptotic, late apoptotic 
and necrotic. 
 
3.3.5 Cytokine measurement 
 
Cytokine production was quantified from cell supernatants using the human 
Th1/Th2/Th17 Cytometric Bead Array (BD Biosciences) with the respective 
preparation of cytokines standard, following the manufacturer’s instructions, and 
samples were acquired using the 96 well plate automate reader system on a Fortessa 
LSRIII supported by FACS diva software (BD Biosciences). Data were analysed by 
FCAP array software (Soft Flow Hungary Ltd). The analysis was performed by 
following these steps (Figure 3.2): 
a) generation of a template plate, to export the single flow cytometry files (.fcs) 
acquired by the Fortessa LSRIII, and assignment of samples dilution factors 
(1/10 to 1/25 dilution of supernatants was used) and of the kit used, the 
Human Th1/Th2/Th17 Cytokine kit - 560484; 
b) assignment of correspondent cytokine to each beads histogram peak of APC-
A (following manufacturer’s instructions) and debris filtering; 
c) assignment of standard curve, with higher standard of 5000 pg/ml cytokine, 
serial 1/2 standards dilutions and lower standard at 0 pg/ml concentration 
(blank); 






















              
  






    
Figure 3.2 Cytometric bead array analysis using the FCAP software 
(a) Graphical interface of the software, where single .fcs files can be exported onto a 
graphical plate (standards reported in blue and samples in red), dilutions can be 
assigned, then the user can follow the 10 steps reported on the left window, starting 
from the step 1 of assignment of the beads model use (in this case the Human 
Th1/Th2/Th17 Cytokine kit – 560484); (b) step 2, the “Instrument settings”, where 
beads are assigned to corresponding cytokines accordingly to the APC-A, then this is 
followed by debris filtering accordingly to the FSC-A, and in some cases by manual 
clustering; (c) standard command, where lower and upper standards value are 
reported, the order (ascending or descending) and dilutions factors are given; (d) the 
step 8, “result per analyte”, in this case for the standards 0 to 5000 ng/mL plus an 




 cells either left non activated (NA) or in vitro activated 
with anti-CD3, anti-CD3 + anti-CD28 or anti-CD3 + anti-CD46 antibodies. It is 
evident that CD8
+
 cells produce only a substantial level of IFN-γ and TNF-α and a 
minimal amount of IL-10, while other cytokines are not detectable. 
  















 from HDs PBMCs, either left non 
activated or in vitro pre-activated for 60 hours with anti-CD3 + anti-CD46, were 
fixed, permeabilised and stained in the same way as for the flow cytometry 
intracellular staining procedure showed above. NLRP3 staining was performed using 
the primary antibody goat anti-human NLRP3 (Abcam) and the secondary antibody 
donkey anti-goat Alexa fluor 488 (Abcam). Cells were mounted using 
VECTASHIELD media with DAPI (Vector labs). Images were acquired with a 
Nikon A1R confocal microscope (Nikon Imaging Centre, KCL) using 100X oil 
immersion objective, and analysed by NIS Elements software (Nikon).  
 
 
3.3.7 Data analysis  
Statistics analyses were performed using the one-way ANOVA or the paired t-test 
and Bonferroni correction where appropriate (GraphPad Prism software). Data were 
assessed for normal distribution using the D'Agostino-Pearson test. Data were 
expressed as mean ± standard error of the mean (SEM), and statistical significance 


















In principle, an approach similar to the one adopted in studying CD4
+
 T cells has 
been implemented for testing the initial hypotheses, in such that it has been firstly 
assessed if the complement receptors and components in questions and the NLRP3 
inflammasome components are present in human CD8
+
 T cells and whether they are 
affected by cell activation. The cytokines production and cytotoxic activity of cells 
were assessed upon TCR and CD46 stimulation in presence or absence of an agonist 
modulating the activity of the surface C5aR2 or the inflammasome specific inhibitor 
MCC950. In vivo significance of the observations herein reported would then be 
planned by utilising CD8
+
 T cells from CAPS patients and from Nlrp3 and Il1b and 
Il1r deficient animals in suitable in vivo models.  
Below it is listed the set of experiments that I have been able to perform so far with a 
discussion on the strengths and shortcomings of the data, their implications for the 
role of the autocrine/intracellular complement and the NLRP3 inflammasome in 
CD8
+
 T cell responses and an outlook into potential future follow-up studies.  
 
 
3.4.1 Effects of CD46 in vitro co-stimulation on CD8
+
 T cell cytokine 
production and granzyme B expression/degranulation  
 
Before starting in vitro functional studies on human CD8
+
 T lymphocytes, a 





T lymphocyte subsets sorted by flow cytometry from the fresh blood of healthy 
volunteers. Cells were also sorted for lack of CD56 expression, which is an NK cell 
marker (CD56
-
), to exclude the contamination with NK or NKT cellular subsets 
(Bendelac et al., 2007). Flow cytometry staining demonstrated that, in line with 
published literature, CD8
+
 T cells express CD46 and that total CD46 protein 
expression levels are not significantly different between the two T cell subsets - 
although there is a trend towards less CD46 protein expression in CD8
+
 cells versus 
CD4
+
 T cells (Figure 3.3A). Because the CYT-1-bearing isoforms of CD46 drive 
IFN- production in CD4+ T cells, the CD46 tails expression pattern was assessed in 
freshly isolated resting CD8
+
 T cells. These experiments suggested that there is a 
  







 T lymphocytes towards higher mRNA expression for the CD46 
isoforms bearing the CYT-1 and CYT-2 tails, evident in 2 out of 3 healthy donors 
used (and normalised to CD4
+
 T cells from the same donor). Interestingly, a third 
donor showed much lower CD46-CYT-1 and CD46-CYT-2 mRNA expression in 
this cell subset when normalised to expression levels in CD4
+
 cells (Figure 3.3B). 
Noteworthy, this reduced expression did not affect in vitro cytokine production by 
CD8
+
 lymphocytes from this donor (data not shown).  Overall, CD46 is expressed 
also by CD8
+
 T cells, without substantial differences for CYT-1 and CYT-2 tails 
transcripts levels. 
Next, the effect of CD46 co-stimulation during CD8
+
 T lymphocyte activation on 
cytokine production and on granzyme B degranulation (which is a key part of their 









cells, isolated from the same HDs by FACS sorting (purity ≥ 99%), were activated 
with anti-CD3 antibody alone or in combination with either anti-CD28 or anti-CD46 
antibodies. Both cytokine production and degranulation were analysed after 60h of in 
vitro activation. 
In analogy to CD4
+
 T cells, CD8
+
 T cells respond to CD46 co-stimulation with 
significantly increased IFN- and TNF- production. However CD8+ lymphocytes 
do not respond to CD46 co-stimulation with an increased switch into an IL-10-
producing phenotype as IL-10 secretion by these cells is in the order of pg/ml and 
with an average IFN-γ to IL-10 ratio of 100 in CD8+ cells versus 1.5 in CD4+ cells 
(Figure 3.4). Secretion of IL-2, IL-4, IL-6 and IL-17 was barely detectable from 
CD8
+
 cells (data not shown). Importantly, CD28 co-stimulation does not affect 
production of these cytokines when compared to the stimulation of TCR alone with 
immobilised anti-CD3 antibody. 
Similarly to its effect on cytokines production, CD46 in vitro co-stimulation of CD8
+
 
T cells induces significantly increased degranulation when compared to anti-CD3 
and anti-CD3 + anti-CD28 co-stimulation, as demonstrated by up-regulation of 














         
 
Figure 3.3 Analysis of CD46 protein and mRNA coding for CYT-1 versus CYT-
2 tails in CD8
+
 T lymphocytes 







 to exclude NK cells) from freshly isolated PBMCs, 
with relative variation in the geometric mean fluorescence intensity (ΔMFI) 





 T lymphocytes sorted from HDs fresh blood, with 
relative quantification (RQ) showed as individual values for 3 healthy donors or 
together in bar graphs (average of 3 technical replicates of n=3 biological replicates): 
RQ = 2
-ΔΔCt
, with ΔΔCt = ΔCt (CD8+ cells) – (ΔCt CD4+ cells), ΔCT = Ct (CYT-1 or 
CYT-2) – Ct (RNA 18S), Ct = threshold cycles. The RT-PCR experiments under (b) 









           
          
Figure 3.4 CD8
+
 T lymphocytes cytokine secretion upon CD46 co-stimulation  
Secreted IFN-γ, IL-10 and TNF-α (ng/mL) by CD8+CD56- versus CD4+CD56- T 
lymphocytes from the same donors, where FACS-sorted cells from the blood of 
HDs, left either non-activated (NA) or activated in vitro (60 hours) with anti-CD3 
(α-CD3), α-CD3 + α-CD28, or α-CD3 + α-CD46. Data are represented as means ± 
standard error of the mean (SEM), n=5. *P < 0.05, **P < 0.01, ns = not significant, 





















 T lymphocytes degranulation upon CD46 co-stimulation  





 FACS-sorted cells isolated from the blood of HDs, left non activated or 
activated in vitro (60 hours) with anti-CD3 (α-CD3), α-CD3 + α-CD28, or α-CD3 + 
α-CD46, in presence of 10U/mL IL-2. Data are represented as means ± SEM, n=3 (a) 
and n=4 (b). *P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant, one-way 

















3.4.2 Effect of CD46 co-stimulation on CD8
+
 T cell cytotoxicity  
 
Having observed that CD46 co stimulation of CD8
+
 T cells induces increased IFN- 
production and granzyme B expression and cell degranulation, the next step was to 
test if this possibly translates into increased cytotoxicity of these cells towards cancer 
cell killing. For this, a cytotoxicity assay involving activated CD8
+
 T cells and the 
prostate cancer cells DU145 was established. 
As CD46 is expressed ubiquitously in all human nucleated cells (Yamamoto et al., 
2013), to analyse the specific effect of CD46 antibody-mediated stimulation on 
CD8
+
 T lymphocytes, excluding any direct effect of stimulation of surface CD46 
expressed by the prostate cancer cells, a cytotoxicity assay was set by transferring 
pre-activated CD8
+
 cells onto DU145 cells cultured in 48-well plates. Further, to 
distinguish epithelial cancer cells from blasting activated CD8
+
 T cells, whose size 
does overlap in terms of forward scatter (FSC) and side scatter (SSC) in FACS 
analyses, CD8
+
 lymphocytes were first stained with a cell permeable not toxic dye 
(CSFE) before undergoing in vitro activation. Thus, DU145 cells were distinguished 
from CD8
+
 T cells after co-culture for their bigger size and the lack of the green 
CSFE staining. Once co-incubated with pre-activated CD8
+
 cells for 12 hours, 
DU145 cells were stained for the apoptosis marker Annexin V, which is upregulated 
on the cell surface of apoptotic cells (Vermes et al., 1995), and the necrosis marker 
propidium iodide (PI, which is cell impermeable and enters only into dying cells 
with loss of cytoplasmic membrane integrity). CD8
+
 T lymphocytes pre-activated 
with CD46 co-stimulation demonstrated an increased ability to kill DU145 cells, 
with a 21.2 % versus 10.42 % of late apoptotic cells and 22.6% versus 20.8% 
necrotic cells when compared with the CD28 co-stimulation (Figure 3.6A). To 
monitor for proper CD46 co-stimulation, IFN- production was also measured in 
cultures and was increased in those containing α-CD3 + α-CD46 pre-activated CD8+ 
T cells (Figure 3.6B). 
These experiments need to be repeated with T cells from different donors (thus 
allowing to perform statistical analyses), but this assay may be used in future to 
investigate the mechanisms of CD46-mediated CD8
+
 T cell cytotoxicity and the role 
of specific molecules (using specific agonists and/or inhibitors) in this process.  
  





In sum, CD46 appears to provide a much more potent co-stimulatory signal 
compared to CD28 for in vitro activation of human CD8
+
 T lymphocytes and their 
effector functions including IFN- and TNF- cytokine production, cytotoxic 
granules release and cytotoxic activity at least towards a cancer cell line. However, 
different from human CD4
+
 T cells, CD46 co-stimulation does not induce substantial 
levels of IL-10 (switching) in CD8
+
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Figure 3.6 Effect of CD46 co-stimulation on CD8
+
 T cell-mediated killing of 
DU145 cells. 1.0x10
4
 DU145 cells (5.0x10
4
 cells/mL) were cultured in 48 well 




 cells, bead-isolated from HDs 
fresh blood and stained with a green dye (CSFE), were left either non-activated or 
were activated in vitro, as described under Fig. 3.4, with α-CD3, α-CD3 + α-CD28 or 
α-CD3 + α-CD46 antibodies for 24 hrs. These pre-activated CD8+ T cells were then 
added on top of the plated DU145 cells at approximately 1/8 ratio (2.0x10
5
 T cells on 
top of ~2.5x104 DU145 cells). (a) Cells were stained for Annexin V (apoptosis 
marker) and PI (necrosis marker). The cell mixtures were cultured for another 12 hrs 
and the killing of the CSFE-negative DU145 target cells by the CSFE-positive CD8
+
 
T cells was assessed using the annexin V and PI staining. The top panel shows the 
gating strategy: the cancer epithelial cells were selected accordingly to the bigger 
size (in term of FSC-H and SSC-H), green positive cells (bigger blasting T 














bottom panel shows the dot plots for the Annexin V and PI co-staining for DU145 
cells gated as on top panel. (b) Pre-activation of CD8
+
 T cells was monitored by 
measuring secreted IFN-γ (ng/ml) by the CD8+CD56- after 24h of activation. 
  





3.4.3 Investigating a C5 complement system in CD8
+
 T lymphocytes  
 
After clearly demonstrating an intrinsic C3 and C5 complement system in CD4
+
 T 
lymphocytes and its role in modulating Th1 responses, and showing that CD8
+ 
T 
cells also respond to CD46 activation (hence C3-derived signals), preliminary 
experiments were performed to investigate whether a ‘C5 system’ may also exist in 
CD8
+
 T lymphocytes and its possible role in regulating cell activation and effector 
cytotoxic functions. In the same way as for CD4
+
 cells, also CD8
+
 T lymphocytes 
demonstrate an exclusive intracytoplasmic C5aR1 protein expression and both 





 T lymphocytes display total levels of the complement component C5 





lymphocytes from the same HDs PMBCs (Figure 3.8). An outstanding experiment 
that still needs to be performed is the measurement of whether activated CD8
+
 T 
cells generate intracellular C5a.  
Because surface-expressed C5aR2 has been shown to negatively regulate Th1 
responses (Chapter 2), a possible effect of C5aR2 agonism, using the same specific 
C5aR2 peptide agonist tested on human CD4
+
 T cells, was studied in CD8
+
 T cells. 





 FACS-sorted lymphocytes treated with the C5aR2 agonist showed 
significantly reduced IFN-γ secretion without significant effects on IL-10 and TNF-α 
production, although there is a trend towards augmented IL-10 and reduced TNF-α 
(Figure 3.9). This reduction in cytokine production is also accompanied by a similar 
effect on cytotoxic granule release, as demonstrated by decreased surface CD107a 
and intracellular granzyme B in CD8
+
 T cells activated in presence of C5aR2 
agonism (Figure 3.10). Of note, FSC versus SSC analyses of FACS plots suggest 
that cell viability is not affected by C5aR2 agonism in CD8
+
 T cells (data not 
shown).  
 
Overall, these data demonstrate (similar to CD4
+
 T cells) the existence of a “C5 
system” also in human CD8+ T lymphocytes, and further support a functional role 
for C5aR2 in the negative regulation of CD8
+
 T cell effector functions. 
 
  







Figure 3.7 C5aRs expression by human CD8
+
 T lymphocytes 
Flow cytometry analysis of extracellular and intracellular (total) protein expression 




 T lymphocytes isolated from HDs 
PBMCs, with histogram plots (representative of n=3 experiments), showing the 

















            
 





Flow cytometry dot plots representative of C5aR1, C5aR2  and C5 total 




 T lymphocytes (CD56
-
 to 
exclude NK cells) from HDs fresh blood isolated PBMCs, with the respective 


























Secreted IFN-γ, IL-10 and TNF-α (ng/mL) by CD8+CD56- FACS-sorted cells from 
HDs and activated in vitro (60 hours) with α-CD3 + α-CD46, in presence of C5aR2 
peptide agonist (100 μM) or vehicle control. Data are represented as means ± SEM, 
































Figure 3.10 Effect of C5aR2 agonism on in vitro degranulation and granzyme B 
expression by CD8
+
 T cells 





 FACS-sorted cells from HDs fresh blood, activated in vitro (60 hours) 
with α-CD3 + α-CD46, in presence of C5aR2 peptide agonist (100 μM) or vehicle 
control. Data are represented as means ± SEM, n=3 (a) and n=4 (b). *P < 0.05, 

















3.4.4 NLRP3 expression and modulation in CD8
+
 T lymphocytes 
 
Having established that human CD8
+
 T cells seem to contain a similar autocrine C3 
and C5 ‘machinery’ as observed in human CD4+ T cells, the next set of experiments 
then aimed at addressing whether CD8
+
 lymphocytes can also assemble a functional 
NLRP3 inflammasome and whether this intrinsic inflammasome may contribute to 





 T cells, as shown by techniques including intracellular immunostaining, 
using flow cytometry and confocal microscopy (Fig. 3.11). Levels of expression of 





cells (Fig. 3.11A and B). Moreover, activated CD8
+
 T lymphocytes, particularly 
upon CD46 co-stimulation, show up-regulated NLRP3 protein (Fig. 3.11C). 
Therefore, this study proceeded with investigating whether a canonical NLRP3 
inflammasome assembles in CD8
+
 T lymphocytes. Very surprisingly though, and in 
contrast to observations in human CD4
+ 





sorted from HDs were activated in vitro in presence of the specific NLRP3 
inflammasome antagonist MCC950 (Coll et al., 2015), no effects were observed on 
IFN-γ, IL-10 and TNF-α cytokine production (Fig. 3.12), caspase-1 cleavage (Fig. 
3.13A) or granzyme B production (Fig. 3.13B).  This was unexpected (a reduction at 
minimum in IFN- secretion was anticipated) and suggests that either 1) intrinsic 
assembly of a functional canonical NLRP3 inflammasome might not occur in CD8
+
 
cytotoxic T cells or, 2) if present, optimal/normal IFN- production by CD8+ T cells 
is not dependent on intrinsic NLRP3-inflammsome driven IL-1 secretion. This 
latter idea is supported by the fact that both IL-1β and IL-18 cytokines secretion was 
not detectable by CD8
+
 cells (data not shown).  
In sum, human CD8
+ 
T cells clearly express NLRP3 and can generate active caspase-
1 but neither activity seems to be required for optimal IFN- secretion in these cells – 
which is in contrast to observations in human CD4
+
















   
 
Figure 3.11 NLRP3 protein expression by resting and activated CD8
+
 T cells 





lymphocytes isolated from HDs, with relative variation in the geometric mean 
fluorescence intensity (ΔMFI) to the isotype control (n=4). (b) NLRP3 confocal 
staining (green) in resting and α-CD3 + α-CD46 activated CD4+ and CD8+ cells from 
2 HDs, nuclei in DAPI, scale bar = 10 μm. (c) Flow cytometry histogram plots for 




 FACS-sorted cells from HDs 
(n=4), left either non-activated or activated in vitro (60 hours) with α-CD3, α-CD3 + 
α-CD28, or α-CD3 + α-CD46, in presence of 10U/mL IL-2. Data are represented as 
means ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with Tukey 
multiple comparison test. 
  









             
 
 
Figure 3.12 Effect of NLRP3 inflammasome inhibition (MCC950) on cytokine 
secretion by CD8
+
 T cells 
(a) Secreted IFN-γ, IL-10 and TNF-α (ng/mL) by CD8+CD56- FACS-sorted cells 
from HDs, activated in vitro (60 hours) with α-CD3 + α-CD46, in presence of 





 FACS-sorted T cells from the same HDs (n=4), activated in vitro 
(60 hours) with α-CD3 + α-CD46, in presence of MCC950 (+) or vehicle control (-). 
Data are represented as means ± SEM, *P < 0.05, ns = not significant, paired 
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Figure 3.13 Effect of NLRP3 inflammasome inhibition on caspase-1 activation 
and degranulation in CD8
+
 T cells  
Flow cytometric staining for activated caspase-1 (cleaved caspase-1 measured by 





sorted cells from HDs, activated in vitro (60 hours) with α-CD3 + α-CD46, in 
presence of MCC950 (10 μM) or vehicle control. Data are represented as means ± 

























In the remaining part of these PhD studies, preliminary data have been produced 
about the involvement of complement CD46 and C5-mediated signals during 
activation and induction of effector functions of human CD8
+
 cytotoxic T cells. 




 T cells were included to exclude any 
effects derived from ‘contaminating’ CD8+CD56+ natural killer T cells that can also 
produce IFN- and have cytotoxic activity (Godfrey et al., 2004). 
 
As expected from previous studies (Astier et al., 2000), CD46 expression has been 
observed at mRNA and protein level also in CD8
+
 T lymphocytes (Figure 3.3). Not 





 cells from the peripheral blood of the same HDs, although previous 
studies reported higher extracellular CD46 expression in CD8
+
 lymphocytes 
(Christmas et al., 2006). In line with this latter observation, higher expression of the 
transcripts for CD46 isoforms bearing both tail 1 and tail 2 was detected in CD8
+
 T 
cells from two out of three healthy donors when compared with CD4
+
 cells (Figure 
3.3B). However, only further studies on an enlarged group of HDs will help to 
evaluate difference in CD46 expression among different lymphocytic subsets and its 
biological significance. In addition, it may be helpful to also sort the CD8
+
 T cells 
into naïve and memory cells and use resting and α-CD3, α-CD3 + α-CD28 and α-
CD3 + α-CD46-activated T cells for the analysis of CD46 isoforms in the future to 





 T cells. 
 
Importantly, in vitro co-stimulation with CD46 leads to a stronger CD8
+
 T cell 
activation when compared to anti-CD3 stimulation either alone or with anti-CD28 
co-stimuli: anti-CD3 + anti-CD46 treatment results in increased CD8
+
 T 
lymphocytes blasting (not showed), increased IFN-γ and TNFα secretion (Figure 
3.4) and degranulation, as assessed by surface-expressed LAMP1 and intracellular 
produced granzyme B (Figure 3.5). Also increased perforin has been observed upon 
anti-CD3 + anti-CD46 in vitro stimulation but the data are not shown here as more 
  





biological replicates are needed to obtain statistical significance. It should be noted 
here, that the measurement of intracellular C3 and intracellular C3a and C3b 
generation as well as the definition of C3aR expression in resting and activated 
CD8
+
 T cells is currently missing but underway. Also, cathepsin L cleaves 
intracellular C3 into bioactive C3a and C3b in CD4
+
 T cells (Liszewski et al., 2013) 
and it will be interesting to assess if cathepsin L plays a similar role in CD8
+
 T cell 
C3 activation. Further, to better assess the functions of CD46, C3aR and C5aR1, it 
has been envisaged the use of the CRISPR-Cas9 technique (Sander and Joung, 2014) 
to generate CD4
+
 T cells and CD8
+
 T cells deficient in these molecules.  
 
Interestingly, previous work by Kickler and colleagues (Kickler et al, 2012) reported 
no differences in activation and IFN-γ secretion by CD8+ T cells upon CD46 in vitro 
co-stimulation when compared with anti-CD3 stimuli alone at a similar time point 
post activation (72 hours). Nevertheless, this group used a different anti-CD46 
antibody clone and they did not add IL-2 to cultures, and it is known that signaling 
coming from IL-2 receptor co-operates with CD46 activity in sustaining CD4
+
 T 
cells responses (Cardone et al., 2010). In the future, titration of the signal coming 
from the anti-CD3 stimulation (different concentrations of immobilised antibody) or 
of IL-2 or IL-15 (various cytokines concentration into culture) might help to address 
what are the further signals required by CD46 co-stimulation in enhancing CD8
+
 
lymphocytes effector responses.  
 




 T cells 
is that no substantial IL-10 secretion occurs from in vitro activated CD8
+
 T cells 
upon CD46 stimulation (Figure 3.4). This is in line with previous reports (Kickler et 
al., 2012), and although CD46 co-stimulation results in small detectable levels of 
this cytokine, it is about 100 fold lower than the amount of IL-10 secreted by CD4
+
 
T cells from the same donor controls. The different levels of IL-10 production might 
depend on a different expression of the CD46 CYT-1 and CYT-2 isoforms in CD8
+
 
T cells when compared with CD4
+
 cells, as it is known that CD46 tail 1 and tail 2 
have different roles in regulating Th1 induction and contraction in CD4
+
 





 cells did not demonstrate differences in the proportion of 
  





expression of both CD46 tails (Figure 3.3). However the mRNA and protein 




 T lymphocytes of the 
same healthy donor (possibly at different time points of cell activation) is likely 
more important for the interpretation of such functionally different outcomes. It 
should also be noted that the intracellular domains of CD46 are cleaved by -
secretase upon stimulation in several cell types (Weyand et al., 2010) and translocate 
to the nucleus (Kolev et al., 2015). Thus, an analysis of nuclear CYT-1 and CYT-2 
with specific antibodies generated by the Kemper laboratory will also be included in 
the future.  
 
In accordance with the increased granzyme B (and perforin) expression and 
degranulation, activation of CD8
+
 T cell by CD46 co-stimulation results in 
heightened killing ability towards “antigen presenting cells”, such as the DU145 
cells, a prostate cancer cell line, demonstrated by the increased apoptosis and 
necrosis of cancer cells (Figure 3.6). However, these experiments needs to be 
repeated with T cells from different donors and to obtain statistical significance as 
the ‘cytotoxic activity’ among CD8+ T cells could vary among donors, depending on 
the specificity of their TCR toward the tumor cell line antigens. This cytotoxicity 
assay will also allow in future to assess the ability for complement or inflammasome 
regulators, co-incubated with CD8
+
 cells during in vitro activation, to modulate 
CD8
+
 lymphocytes killing ability. 
 
In similitude to the C3 and CD46 system, CD8
+
 T cells appear to have also the C5 
system with expression of the C5a receptors C5aR1 and C5aR2 similar to CD4
+
 T 
cells: with cytoplasmic expression of both receptors, while only C5aR2 and not 
C5aR1 protein was detectable on the cell surface in resting cells (Figure 3.7). This is 
in contrast to observations by Raedler and colleagues (Raedler et al., 2009), who 
showed evidence for cell surface C5aR1 activity by mouse CD8
+
 T cells as they can 
be activated by the addition of C5a to cultures; nonetheless, this group evaluated the 
effect of C5a T cells activation in co-culture with APCs (thus not accounting for 
paracrine cytokine production upon C5a binding to APCs in driving T cell 
responses) and they only evaluated C5aR1 expression at the mRNA and not at the 
protein level. One novelty of the work performed in this thesis is that there are no 
  





data published with regards to C5aR2 expression in CD8
+
 T cells, and, in addition, 
intracellular total C5 protein expression has been demonstrated for the first time in 
these cells (Figure 3.8). Follow-up experiments should now include the evaluation of 




lymphocytes, possibly C5a radioactive binding 
studies on this cell type (in analogy to the studies performed on CD4
+
 T cells, 
Chapter 2), and a thorough assessment of C5aR1 and C5aR2 transcript and protein 
expression in resting and activated CD8
+
 T cells. 
 
In line with extracellular expression of C5aR2 by CD8
+
 T cells, use of a C5aR2 
specific peptide agonist (Croker et al., 2016) leads to significantly diminished IFN- 
secretion (Figure 3.9) and degranulation, with significant reduced extracellular 
LAMP1 and intracellular granzyme B upon anti-CD3 + anti-CD46 in vitro activation 
(Figure 3.10). These data suggest a role for extracellular C5aR2 signaling in 
negatively regulating CD8
+
 T cell responses. A better understanding of the 
involvement of autocrine C5 complement activation in CD8
+
 lymphocytes effector 
response would be possible only after in depth evaluation of several C5aR2 
agonists/antagonist at different concentrations (dose-dependent affect evaluation by 
titration) and possibly also C5aR1 agonist/antagonist/siRNA/CRISPR-Cas9 with 
downstream assessment on IFN- production (ROS generation) and cytotoxic 
activity. 
 
Apart from the complement immune sensors, also the existence of a potential 
intrinsic NLRP3 inflammasome was investigated in human CD8
+
 T cells, because: 1) 
CD4
+
 T cells have an intracellular NLRP3 inflammasome machinery, which drives 
IL-1 secretion and sustenance of IFN- secretion (Chapter 2); 2) CD8+ T cells have 
the ability to respond to paracrine IL-1 and IL-18 (Ben-Sasson et al., 2013, Soudja 
et al., 2012). In line with our observations in CD4
+
 T cells, also CD8
+
 T 
lymphocytes express the NLRP3 protein (Figure 3.11), which, similarly to CD4
+
 
cells, increases significantly upon CD46 co-stimulation. Therefore, the existence of 
an NLRP3 inflammasome within CD8
+





 cytotoxic lymphocytes with the NLRP3 specific antagonist 
MCC950 (Coll et al., 2015). Noteworthy, CD8
+
 lymphocytes (n=8 healthy donors) 
  





did not show reduced IFN- secretion upon NLRP3 inflammasome inhibition (Figure 
3.12A), while CD4
+
 cells from the same healthy donor produced less IFN- upon 
MCC950 treatment (Figure 3.12B) in analogy with previous data (Chapter 2). In 
addition, MCC950 treatment did not result in reduced caspase-1 cleavage in CD8
+
 
cells activated in vitro (Figure 3.13A). These evidences suggest that although 
NLRP3 is present in CD8
+
 lymphocytes, it does not participate in the formation of a 
canonical caspase-1 dependent inflammasome in regulating IFN- production by this 
cell type. Future experiments will measure whether the inhibition of caspase-1 with a 
specific inhibitor (see Chapter 2) has also no effect on IFN- production by CD8+ T 
cells and whether NLRP3-ASC ‘specks’ assembly in this cell type following 
activation. If it is the case, the absence of specks formation and of caspase-1 
inhibitory effect would further indicate that the NLRP3 inflammasome does not form 
in CD8
+
 T cells and/or is not required for normal IFN- activity in this cell type. Of 
note, caspase-1 can also be activated in an NLRP3 inflammasome independent 
fashion via TNF- (Furuoka et al., 2016).  
Because, it had previously been shown that granzyme B, produced by cytotoxic T 
and natural killer cells, is another enzyme which stimulates IL-18 maturation (Omoto 
et al., 2010), it was assessed the possibility that the NLRP3 inflammasome operates 
together with granzyme B and not caspase-1 to induce autocrine IL-18 production. 
Notwithstanding, in contrast with this hypothesis, MCC950 treatment did not result 
in substantial differences in granzyme B expression (Figure 3.13B), but more 
replicates are needed to obtain statistical significance. Finally, the potential 
functional granzyme B/NLRP3 interaction can be studied in future by means of 
colocalization in immunofluorescence experiments or protein co-
immunoprecipitation.  
In support of the absence of a functional NLRP3 inflammasome in CD8
+
 T cells, 





 T cells activated in vitro via ELISA (data not shown). 
Although, it is possible that these cytokines are not detected because they are quickly 
engaged by their receptors in an autocrine fashion, therefore this possibility should 
be addressed by measuring the mRNA for these cytokines and by performing 
intracellular cytokine staining as well as the use of in vitro assays which include the 
  





addition of either the IL1RA or IL18BP, which respectively block the IL-1/IL-1R1 
and the IL-18/IL-18R binding in the future. 
 
To further define how the autocrine complement system drives IFN- production and 
cytotoxic activity in an NLRP3 inflammasome-independent fashion in CD8
+
 T cells, 
we have performed comparative gene microarray experiments using in vitro 
activated CD8
+
 T lymphocytes after anti-CD3 alone or anti-CD3 + anti-CD46 
stimulation. These data are currently being analysed and hopefully give clues which 
signaling pathways are driven specifically by CD46 in CD8
+
 T cells. These array 
data will also be complemented by gene arrays derived from similarly activated 
CD8
+
 T cells isolated from a CD46-deficient patient.  
Previous work using mouse T cells indicated already an inflammasome independent 
role for NLRP3 in T cell activation: in one study (Bruchard et al., 2015), it was 
demonstrated that NLRP3 in mouse CD4
+
 T cells can translocate to the nucleus and 
function as transcription factor to regulate Il4 gene expression and Th2 induction. 
Thus, NLRP3 in human CD8
+
 T cells may operate also via an alternative mechanism 
independent from the formation of an oligomeric inflammasome complex, which can 
involve nuclear translocation and activity as transcriptional regulator. There is also 
other work supporting an ‘alternative’ function for NLRP3. NLRP3, in analogy with 
other NOD-like receptors, may act as intracellular PAMPs sensor without 
assembling in an inflammasome machinery: it has been demonstrated that NOD1, 
another NLR, is able to co-operate with TLR2 and TCR stimulation intrinsically in 
mouse and human CD8
+
 lymphocytes to induce their proliferation and effector 
functions (IFN- and TNF- secretion) (Mercier et al., 2012). The author of this 
study did not report any NLRP3 expression by murine CD8
+
 T cells, although 
expression by human cells was not investigated, and there might be species-specific 
differences for NLRP3 expression in CD8
+
 lymphocytes. Further experiments to 
assess this hypothesis include the evaluation of NLRP3 nuclear translocation 





 lymphocytes. In addition, gene array analyses will be 
performed using CD8
+
 T cells from CAPS patients in order to define the role of 
NLRP3 in CD8
+
 T cells.  
 
  





When the data derived from the in vitro experiments using CD8
+
 T cells from HDs, 
CAPS patients and T cells in which key proteins have been knocked down are 
conclusive and have pinpointed the role of complement receptors and/or NLRP3 in 
these cells, additional studies can then be planned which includes suitable in vivo 
mouse models (for example, induced colitis experiments with adoptive transfer of 
CD8
+
 T lymphocytes).  
 
Finally, preliminary observations have also been generated showing that bulk CD8
+ 




 cytotoxic T lymphocytes (that are 
devoid of NKT cells), respond to MCC950 treatment with reduced IFN- production 
after in vitro anti-CD3 + anti-CD46 stimulation (data not shown). This indicates that 
NKT cells, like CD4
+
 T cells, may produce IFN- indeed in a canonical NLRP3 












(Godfrey et al., 2004; Wang et al., 2015), will also be included into a comparative 
analysis of the NLRP3 function in different cell subsets. The rationale behind this 
approach is to generate a ‘T cell lineage relationship tree’ based on the usage (or not) 
of the new ‘complement-inflammasome’ axis for effector function. This work 
complements on-going parallel but independent work in the Kemper laboratory that 
evaluates the function of intracellular complement in the thymic selection process of 
T cell lineage development.  
 
In conclusion, as both complement and inflammasome activation products, 
modulating CD8
+
 T cell function in a paracrine and/or autocrine fashion, have been 
demonstrated to profoundly control in vivo infection (Fang et al., 2007; Soudja et al., 
2012), transplantation (Vieyra et al., 2011), and cancer (Ghiringhelli et al., 2009; 
Vadrevu et al., 2014) outcome, a better understanding of how complement and 
inflammasome, operate - intrinsically or not - in human CD8
+
 T lymphocytes can 
help in designing therapeutic strategies to target these pathways in infectious, 
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